# EDGAR Filing Document

**Accession Number:** 0000898174
**File Stem:** 0000898174-26-000025
**Filing Date:** 2026-5
**Character Count:** 449664
**Document Hash:** 608d0c6055d9c796f117206760f82f62
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000898174-26-000025.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0000898174-26-000025

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 122

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REINSURANCE GROUP OF AMERICA INC
- **CENTRAL INDEX KEY:** 0000898174
- **STANDARD INDUSTRIAL CLASSIFICATION:** LIFE INSURANCE [6311]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 431627032
- **STATE OF INCORPORATION:** MO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11848
- **FILM NUMBER:** 26957490

**BUSINESS ADDRESS:**
- **STREET 1:** 16600 SWINGLEY RIDGE ROAD
- **CITY:** CHESTERFIELD
- **STATE:** MO
- **ZIP:** 63017
- **BUSINESS PHONE:** 6367367000

**MAIL ADDRESS:**
- **STREET 1:** 16600 SWINGLEY RIDGE ROAD
- **CITY:** CHESTERFIELD
- **STATE:** MO
- **ZIP:** 63017

?xml version='1.0' encoding='ASCII'? rga-20260331

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q** 

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026** 

**OR**

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number 1-11848** 

**REINSURANCE GROUP OF AMERICA, INCORPORATED** 

**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Missouri** | **43-1627032** |
| **(State or other jurisdiction&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** | **(IRS employer** |
| **of incorporation or organization)** | **identification number)** |

---

**16600 Swingley Ridge Road** 

**Chesterfield, Missouri 63017** 

**(Address of principal executive offices)**

**(636) 736-7000** 

**(Registrant's telephone number, including area code)**

**Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.**

**Yes** ⌧ **No** □

**Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).**

**Yes** ☒ **No** □

**Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.**

**Large accelerated filer** ⌧ **&nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer** □ **Non-accelerated filer** □ **&nbsp;&nbsp;&nbsp;&nbsp;**

**Smaller reporting company** ☐ **Emerging growth company** ☐

**If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.** ☐

**Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes** ☐ **No** ☒

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| **Common Stock, par value $0.01** | **RGA** | **New York Stock Exchange** |
| **5.75% Fixed-To-Floating Rate Subordinated Debentures due 2056** | **RZB** | **New York Stock Exchange** |
| **7.125% Fixed Rate Subordinated Debentures due 2052** | **RZC** | **New York Stock Exchange** |

---

**As of April 27, 2026, 65,513,163 shares of the registrant's common stock were outstanding.**

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **<u>Item</u>** | | **<u>Page</u>** |
| | **<u>PART I – FINANCIAL INFORMATION</u>** | |
| 1 | Financial Statements (Unaudited) as of March 31, 2026 and December 31, 2025 and for the Three Months Ended March 31, 2026 and 2025 |  |
|  | <u>[Condensed Consolidated Balance Sheets](#i308ff4d2adb242a0b9b47d3fd0f5b98c_10)</u> | <u>[3](#i308ff4d2adb242a0b9b47d3fd0f5b98c_10)</u> |
|  | <u>[Condensed Consolidated Statements of Income](#i308ff4d2adb242a0b9b47d3fd0f5b98c_13)</u> | <u>[4](#i308ff4d2adb242a0b9b47d3fd0f5b98c_13)</u> |
|  | <u>[Condensed Consolidated Statements of Comprehensive Income](#i308ff4d2adb242a0b9b47d3fd0f5b98c_16)</u> | <u>[5](#i308ff4d2adb242a0b9b47d3fd0f5b98c_16)</u> |
|  | <u>[Condensed Consolidated Statements of Equity](#i308ff4d2adb242a0b9b47d3fd0f5b98c_19)</u> | <u>[6](#i308ff4d2adb242a0b9b47d3fd0f5b98c_19)</u> |
|  | <u>[Condensed Consolidated Statements of Cash Flows](#i308ff4d2adb242a0b9b47d3fd0f5b98c_22)</u> | <u>[7](#i308ff4d2adb242a0b9b47d3fd0f5b98c_22)</u> |
|  | Notes to Condensed Consolidated Financial Statements (Unaudited) |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 1 Business and Basis of Presentation](#i308ff4d2adb242a0b9b47d3fd0f5b98c_28)</u> | <u>[8](#i308ff4d2adb242a0b9b47d3fd0f5b98c_28)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 2 Earnings Per Share](#i308ff4d2adb242a0b9b47d3fd0f5b98c_31)</u> | <u>[8](#i308ff4d2adb242a0b9b47d3fd0f5b98c_31)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 3 Equity](#i308ff4d2adb242a0b9b47d3fd0f5b98c_34)</u> | <u>[9](#i308ff4d2adb242a0b9b47d3fd0f5b98c_34)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 4 Future Policy Benefits](#i308ff4d2adb242a0b9b47d3fd0f5b98c_40)</u> | <u>[11](#i308ff4d2adb242a0b9b47d3fd0f5b98c_40)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 5 Policyholder Account Balances](#i308ff4d2adb242a0b9b47d3fd0f5b98c_43)</u> | <u>[18](#i308ff4d2adb242a0b9b47d3fd0f5b98c_43)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 6 Unpaid Claims and Claim Expense – Short-Duration Contracts](#i308ff4d2adb242a0b9b47d3fd0f5b98c_46)</u> | <u>[20](#i308ff4d2adb242a0b9b47d3fd0f5b98c_46)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 7 Market Risk Benefits](#i308ff4d2adb242a0b9b47d3fd0f5b98c_49)</u> | <u>[21](#i308ff4d2adb242a0b9b47d3fd0f5b98c_49)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 8 Deferred Policy Acquisition Costs and Other](#i308ff4d2adb242a0b9b47d3fd0f5b98c_52)</u> | <u>[22](#i308ff4d2adb242a0b9b47d3fd0f5b98c_52)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 9 Reinsurance](#i308ff4d2adb242a0b9b47d3fd0f5b98c_55)</u> | <u>[23](#i308ff4d2adb242a0b9b47d3fd0f5b98c_55)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 10 Investments](#i308ff4d2adb242a0b9b47d3fd0f5b98c_58)</u> | <u>[24](#i308ff4d2adb242a0b9b47d3fd0f5b98c_58)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 11 Derivative Instruments](#i308ff4d2adb242a0b9b47d3fd0f5b98c_61)</u> | <u>[33](#i308ff4d2adb242a0b9b47d3fd0f5b98c_61)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 12 Fair Value of Assets and Liabilities](#i308ff4d2adb242a0b9b47d3fd0f5b98c_64)</u> | <u>[38](#i308ff4d2adb242a0b9b47d3fd0f5b98c_64)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 13 Income Tax](#i308ff4d2adb242a0b9b47d3fd0f5b98c_67)</u> | <u>[44](#i308ff4d2adb242a0b9b47d3fd0f5b98c_67)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 1](#i308ff4d2adb242a0b9b47d3fd0f5b98c_73)[4](#i308ff4d2adb242a0b9b47d3fd0f5b98c_73)[Commitments, Contingencies and Guarantees](#i308ff4d2adb242a0b9b47d3fd0f5b98c_73)</u> | <u>[45](#i308ff4d2adb242a0b9b47d3fd0f5b98c_73)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 1](#i308ff4d2adb242a0b9b47d3fd0f5b98c_76)[5](#i308ff4d2adb242a0b9b47d3fd0f5b98c_76)[Segment Information](#i308ff4d2adb242a0b9b47d3fd0f5b98c_76)</u> | <u>[46](#i308ff4d2adb242a0b9b47d3fd0f5b98c_76)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 16 Financing Activities](#i308ff4d2adb242a0b9b47d3fd0f5b98c_79)</u> | <u>[49](#i308ff4d2adb242a0b9b47d3fd0f5b98c_79)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp; <u>[Note 1](#i308ff4d2adb242a0b9b47d3fd0f5b98c_82)[7](#i308ff4d2adb242a0b9b47d3fd0f5b98c_82)[New Accounting Standards](#i308ff4d2adb242a0b9b47d3fd0f5b98c_82)</u> | <u>[50](#i308ff4d2adb242a0b9b47d3fd0f5b98c_82)</u> |
| 2 | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i308ff4d2adb242a0b9b47d3fd0f5b98c_85)</u> | <u>[51](#i308ff4d2adb242a0b9b47d3fd0f5b98c_85)</u> |
| 3 | <u>[Quantitative and Qualitative Disclosure About Market Risk](#i308ff4d2adb242a0b9b47d3fd0f5b98c_100)</u> | <u>[76](#i308ff4d2adb242a0b9b47d3fd0f5b98c_100)</u> |
| 4 | <u>[Controls and Procedures](#i308ff4d2adb242a0b9b47d3fd0f5b98c_103)</u> | <u>[76](#i308ff4d2adb242a0b9b47d3fd0f5b98c_103)</u> |
|  | **<u>PART II – OTHER INFORMATION</u>** |  |
| 1 | <u>[Legal Proceedings](#i308ff4d2adb242a0b9b47d3fd0f5b98c_109)</u> | <u>[77](#i308ff4d2adb242a0b9b47d3fd0f5b98c_109)</u> |
| 1A | <u>[Risk Factors](#i308ff4d2adb242a0b9b47d3fd0f5b98c_112)</u> | <u>[77](#i308ff4d2adb242a0b9b47d3fd0f5b98c_112)</u> |
| 2 | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i308ff4d2adb242a0b9b47d3fd0f5b98c_115)</u> | <u>[77](#i308ff4d2adb242a0b9b47d3fd0f5b98c_115)</u> |
| 5 | <u>[Other Information](#i308ff4d2adb242a0b9b47d3fd0f5b98c_118)</u> | <u>[77](#i308ff4d2adb242a0b9b47d3fd0f5b98c_118)</u> |
| 6 | <u>[Exhibits](#i308ff4d2adb242a0b9b47d3fd0f5b98c_121)</u> | <u>[77](#i308ff4d2adb242a0b9b47d3fd0f5b98c_121)</u> |
|  | <u>[Index to Exhibits](#i308ff4d2adb242a0b9b47d3fd0f5b98c_124)</u> | <u>[78](#i308ff4d2adb242a0b9b47d3fd0f5b98c_124)</u> |
|  | <u>[Glossary of Selected Terms](#i308ff4d2adb242a0b9b47d3fd0f5b98c_127)</u> | <u>[79](#i308ff4d2adb242a0b9b47d3fd0f5b98c_127)</u> |
|  | <u>[Signatures](#i308ff4d2adb242a0b9b47d3fd0f5b98c_136)</u> | <u>[83](#i308ff4d2adb242a0b9b47d3fd0f5b98c_136)</u> |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**<u>PART I</u>** <u>–</u> **<u>FINANCIAL INFORMATION</u>**

**REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in millions, except share data)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | March 31,<br>2026 | December 31,<br>2025 |
| **Assets** |  |  |
| Fixed maturity securities available-for-sale, at fair value (amortized cost of $114,976 and $107,264; allowance for credit losses of $232 and $210) | $107328 | $101769 |
| Equity securities, at fair value | 300 | 311 |
| Mortgage loans (net of allowance for credit losses of $115 and $117) | 11318 | 11104 |
| Policy loans | 3703 | 3541 |
| Funds withheld at interest | 8390 | 8149 |
| Limited partnerships and real estate joint ventures | 4093 | 3747 |
| Short-term investments | 357 | 346 |
| Other invested assets | 1525 | 1514 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments | 137014 | 130481 |
| Cash and cash equivalents | 4993 | 4168 |
| Accrued investment income | 1361 | 1296 |
| Premiums receivable and other reinsurance balances | 4259 | 4475 |
| Reinsurance ceded receivables and other | 6743 | 7175 |
| Deferred policy acquisition costs and other | 6191 | 6079 |
| Other assets | 3503 | 2916 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $164064 | $156590 |
| **Liabilities and equity** |  |  |
| Future policy benefits | $72308 | $66425 |
| Interest-sensitive contract liabilities | 53540 | 52095 |
| Market risk benefits, at fair value | 249 | 234 |
| Other policy claims and benefits | 3051 | 3011 |
| Other reinsurance balances | 1495 | 1888 |
| Income taxes | 3182 | 2998 |
| Funds withheld payable | 6494 | 6805 |
| Other liabilities | 4256 | 3873 |
| Long-term debt | 6105 | 5710 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 150680 | 143039 |
| Commitments and contingent liabilities (See Note 14) |  |  |
| Equity |  |  |
| &nbsp;&nbsp;Preferred stock (par value $0.01 per share, 10,000,000 shares authorized, no shares issued or outstanding) |  |  |
| &nbsp;&nbsp;Common stock (par value $0.01 per share, 140,000,000 shares authorized, 85,310,598 shares issued at March 31, 2026 and December 31, 2025) | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Additional paid-in-capital | 2661 | 2640 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 10375 | 10151 |
| &nbsp;&nbsp;Treasury stock, at cost – 19,801,364 and 19,846,934 shares at March 31, 2026 and December 31, 2025 | (2057) | (2013) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 2314 | 2682 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Reinsurance Group of America, Inc. shareholders' equity | 13294 | 13461 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest | 90 | 90 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 13384 | 13551 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $164064 | $156590 |

---

See accompanying notes to condensed consolidated financial statements (unaudited).

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**

**(in millions, except per share amounts)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| **Revenues** |  |  |
| Net premiums | $4595 | $4019 |
| Net investment income | 1701 | 1232 |
| Investment related gains (losses), net | (170) | (79) |
| Other revenues | 368 | 88 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 6494 | 5260 |
| **Benefits and expenses** |  |  |
| Claims and other policy benefits | 4621 | 3822 |
| Future policy benefits remeasurement (gains) losses | (7) | (56) |
| Market risk benefits remeasurement (gains) losses | 22 | 29 |
| Interest credited | 480 | 299 |
| Policy acquisition costs and other insurance expenses | 512 | 417 |
| Other operating expenses | 326 | 300 |
| Interest expense | 99 | 80 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total benefits and expenses | 6053 | 4891 |
| **Income before income taxes** | 441 | 369 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 110 | 81 |
| **Net income** | 331 | 288 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interest | 1 | 2 |
| **Net income available to Reinsurance Group of America, Inc. shareholders** | $330 | $286 |
| **Earnings per share** |  |  |
| Basic earnings per share | $5.04 | $4.33 |
| Diluted earnings per share | $4.98 | $4.27 |

---

See accompanying notes to condensed consolidated financial statements (unaudited).

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(in millions)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| **Comprehensive income (loss)** |  |  |
| Net income | $331 | $288 |
| Other comprehensive income (loss), net of income taxes: |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | (20) | 11 |
| &nbsp;&nbsp;&nbsp;Net unrealized investment gains (losses) | (1659) | 83 |
| &nbsp;&nbsp;&nbsp;Effect of updating discount rates on future policy benefits | 1308 | 290 |
| &nbsp;&nbsp;&nbsp;Change in instrument-specific credit risk for market risk benefits | 2 | 4 |
| &nbsp;&nbsp;&nbsp;Defined benefit pension and postretirement plan adjustments | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss), net of income taxes | (368) | 389 |
| Total comprehensive income (loss) | (37) | 677 |
| &nbsp;&nbsp;Comprehensive income (loss) attributable to noncontrolling interest | 1 | 2 |
| **Total comprehensive income (loss) attributable to Reinsurance Group of America, Inc.** | $(38) | $675 |

---

See accompanying notes to condensed consolidated financial statements (unaudited).

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF EQUITY**

**(in millions except per share amounts)**

**(Unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Common<br>Stock | Additional Paid In Capital | Retained<br>Earnings | Treasury<br>Stock | Accumulated Other Comprehensive Income (Loss) | Total RGA, Inc. Shareholders' Equity | Noncontrolling Interest | Total Equity |
| Balance, December 31, 2025 | $1 | $2640 | $10151 | $(2013) | $2682 | 13461 | $90 | $13551 |
| &nbsp;&nbsp;Change in equity of noncontrolling interest |  |  |  |  |  |  | (1) | (1) |
| &nbsp;&nbsp;Net income |  |  | 330 |  |  | 330 | 1 | 331 |
| &nbsp;&nbsp;Other comprehensive income (loss), net of income taxes |  |  |  |  | (368) | (368) |  | (368) |
| &nbsp;&nbsp;Dividends to shareholders, $0.93 per share |  |  | (61) |  |  | (61) |  | (61) |
| &nbsp;&nbsp;Share repurchase program |  |  |  | (50) |  | (50) |  | (50) |
| &nbsp;&nbsp;Equity based plans, net of shares withheld for taxes |  | 21 | (45) | 6 |  | (18) |  | (18) |
| Balance, March 31, 2026 | $1 | $2661 | $10375 | $(2057) | $2314 | $13294 | $90 | $13384 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Common<br>Stock | Additional Paid In Capital | Retained<br>Earnings | Treasury<br>Stock | Accumulated Other Comprehensive Income (Loss) | Total RGA, Inc. Shareholders' Equity | Noncontrolling Interest | Total Equity |
| Balance, December 31, 2024 | $1 | $2600 | $9255 | $(1889) | $849 | 10816 | $90 | $10906 |
| &nbsp;&nbsp;Change in equity of noncontrolling interest |  |  |  |  |  |  | (2) | (2) |
| &nbsp;&nbsp;Net income |  |  | 286 |  |  | 286 | 2 | 288 |
| &nbsp;&nbsp;Other comprehensive income, net of income taxes |  |  |  |  | 389 | 389 |  | 389 |
| &nbsp;&nbsp;Dividends to shareholders, $0.89 per share |  |  | (59) |  |  | (59) |  | (59) |
| &nbsp;&nbsp;Share repurchase program |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Equity based plans, net of shares withheld for taxes |  | 8 | (39) | 1 |  | (30) |  | (30) |
| Balance, March 31, 2025 | $1 | $2608 | $9443 | $(1888) | $1238 | $11402 | $90 | $11492 |

---

See accompanying notes to condensed consolidated financial statements (unaudited).

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in millions)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| **Net cash provided by operating activities** | 2873 | 1429 |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Sales of fixed maturity securities available-for-sale | 9596 | 7187 |
| &nbsp;&nbsp;&nbsp;Purchases of fixed maturity securities available-for-sale | (13149) | (8512) |
| &nbsp;&nbsp;&nbsp;Maturities of fixed maturity securities available-for-sale | 326 | 217 |
| &nbsp;&nbsp;&nbsp;Sales of equity securities | 16 |  |
| &nbsp;&nbsp;&nbsp;Principal payments on mortgage loans | 373 | 163 |
| &nbsp;&nbsp;&nbsp;Cash invested in mortgage loans | (603) | (635) |
| &nbsp;&nbsp;&nbsp;Net deposits in funds withheld at interest | 82 | 120 |
| &nbsp;&nbsp;&nbsp;Sales of limited partnerships and real estate joint ventures | 136 | 52 |
| &nbsp;&nbsp;&nbsp;Purchases of limited partnerships and real estate joint ventures | (436) | (239) |
| &nbsp;&nbsp;&nbsp;Sales of short-term investments | 251 | 200 |
| &nbsp;&nbsp;&nbsp;Purchases of short-term investments | (358) | (394) |
| &nbsp;&nbsp;&nbsp;Maturities of short-term investments | 140 | 110 |
| &nbsp;&nbsp;&nbsp;Change in other invested assets | (84) | 8 |
| &nbsp;&nbsp;Other, net | 13 | 28 |
| Net cash used in investing activities | (3697) | (1695) |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Dividends to shareholders | (61) | (59) |
| &nbsp;&nbsp;&nbsp;Proceeds from long-term debt issuance, net | 395 | 691 |
| &nbsp;&nbsp;&nbsp;Principal payments of long-term debt | (1) | (1) |
| &nbsp;&nbsp;&nbsp;Purchases of treasury stock | (94) | (38) |
| &nbsp;&nbsp;&nbsp;Treasury stock reissued | 5 |  |
| &nbsp;&nbsp;&nbsp;Change in cash collateral for derivatives and repurchase/reverse repurchase agreements | (199) | (8) |
| &nbsp;&nbsp;&nbsp;Change in deposit asset on reinsurance | 43 | 50 |
| &nbsp;&nbsp;&nbsp;Deposits on investment-type policies and contracts | 2990 | 2559 |
| &nbsp;&nbsp;&nbsp;Withdrawals on investment-type policies and contracts | (1412) | (1127) |
| Net cash provided by financing activities | 1666 | 2067 |
| Effect of exchange rate changes on cash | (17) | 24 |
| Change in cash and cash equivalents | 825 | 1825 |
| Cash and cash equivalents, beginning of period | 4168 | 3326 |
| Cash and cash equivalents, end of period | $4993 | $5151 |
| **Supplemental disclosures of cash flow information** |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid | $87 | $61 |
| &nbsp;&nbsp;&nbsp;Income taxes paid, net of refunds | $37 | $63 |
| **Non-cash investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Transfer of invested assets | $4619 | $4707 |

---

See accompanying notes to condensed consolidated financial statements (unaudited).

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

NOTE 1 BUSINESS AND BASIS OF PRESENTATION

**Business**

Reinsurance Group of America, Incorporated ("RGA" and, collectively with its subsidiaries, the "Company") is an insurance holding company that was formed on December 31, 1992. The Company is engaged in providing traditional reinsurance, which includes individual and group life and health, disability and critical illness reinsurance. The Company also provides financial solutions, which includes longevity reinsurance, asset-intensive products, primarily annuities, financial reinsurance, capital solutions, pension risk transfer ("PRT") and stable value products.

**Basis of Presentation**

The unaudited condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission ("SEC"). Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company's 2025 Annual Report on Form 10-K filed with the SEC on February 20, 2026 (the "2025 Annual Report").

In the opinion of management, all adjustments, including normal recurring adjustments necessary for a fair presentation, have been included. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2026.

**Consolidation**

These unaudited condensed consolidated financial statements include the accounts of RGA and its subsidiaries, and all intercompany accounts and transactions have been eliminated. Entities for which the Company has significant influence over the operating and financing decisions but are not required to be consolidated are reported under the equity method of accounting.

NOTE 2 EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per share on net income (in millions, except per share information):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Earnings: |  |  |
| &nbsp;&nbsp;&nbsp;Net income (numerator for basic and diluted calculations) | $331 | $288 |
| &nbsp;&nbsp;Less: Net income attributable to noncontrolling interest | 1 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income available to RGA, Inc. shareholders | $330 | $286 |
| Shares: |  |  |
| &nbsp;&nbsp;Weighted average outstanding shares (denominator for basic calculation) | 65 | 66 |
| &nbsp;&nbsp;&nbsp;Equivalent shares from outstanding stock awards | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted shares (denominator for diluted calculation) | 66 | 67 |
| Earnings per share: |  |  |
| &nbsp;&nbsp;Basic | $5.04 | $4.33 |
| &nbsp;&nbsp;Diluted | $4.98 | $4.27 |

---

The calculation of common equivalent shares does not include the impact of stock awards with a conversion price that exceeds the average stock price for the earnings period as the result would be antidilutive. The calculation of common equivalent shares also excludes the impact of outstanding performance share awards as the conditions necessary for their issuance have not been satisfied as of the end of the reporting period.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

NOTE 3 EQUITY

*Common stock*

The changes in number of common stock shares issued, held in treasury and outstanding are as follows for the periods presented:

---

| | | | |
|:---|:---|:---|:---|
| | Issued | Held In Treasury | Outstanding |
| Balance, December 31, 2025 | 85310598 | 19846934 | 65463664 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock acquired |  | 225638 | (225638) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity based plans |  | (271208) | 271208 |
| Balance, March 31, 2026 | 85310598 | 19801364 | 65509234 |

---

---

| | | | |
|:---|:---|:---|:---|
| | Issued | Held In Treasury | Outstanding |
| Balance, December 31, 2024 | 85310598 | 19438336 | 65872262 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock acquired |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity based plans |  | (213499) | 213499 |
| Balance, March 31, 2025 | 85310598 | 19224837 | 66085761 |

---

*Common Stock Held in Treasury*

Common stock held in treasury is accounted for at average cost. Gains resulting from the reissuance of common stock held in treasury are credited to additional paid-in capital. Losses resulting from the reissuance of common stock held in treasury are charged first to additional paid-in capital to the extent that the Company has previously recorded gains on treasury share transactions, then to retained earnings.

On January 29, 2026, the board of directors authorized a share repurchase program for up to $500 million of RGA's outstanding common stock. The authorization was effective immediately and does not have an expiration date. During the three months ended March 31, 2026, the Company repurchased 225,638 shares of common stock under this program. As of March 31, 2026, the aggregate amount remaining under the Company's share repurchase authorization was approximately $450 million.

Repurchases will be made in accordance with applicable securities laws, through market transactions, block trades, privately negotiated transactions or other means, or a combination of these methods, with the timing and number of shares repurchased dependent on a variety of factors, including share price, corporate and regulatory requirements, and market and business conditions. Repurchases may be commenced or suspended from time to time without prior notice.

*Noncontrolling Interest*

In 2022, Papara Financing LLC ("Papara"), a subsidiary of RGA Reinsurance Company, issued nonconvertible preferred interests to an unaffiliated third party. The membership interests in Papara consist of common interests, which are held by RGA Reinsurance Company, and preferred interests. The preferred interests total $90 million. The preferred interests are included in noncontrolling interest, and net income attributable to noncontrolling interest was $1 million for the three months ended March 31, 2026.

*Accumulated Other Comprehensive Income (Loss)*

The balance of and changes in each component of accumulated other comprehensive income (loss) ("AOCI") for the three months ended March 31, 2026 and 2025 are as follows (dollars in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax |
| | Foreign Currency Translation Adjustments | Net Unrealized Investment Gains <br>(Losses) <sup>(1)</sup> | Pension and <br>Postretirement <br>Benefits | Effect of Updating Discount Rates on Future Policy Benefits | Instrument-Specific Credit Risk for Market Risk Benefits | Total |
| Balance, December 31, 2025 | $121 | $(4807) | $(6) | $7372 | $2 | $2682 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | (28) | (2251) |  | 1664 | 3 | (612) |
| &nbsp;&nbsp;&nbsp;Amounts reclassified to (from) AOCI |  | 143 | 2 |  |  | 145 |
| &nbsp;&nbsp;&nbsp;Deferred income tax benefit (expense) | 8 | 449 | (1) | (356) | (1) | 99 |
| Balance, March 31, 2026 | $101 | $(6466) | $(5) | $8680 | $4 | $2314 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax | Accumulated Other Comprehensive Income (Loss), Net of Income Tax |
| | Foreign Currency Translation Adjustments | Net Unrealized Investment Gains <br>(Losses) <sup>(1)</sup> | Pension and <br>Postretirement <br>Benefits | Effect of Updating Discount Rates on Future Policy Benefits | Instrument-Specific Credit Risk for Market Risk Benefits | Total |
| Balance, December 31, 2024 | $(19) | $(4526) | $(20) | $5412 | $2 | $849 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | (4) | 27 | 1 | 367 | 5 | 396 |
| &nbsp;&nbsp;&nbsp;Amounts reclassified to (from) AOCI |  | 76 |  |  |  | 76 |
| &nbsp;&nbsp;&nbsp;Deferred income tax benefit (expense) | 15 | (20) |  | (77) | (1) | (83) |
| Balance, March 31, 2025 | $(8) | $(4443) | $(19) | $5702 | $6 | $1238 |

---

(1)Includes cash flow hedges of $(819) and $(748) as of March 31, 2026 and December 31, 2025, respectively, and $(485) and $(495) as of March 31, 2025 and December 31, 2024, respectively. See Note 11 – "Derivative Instruments" for additional information on cash flow hedges.

The following table presents the amounts of AOCI reclassifications for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| | Amount Reclassified from AOCI | Amount Reclassified from AOCI | |
| | Three months ended March 31, | Three months ended March 31, | Affected Line Item in <br>Statements of Income |
| Details about AOCI Components | 2026 | 2025 | Affected Line Item in <br>Statements of Income |
| Net unrealized investment gains (losses): |  |  |  |
| Net unrealized gains (losses) on available-for-sale securities | $(126) | $(60) | Investment related gains (losses), net |
| Cash flow hedges – Interest rate | 1 | 1 | (1) |
| Cash flow hedges – Foreign currency | (18) | (17) | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | (143) | (76) |  |
| Provision for income taxes | 39 | 13 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net unrealized gains (losses), net of tax | $(104) | $(63) |  |
| Amortization of defined benefit plan items: |  |  |  |
| Prior service cost (credit) | $— | $— |  |
| Actuarial gains (losses) | (2) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | (2) |  |  |
| Provision for income taxes |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of defined benefit plans, net of tax | $(2) | $— |  |
| Total reclassifications for the period | $(106) | $(63) |  |

---

(1)See Note 11 for information on cash flow hedges.

*Long-Term Incentive Compensation*

Equity compensation expense was $21 million and $7 million for the three months ended March 31, 2026 and 2025, respectively. In the first quarter of 2026, the Company granted 132,831 stock appreciation rights at $200.50 weighted average exercise price per share, 137,999 performance shares and 93,299 restricted stock units to employees. As of March 31, 2026, 1,184,100 share awards at a weighted average strike price per share of $132.25 were vested and exercisable with a remaining weighted average exercise period of 4.5 years. As of March 31, 2026, the total compensation cost of non-vested awards not yet recognized in the financial statements was $87 million. It is estimated that these costs will vest over a weighted average period of 1.24 years.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

NOTE 4 FUTURE POLICY BENEFITS

It is the Company's policy to complete its annual assumptions review during the third quarter of each year. However, each period, the Company reviews actual and anticipated experience compared to the assumptions used to compute the liability for future policy benefits and will update those assumptions in the period that indicates an assumption update is necessary.

**Traditional Business**

The following tables provide the balances of and changes in the Company's liability for future policy benefits for long-duration reinsurance contracts for its Traditional business, which primarily consists of individual life, group life and critical illness reinsurance for the three months ended March 31, 2026 and 2025 (dollars in millions). During the first quarter, the Company reclassified amounts previously presented in the "Derecognition" line related to recaptures and treaty amendments that resulted in the termination of an existing treaty and the reissuance under a new treaty to the "Effects of actual variances from expected experience" line in the rollforwards below. Prior periods have been recast to conform with the current presentation. This change in presentation did not affect the consolidated balance sheet, income statement or cash flows previously reported.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional |
| **Present Value of Expected Net Premiums** |  |  |  |  |
| Beginning of year balance at original discount rate | $79828 | $23247 | $18353 | $50206 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | (449) | (52) | 322 | 15 |
| Adjusted balance, beginning of year | 79379 | 23195 | 18675 | 50221 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 1371 | 109 | 957 | 2182 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 902 | 201 | 165 | 362 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net premiums collected <sup>(3)</sup> | (1314) | (253) | (531) | (640) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | (314) | (359) | (604) |
| Ending balance at original discount rate | 80338 | 22938 | 18907 | 51521 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (9217) | (4901) | (3560) | (13256) |
| Balance, end of period | $71121 | $18037 | $15347 | $38265 |
| **Present Value of Expected Future Policy Benefits** |  |  |  |  |
| Beginning of year balance at original discount rate | $94710 | $26896 | $20363 | $55572 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | (455) | (56) | 312 | 23 |
| Adjusted balance, beginning of year | 94255 | 26840 | 20675 | 55595 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 1371 | 109 | 967 | 2171 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 1082 | 257 | 177 | 410 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit payments <sup>(4)</sup> | (1369) | (262) | (496) | (529) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | (365) | (394) | (632) |
| Ending balance at original discount rate | 95339 | 26579 | 20929 | 57015 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (11719) | (4461) | (4195) | (15811) |
| Balance, end of period | $83620 | $22118 | $16734 | $41204 |
| Liability for future policy benefits | $12499 | $4081 | $1387 | $2939 |
| Less: reinsurance recoverable | (813) | (248) | (14) | (70) |
| Net liability for future policy benefits | $11686 | $3833 | $1373 | $2869 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| Weighted average duration of the liability (in years) | 11 | 14 | 8 | 15 |
| Weighted average interest accretion rate | 4.6% | 3.7% | 3.5% | 2.9% |
| Weighted average current discount rate | 5.7% | 5.1% | 6.2% | 4.9% |

---

(1)Issuances: The present value, using the original discount rate, of the expected net premiums or the expected future policy benefits related to new insurance contracts that became effective during the current period and new policies assumed on existing contracts.

(2)Interest accrual: The interest earned on the beginning present value of either the expected net premiums or the expected future policy benefits using the original interest rate.

(3)Net premiums collected: The portion of gross premiums collected from the ceding company that is used to fund expected benefit payments.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

(4)Benefit payments: The release of the present value, using the original discount rate, of the expected future policy benefits due to death, lapse/withdrawal and other benefit payments based on current assumptions.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional |
| **Present Value of Expected Net Premiums** |  |  |  |  |
| Beginning of year balance at original discount rate | $77881 | $20928 | $15911 | $44801 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | (300) | 23 | 199 | (195) |
| Adjusted balance, beginning of year | 77581 | 20951 | 16110 | 44606 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 3467 | 100 | 438 | 1327 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 887 | 179 | 140 | 304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net premiums collected <sup>(3)</sup> | (3049) | (231) | (454) | (594) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | 1 | (6) | 517 | 135 |
| Ending balance at original discount rate | 78887 | 20993 | 16751 | 45778 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (8126) | (3839) | (3099) | (12641) |
| Balance, end of period | $70761 | $17154 | $13652 | $33137 |
| **Present Value of Expected Future Policy Benefits** |  |  |  |  |
| Beginning of year balance at original discount rate | $90711 | $24309 | $17365 | $49712 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | (349) | 23 | 190 | (211) |
| Adjusted balance, beginning of year | 90362 | 24332 | 17555 | 49501 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 3467 | 100 | 438 | 1327 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 1061 | 231 | 150 | 347 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit payments <sup>(4)</sup> | (1332) | (261) | (401) | (524) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | 2 | (5) | 568 | 152 |
| Ending balance at original discount rate | 93560 | 24397 | 18310 | 50803 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (10348) | (3093) | (3481) | (14999) |
| Balance, end of period | $83212 | $21304 | $14829 | $35804 |
| Liability for future policy benefits | $12451 | $4150 | $1177 | $2667 |
| Less: reinsurance recoverable | (800) | (259) | (19) | (75) |
| Net liability for future policy benefits | $11651 | $3891 | $1158 | $2592 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| Weighted average duration of the liability (in years) | 11 | 14 | 8 | 15 |
| Weighted average interest accretion rate | 4.6% | 3.7% | 3.4% | 2.8% |
| Weighted average current discount rate | 5.6% | 4.7% | 5.8% | 4.7% |

---

(1)Issuances: The present value, using the original discount rate, of the expected net premiums or the expected future policy benefits related to new insurance contracts that became effective during the current period and new policies assumed on existing contracts.

(2)Interest accrual: The interest earned on the beginning present value of either the expected net premiums or the expected future policy benefits using the original interest rate.

(3)Net premiums collected: The portion of gross premiums collected from the ceding company that is used to fund expected benefit payments.

(4)Benefit payments: The release of the present value, using the original discount rate, of the expected future policy benefits due to death, lapse/withdrawal and other benefit payments based on current assumptions.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The Company's Traditional business actual-to-expected variances, including the effects of treaty recaptures, and the effects of changes in cash flow and discount rate assumptions for the three months ended March 31, 2026 and 2025 are summarized in the tables below:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** |  |  |  |  |
| Segment | Liability for future policy benefits at original discount rate | Changes in cash flow assumptions | Actual-to-expected variance | Impact of updating discount rate recognized in OCI |  |  |  |  |
| U.S. and Latin America *–* Traditional | $15.0 billion |  | $(6) million | $(305) million |  |  |  |  |
| U.S. and Latin America *–* Traditional | $15.0 billion |  | $(6) million | $(305) million | Canada *–* Traditional  | $3.6 billion | $(4) million | $(54) million |
| Europe, Middle East and Africa *–* Traditional | $2.0 billion |  | $(10) million | $(70) million | Canada *–* Traditional  | $3.6 billion | $(4) million | $(54) million |
| Europe, Middle East and Africa *–* Traditional | $2.0 billion |  | $(10) million | $(70) million | Asia Pacific *–* Traditional | $5.5 billion | $8 million | $(68) million |
| Asia Pacific *–* Traditional | $5.5 billion |  | $8 million | $(68) million |  |  |  |  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** |  |  |  |  |
| Segment | Liability for future policy benefits at original discount rate | Change in cash flow assumptions | Actual-to-expected variance | Impact of updating discount rate recognized in OCI |  |  |  |  |
| U.S. and Latin America *–* Traditional | $14.7 billion |  | $(49) million | $70 million |  |  |  |  |
| U.S. and Latin America *–* Traditional | $14.7 billion |  | $(49) million | $70 million | Canada *–* Traditional | $3.4 billion |  | $27 million |
| Europe, Middle East and Africa *–* Traditional | $1.6 billion |  | $(9) million | $(48) million | Canada *–* Traditional | $3.4 billion |  | $27 million |
| Europe, Middle East and Africa *–* Traditional | $1.6 billion |  | $(9) million | $(48) million | Asia Pacific *–* Traditional | $5.0 billion | $(16) million | $(50) million |
| Asia Pacific *–* Traditional | $5.0 billion |  | $(16) million | $(50) million |  |  |  |  |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**Financial Solutions Business**

The following tables provide the balances of and changes in the Company's liability for future policy benefits, including the deferred profit liability related to the longevity business, for its Financial Solutions business, which primarily consists of longevity reinsurance, asset-intensive products (primarily annuities), financial reinsurance and pension risk transfer transactions, for the three months ended March 31, 2026 and 2025 (dollars in millions). During the first quarter the Company reclassified amounts previously presented in the "Derecognition" line related to recaptures and treaty amendments that resulted in the termination of an existing treaty and the reissuance under a new treaty to the "Effects of actual variances from expected experience" line in the rollforwards below. Prior periods have been recast to conform with the current presentation. This change in presentation did not affect the consolidated balance sheet, income statement or cash flows previously reported.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions |
| **Present Value of Expected Net Premiums** |  |  |  |  |
| Beginning of year balance at original discount rate | $2627 | $3518 | $87259 | $2106 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | (12) | 2 | 62 | 15 |
| Adjusted balance, beginning of year | 2615 | 3520 | 87321 | 2121 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 528 |  | 5662 | 6553 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 26 | 32 | 871 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net premiums collected <sup>(3)</sup> | (567) | (90) | (1765) | (7015) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | (48) | (1684) | (19) |
| Ending balance at original discount rate | 2602 | 3414 | 90405 | 1651 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (219) | (231) | (13781) | (836) |
| Balance, end of period | $2383 | $3183 | $76624 | $815 |
| **Present Value of Expected Future Policy Benefits** |  |  |  |  |
| Beginning of year balance at original discount rate | $13388 | $8160 | $98153 | $16870 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience |  | 1 | 51 | 14 |
| Adjusted balance, beginning of year | 13388 | 8161 | 98204 | 16884 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 534 |  | 5662 | 6553 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 160 | 88 | 976 | 131 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit payments <sup>(4)</sup> | (330) | (133) | (1995) | (231) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | (110) | (1873) | (237) |
| Ending balance at original discount rate | 13752 | 8006 | 100974 | 23100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (583) | (294) | (15093) | (4993) |
| Balance, end of period | $13169 | $7712 | $85881 | $18107 |
| Cumulative amount of fair value hedging adjustments | $(3) | $— | $— | $— |
| Liability for future policy benefits | $10783 | $4529 | $9257 | $17292 |
| Less: reinsurance recoverable | (2984) |  |  |  |
| Net liability for future policy benefits | $7799 | $4529 | $9257 | $17292 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| Weighted average duration of the liability (in years) | 9 | 12 | 9 | 12 |
| Weighted average interest accretion rate | 4.4% | 4.1% | 4.0% | 2.5% |
| Weighted average current discount rate | 5.5% | 5.0% | 5.9% | 5.0% |

---

(1)Issuances: The present value, using the original discount rate, of the expected net premiums or the expected future policy benefits related to new insurance contracts that became effective during the current period and new policies assumed on existing contracts.

(2)Interest accrual: The interest earned on the beginning present value of either the expected net premiums or the expected future policy benefits using the original interest rate.

(3)Net premiums collected: The portion of gross premiums collected from the ceding company that is used to fund expected benefit payments.

(4)Benefit payments: The release of the present value, using the original discount rate, of the expected future policy benefits due to death, lapse/withdrawal and other benefit payments based on current assumptions.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions |
| **Present Value of Expected Net Premiums** |  |  |  |  |
| Beginning of year balance at original discount rate | $1346 | $3614 | $71360 | $2758 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience |  | (7) | (261) | 3 |
| Adjusted balance, beginning of year | 1346 | 3607 | 71099 | 2761 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 2113 |  | 1347 | 1731 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 10 | 33 | 622 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net premiums collected <sup>(3)</sup> | (2178) | (92) | (1354) | (2085) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | (2) | 2485 | 146 |
| Ending balance at original discount rate | 1291 | 3546 | 74199 | 2564 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (231) | (149) | (10155) | (394) |
| Balance, end of period | $1060 | $3397 | $64044 | $2170 |
| **Present Value of Expected Future Policy Benefits** |  |  |  |  |
| Beginning of year balance at original discount rate | $9489 | $7934 | $78290 | $14626 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | (1) | (7) | (264) |  |
| Adjusted balance, beginning of year | 9488 | 7927 | 78026 | 14626 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances <sup>(1)</sup> | 2113 |  | 1347 | 1731 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual <sup>(2)</sup> | 133 | 86 | 684 | 70 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit payments <sup>(4)</sup> | (259) | (110) | (1472) | (150) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | (2) | 2712 | 638 |
| Ending balance at original discount rate | 11475 | 7901 | 81297 | 16915 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in discount rate assumptions | (535) | 92 | (11177) | (2345) |
| Balance, end of period | $10940 | $7993 | $70120 | $14570 |
| Cumulative amount of fair value hedging adjustments | $6 | $— | $— | $— |
| Liability for future policy benefits | $9886 | $4596 | $6076 | $12400 |
| Less: reinsurance recoverable | (1370) |  |  |  |
| Net liability for future policy benefits | $8516 | $4596 | $6076 | $12400 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| Weighted average duration of the liability (in years) | 9 | 13 | 9 | 15 |
| Weighted average interest accretion rate | 4.1% | 4.1% | 3.5% | 1.7% |
| Weighted average current discount rate | 5.5% | 4.6% | 5.4% | 3.3% |

---

(1)Issuances: The present value, using the original discount rate, of the expected net premiums or the expected future policy benefits related to new insurance contracts that became effective during the current period and new policies assumed on existing contracts.

(2)Interest accrual: The interest earned on the beginning present value of either the expected net premiums or the expected future policy benefits using the original interest rate.

(3)Net premiums collected: The portion of gross premiums collected from the ceding company that is used to fund expected benefit payments.

(4)Benefit payments: The release of the present value, using the original discount rate, of the expected future policy benefits due to death, lapse/withdrawal and other benefit payments based on current assumptions.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The Company's Financial Solutions business actual-to-expected variances, including the effects of model updates and treaty recaptures, and the effects of changes in cash flow and discount rate assumptions for the three months ended March 31, 2026 and 2025 are summarized in the tables below:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** |  |  |  |  |
| Segment | Liability for future policy benefits at original discount rate | Changes in cash flow assumptions | Actual-to-expected variance | Impact of updating discount rate recognized in OCI |  |  |  |  |
| U.S. and Latin America *–* Financial Solutions | $11.2 billion |  | $12 million | $(166) million |  |  |  |  |
| U.S. and Latin America *–* Financial Solutions | $11.2 billion |  | $12 million | $(166) million | Canada *–* Financial Solutions | $4.6 billion | $(1) million | $(35) million |
| Europe, Middle East and Africa *–* Financial Solutions | $10.6 billion |  | $(11) million | $(421) million | Canada *–* Financial Solutions | $4.6 billion | $(1) million | $(35) million |
| Europe, Middle East and Africa *–* Financial Solutions | $10.6 billion |  | $(11) million | $(421) million | Asia Pacific *–* Financial Solutions | $21.4 billion | $(1) million | $(619) million |
| Asia Pacific *–* Financial Solutions | $21.4 billion |  | $(1) million | $(619) million |  |  |  |  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** |  |  |  |  |
| Segment | Liability for future policy benefits at original discount rate | Changes in cash flow assumptions | Actual-to-expected variance | Impact of updating discount rate recognized in OCI |  |  |  |  |
| U.S. and Latin America *–* Financial Solutions | $10.2 billion |  | $(1) million | $93 million |  |  |  |  |
| U.S. and Latin America *–* Financial Solutions | $10.2 billion |  | $(1) million | $93 million | Canada *–* Financial Solutions | $4.4 billion |  | $49 million |
| Europe, Middle East and Africa *–* Financial Solutions | $7.1 billion |  | $(3) million | $(127) million | Canada *–* Financial Solutions | $4.4 billion |  | $49 million |
| Europe, Middle East and Africa *–* Financial Solutions | $7.1 billion |  | $(3) million | $(127) million | Asia Pacific *–* Financial Solutions | $14.4 billion | $(3) million | $(365) million |
| Asia Pacific *–* Financial Solutions | $14.4 billion |  | $(3) million | $(365) million |  |  |  |  |

---

**Reconciliation and Other Disclosures** 

The reconciliation of the rollforward of the liability for future policy benefits to the condensed consolidated balance sheets as of March 31, 2026, and 2025 are as follows (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Liability for future policy benefits included in the rollforwards: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Traditional: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | $12499 | $12451 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canada | 4081 | 4150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 1387 | 1177 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 2939 | 2667 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial Solutions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | 10783 | 9886 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canada | 4529 | 4596 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 9257 | 6076 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 17292 | 12400 |
| Other long-duration contracts | 265 | 136 |
| Claims liability and incurred but not reported claims | 6420 | 5367 |
| Additional liability | 442 | 101 |
| Unearned revenue liability | 793 | 829 |
| Cost of reinsurance liability | 1621 |  |
| Total liability for future policy benefits | $72308 | $59836 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The amount of undiscounted and discounted expected future gross premiums and expected future benefit payments for the liability for future policy benefits included in the rollforwards as of March 31, 2026, and 2025 is as follows (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2026 | 2025 | 2025 |
| | Undiscounted | Discounted | Undiscounted | Discounted |
| **Expected future gross premiums** |  |  |  |  |
| Traditional: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | $195188 | $85394 | $183915 | $84218 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canada | 57804 | 22345 | 52094 | 21326 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 32244 | 17060 | 28701 | 15240 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 127336 | 48532 | 104940 | 42040 |
| Financial Solutions: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | 5240 | 3258 | 2648 | 1666 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canada | 5344 | 3506 | 5689 | 3768 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 165527 | 77830 | 129865 | 65091 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 5957 | 3776 | 5292 | 3707 |
| **Expected future benefit payments** |  |  |  |  |
| Traditional: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | $201880 | $83620 | $196448 | $83212 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canada | 58661 | 22118 | 53586 | 21304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 32795 | 16734 | 28718 | 14829 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 121664 | 41204 | 101929 | 35804 |
| Financial Solutions: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | 26202 | 13169 | 22679 | 10940 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canada | 17277 | 7712 | 17252 | 7993 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 179589 | 85881 | 139460 | 70120 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 43292 | 18107 | 27778 | 14570 |

---

The amount of gross premiums and interest expense recognized in the condensed consolidated statements of income for the liability for future policy benefits included in the rollforwards for the three months ended March 31, 2026 and 2025 are as follows (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Gross Premiums | Gross Premiums | Interest Expense | Interest Expense |
| | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2025 | 2026 | 2025 |
| Traditional: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | $1584 | $1589 | $180 | $174 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canada | 282 | 264 | 56 | 52 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 492 | 444 | 12 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 807 | 738 | 48 | 43 |
| Financial Solutions: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | 189 | 105 | $134 | $123 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canada | 45 | 52 | 56 | 53 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 347 | 255 | 105 | 62 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 149 | 111 | 120 | 59 |
| Total | $3895 | $3558 | $711 | $576 |

---

During the three months ended March 31, 2026 and 2025, no material charges were incurred resulting from net premiums exceeding gross premiums.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

NOTE 5 POLICYHOLDER ACCOUNT BALANCES

**Policyholder Account Balances**

The following tables provide the balances of and changes in the Company's liability for its policyholder account balances, reflected in interest-sensitive contract liabilities, for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | U.S. and Latin America – Traditional | U.S. and Latin America – Financial Solutions | Asia Pacific – Financial Solutions |
| Balance, beginning of year | $3318 | $26186 | $7804 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deposits | 93 | 630 | 1453 |
| &nbsp;&nbsp;&nbsp;&nbsp;Policy charges | (81) | (198) | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Surrenders and withdrawals | (27) | (416) | (182) |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit payments | (101) | (167) | (77) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest credited | 39 | 264 | 93 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  |  | 21 |
| Balance, end of period | $3241 | $26299 | $9103 |
| Less: reinsurance recoverable |  | (2573) |  |
| Balance, end of period, after reinsurance | $3241 | $23726 | $9103 |
| Weighted average crediting rate | 3.1% | 3.6% | 4.5% |
| Net amount at risk <sup>(1)</sup> | $27485 | $131090 | $— |
| Cash surrender value | $3234 | $25993 | $8634 |

---

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | U.S. and Latin America – Traditional | U.S. and Latin America – Financial Solutions | Asia Pacific – Financial Solutions |
| Balance, beginning of year | $3273 | $16432 | $4285 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deposits | 105 | 877 | 390 |
| &nbsp;&nbsp;&nbsp;&nbsp;Policy charges | (84) | (20) | (5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Surrenders and withdrawals | (25) | (418) | (73) |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit payments | (18) | (123) | (75) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest credited | 45 | 144 | 45 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  |  | 5 |
| Balance, end of period | $3296 | $16892 | $4572 |
| Less: reinsurance recoverable |  | (2746) |  |
| Balance, end of period, after reinsurance | $3296 | $14146 | $4572 |
| Weighted average crediting rate | 3.1% | 3.6% | 4.0% |
| Net amount at risk <sup>(1)</sup> | $25951 | $6422 | $— |
| Cash surrender value | $3280 | $16680 | $4179 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Net amount at risk is defined as the guaranteed amount less the account value as of the balance sheet date. The balance represents the amount of the claim the Company would incur if death claims were filed on all contracts on the balance sheet date.

Information regarding the Company's policyholder account balances as of March 31, 2026 and 2025 are as follows (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Policyholder account balances included in the rollforwards: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Traditional: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | $3241 | $3296 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial Solutions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | 26299 | 16892 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 9103 | 4572 |
| Other policyholder account balances |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America – Financial Solutions | 36 | 48 |
| Total policyholder account balances | $38679 | $24808 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The balance of account values by range of guaranteed minimum crediting rates and the related range of difference, in basis points, between rates credited to policyholders and the respective guaranteed minimums as of March 31, 2026 and 2025 is as follows (dollars in millions):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2026 |
| | Range of Guaranteed Minimum Crediting Rate | At Guaranteed Minimum | 1 Basis Point – 50 Basis Points Above | 51 Basis Points – 100 Basis Points Above | 101 Basis Points – 150 Basis Points Above | Greater Than 150 Basis Points Above | Total |
| U.S. and Latin America – Traditional | Less than 1.00% | $788 | $— | $— | $— | $— | $788 |
|  | 1.00 – 1.99% | 60 | 1 | 8 |  |  | 69 |
|  | 2.00 – 2.99% | 111 |  |  | 1 |  | 112 |
|  | 3.00 – 3.99% | 501 | 7 | 112 |  |  | 620 |
|  | 4.00% and Greater | 692 |  | 45 | 915 |  | 1652 |
|  | Total | $2152 | $8 | $165 | $916 | $— | $3241 |
| U.S. and Latin America – Financial Solutions | Less than 1.00% | $110 | $— | $— | $— | $814 | $924 |
|  | 1.00 – 1.99% | 964 | 18 | 209 | 154 | 137 | 1482 |
|  | 2.00 – 2.99% | 2836 | 601 | 389 | 728 | 445 | 4999 |
|  | 3.00 – 3.99% | 3965 | 589 | 120 | 3 | 3 | 4680 |
|  | 4.00% and Greater | 14188 | 26 |  |  |  | 14214 |
|  | Total | $22063 | $1234 | $718 | $885 | $1399 | $26299 |
| Asia Pacific – Financial Solutions | Less than 1.00% | $272 | $— | $— | $— | $— | $272 |
|  | 1.00 – 1.99% | 420 |  |  |  |  | 420 |
|  | 2.00 – 2.99% | 716 |  |  |  |  | 716 |
|  | 3.00 – 3.99% | 999 |  |  |  |  | 999 |
|  | 4.00% and Greater | 6696 |  |  |  |  | 6696 |
|  | Total | $9103 | $— | $— | $— | $— | $9103 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | March 31, 2025 | March 31, 2025 | March 31, 2025 | March 31, 2025 | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| | Range of Guaranteed Minimum Crediting Rate | At Guaranteed Minimum | 1 Basis Point – 50 Basis Points Above | 51 Basis Points – 100 Basis Points Above | 101 Basis Points – 150 Basis Points Above | Greater Than 150 Basis Points Above | Total |
| U.S. and Latin America – Traditional | Less than 1.00% | $710 | $— | $— | $— | $— | $710 |
|  | 1.00 – 1.99% | 56 | 2 | 8 |  |  | 66 |
|  | 2.00 – 2.99% | 108 |  |  | 1 |  | 109 |
|  | 3.00 – 3.99% | 491 | 7 | 115 |  |  | 613 |
|  | 4.00% and Greater | 721 | 50 | 973 | 54 |  | 1798 |
|  | Total | $2086 | $59 | $1096 | $55 | $— | $3296 |
| U.S. and Latin America – Financial Solutions | Less than 1.00% | $— | $— | $— | $— | $— | $— |
|  | 1.00 – 1.99% | 1203 | 12 | 8 | 30 | 26 | 1279 |
|  | 2.00 – 2.99% | 1180 | 9 | 23 | 540 | 140 | 1892 |
|  | 3.00 – 3.99% | 3423 | 212 | 164 |  |  | 3799 |
|  | 4.00% and Greater | 9892 | 30 |  |  |  | 9922 |
|  | Total | $15698 | $263 | $195 | $570 | $166 | $16892 |
| Asia Pacific – Financial Solutions | Less than 1.00% | $262 | $— | $— | $— | $— | $262 |
|  | 1.00 – 1.99% | 442 |  |  |  |  | 442 |
|  | 2.00 – 2.99% | 479 |  |  |  |  | 479 |
|  | 3.00 – 3.99% | 984 |  |  |  |  | 984 |
|  | 4.00% and Greater | 2405 |  |  |  |  | 2405 |
|  | Total | $4572 | $— | $— | $— | $— | $4572 |

---

NOTE 6 UNPAID CLAIMS AND CLAIM EXPENSE – SHORT-DURATION CONTRACTS

*Rollforward of Claims and Claim Adjustment Expenses*

The liability for unpaid claims for short-duration contracts is reported in other policy claims and benefits. Activity associated with unpaid claims is summarized below (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Balance, beginning of year | $3011 | $2693 |
| Less: reinsurance recoverable | (43) | (53) |
| &nbsp;&nbsp;&nbsp;Net balance, beginning of year | 2968 | 2640 |
| Incurred: |  |  |
| &nbsp;&nbsp;&nbsp;Current year | 366 | 505 |
| &nbsp;&nbsp;&nbsp;Prior years | (7) | (13) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total incurred | 359 | 492 |
| Payments: |  |  |
| &nbsp;&nbsp;&nbsp;Current year | (28) | (23) |
| &nbsp;&nbsp;&nbsp;Prior years | (308) | (307) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total payments | (336) | (330) |
| Other: |  |  |
| &nbsp;&nbsp;&nbsp;Interest accretion | 11 | 9 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation | (1) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other | 10 | 10 |
| Net balance, end of period | 3001 | 2812 |
| Plus: reinsurance recoverable | 50 | 58 |
| &nbsp;&nbsp;Balance, end of period | $3051 | $2870 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

Incurred claims associated with prior periods are primarily due to the development of claims for prior years being different than anticipated when the liabilities for unpaid claims were originally estimated. These trends have been considered in establishing the current year's liability for unpaid claims.

NOTE 7 MARKET RISK BENEFITS

The following table provides the balances of and changes in the Company's market risk benefits for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | |
|:---|:---|:---|
| | U.S. and Latin America – Financial Solutions | U.S. and Latin America – Financial Solutions |
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Balance, beginning of year | $215 | $206 |
| Balance, beginning of year, before effect of changes in the instrument-specific credit risk | 217 | 209 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accrual | 1 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Attributed fees collected | 6 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit payments |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in interest rates |  | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in equity markets | 3 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in volatility | 4 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other market impacts | 2 | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Actual policyholder behavior different from expected behavior | 5 | 5 |
| Balance, end of period, before effect of changes in the instrument-specific credit risk | 238 | 238 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in the instrument-specific credit risk | (4) | (8) |
| Balance, end of period | 234 | 230 |
| Less: reinsurance recoverable |  |  |
| Balance, end of period, after reinsurance | $234 | $230 |
| Net amount at risk | $1180 | $1264 |
| Weighted average attained age of contract holders (in years) | 72 | 72 |

---

The reconciliation of the rollforward for market risk benefits to the condensed consolidated balance sheets as of March 31, 2026 and 2025 are as follows (dollars in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | March 31, | March 31, | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2026 | 2026 | 2025 | 2025 | 2025 |
| | Asset <sup>(1)</sup> | Liability | Net | Asset <sup>(1)</sup> | Liability | Net |
| U.S. and Latin America – Financial Solutions | $15 | $249 | $(234) | $13 | $243 | $(230) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total market risk benefits | $15 | $249 | $(234) | $13 | $243 | $(230) |

---

(1)Included in Other assets.

*Fair Value Measurement*

See Note 12 – "Fair Value of Assets and Liabilities" for information about fair value measurement of assets and liabilities, except for market risk benefits.

Market risk benefits are classified within Level 3 on the fair value hierarchy. The fair value of market risk benefits is monitored through the use of attribution reports to quantify the effect of underlying sources of fair value change, including capital market inputs based on policyholder account values, interest rates and short-term and long-term implied volatility from period to period.

During the three months ended March 31, 2026 and 2025, there were no material changes made to the inputs in the market risk benefits calculations, and nonfinancial assumptions were unchanged.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

NOTE 8 DEFERRED POLICY ACQUISITION COSTS AND OTHER

Deferred policy acquisition costs and other on the condensed consolidated balance sheets include deferred policy acquisition costs and cost of reinsurance assets.

The following tables provide the balances of and changes in deferred policy acquisition costs for the Company's Traditional business for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional |
| Balance, beginning of year | $3068 | $166 | $478 | $1285 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitalization | 85 | 4 | 14 | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization expense | (56) | (3) | (17) | (17) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | (3) | (9) | (4) |
| Balance, end of period | $3097 | $164 | $466 | $1293 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional |
| Balance, beginning of year | $2986 | $157 | $354 | $1178 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitalization | 72 | 4 | 31 | 34 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization expense | (56) | (3) | (12) | (16) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  |  | 14 | 3 |
| Balance, end of period | $3002 | $158 | $387 | $1199 |

---

The following tables provide the balances of and changes in deferred policy acquisition costs for the Company's Financial Solutions business for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions |
| Balance, beginning of year | $508 | $21 | $— | $525 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitalization | 11 |  |  | 52 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization expense | (15) |  |  | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  |  |  | 1 |
| Balance, end of period | $504 | $21 | $— | $558 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions |
| Balance, beginning of year | $506 | $20 | $— | $324 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitalization | 21 |  |  | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization expense | (10) |  |  | (13) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  |  |  |  |
| Balance, end of period | $517 | $20 | $— | $349 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The reconciliation of deferred policy acquisition costs included in the rollforwards to deferred policy acquisitions costs and other on the condensed consolidated balance sheets as of March 31, 2026 and 2025 are as follows (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Deferred policy acquisition costs included in the rollforwards: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Traditional: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | $3097 | $3002 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canada | 164 | 158 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 466 | 387 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 1293 | 1199 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial Solutions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. and Latin America | 504 | 517 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canada | 21 | 20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific | 558 | 349 |
| Other deferred policy acquisition costs: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate and Other | 13 | 17 |
| Total deferred policy acquisition costs | 6116 | 5649 |
| Cost of reinsurance asset | $75 |  |
| Total deferred policy acquisition costs and other | $6191 | $5649 |

---

NOTE 9 REINSURANCE

*Ceded Reinsurance*

In the normal course of business, the Company seeks to limit its exposure to loss on any single insured and to recover a portion of benefits paid by ceding reinsurance to other insurance or reinsurance companies under excess coverage and coinsurance contracts. During the third quarter of 2024, the Company increased its per life retention limit from $8 million to $30 million effective January 1, 2025, and began notifying the Company's retrocessionaires of the increased per life retention limit and the Company's intention to recapture the risk ceded to the retrocessionaire in the future. The increased retention limit and updated recapture assumption resulted in a future policy benefits remeasurement loss of $136 million recognized in the third quarter of 2024.

Retrocession reinsurance treaties do not relieve the Company from its obligations to direct writing companies. Failure of retrocessionaires to honor their obligations could result in losses to the Company. Consequently, allowances would be established for amounts deemed uncollectible. The Company regularly evaluates the financial condition of the insurance companies from which it assumes and to which it cedes reinsurance. At March 31, 2026 and December 31, 2025, no allowances were deemed necessary.

Retrocessions are arranged through the Company's retrocession pools for amounts in excess of the Company's retention limit. As of March 31, 2026, all rated retrocession pool participants followed by the A.M. Best Company were rated "B++(Good)" or better. The Company verifies retrocession pool participants' ratings on a quarterly basis. For a majority of the retrocessionaires that were not rated, security in the form of letters of credit or trust assets have been posted. In addition, the Company performs annual financial reviews of its retrocessionaires to evaluate financial stability and performance.

During the fourth quarter of 2023, Ruby Reinsurance Company ("Ruby Re"), a Missouri-domiciled life reinsurance company to reinsure U.S. asset-intensive business, was launched with the Company as a sponsor. The Company, which is not an investor in Ruby Re, does not consolidate the entity. As of March 31, 2026, the Company has a ceded reinsurance recoverable from Ruby Re of approximately $4.1 billion.

Excluding amounts retroceded to Ruby Re, three major reinsurance companies account for approximately 33% of reinsurance ceded receivables and other as of March 31, 2026.

As of March 31, 2026 and December 31, 2025, $16 million and $6 million of claims recoverable were in excess of 90 days past due, respectively. Also included in reinsurance ceded receivables and other is a deposit asset on reinsurance of $2.6 billion as of March 31, 2026 and December 31, 2025.

*Funds Withheld*

Certain of the Company's retrocession agreements, including those with Ruby Re, are on a modified coinsurance or funds withheld basis. While the economic benefits of the funds withheld assets are passed on to the assuming company, the Company retains legal ownership of the assets within the funds withheld account and established a funds withheld liability. Net investment income related to the funds withheld assets are reported in other insurance expenses, and net realized gains (losses)

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

related to the assets are reported net of the amount that is passed on to the assuming company. The following assets were held in support of the Company's funds withheld arrangements and are reported in the line items shown in the condensed consolidated balance sheets as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, 2026 | December 31, 2025 |
| Fixed maturity securities available-for-sale | $3907 | $4033 |
| Equity securities | 3 | 2 |
| Mortgage loans | 753 | 821 |
| Funds withheld at interest | 1345 | 1360 |
| Limited partnerships and real estate joint ventures | 100 | 88 |
| Short-term investments and cash and cash equivalents | 93 | 60 |
| Accrued investment income | 49 | 50 |
| Net other assets | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Net assets | $6251 | $6415 |

---

Certain assets are reported at amortized cost while the fair value of those assets is reflected in the funds withheld payable. The Company had a $6,494 million and $6,805 million funds withheld payable, net of an embedded derivative asset of $122 million and $58 million as of March 31, 2026 and December 31, 2025, respectively.

NOTE 10 INVESTMENTS

*Fixed Maturity Securities Available-for-Sale*

The Company holds various types of fixed maturity securities available-for-sale and classifies them as corporate securities ("Corporate"), Canadian and Canadian provincial government securities ("Canadian government"), Japanese government and agencies ("Japanese government"), Korean government and agencies ("Korean government"), asset-backed securities ("ABS"), commercial mortgage-backed securities ("CMBS"), residential mortgage-backed securities ("RMBS"), U.S. government and agencies ("U.S. government"), state and political subdivisions, and other foreign government, supranational and foreign government-sponsored enterprises ("Other foreign government"). ABS, CMBS and RMBS are collectively referred to as "structured securities."

The following tables provide information relating to investments in fixed maturity securities by type as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **March 31, 2026:** | Amortized Cost | Allowance for Credit Losses | Unrealized Gains | Unrealized Losses | Estimated <br>Fair Value | % of Total |
| Available-for-sale: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | $77736 | $211 | $676 | $4973 | $73228 | 68.2% |
| &nbsp;&nbsp;&nbsp;Canadian government | 4897 |  | 251 | 133 | 5015 | 4.7 |
| &nbsp;&nbsp;&nbsp;Japanese government | 9873 |  |  | 2056 | 7817 | 7.3 |
| &nbsp;&nbsp;&nbsp;Korean government | 1346 |  |  | 183 | 1163 | 1.1 |
| &nbsp;&nbsp;&nbsp;ABS | 7436 | 21 | 44 | 178 | 7281 | 6.8 |
| &nbsp;&nbsp;&nbsp;CMBS | 2367 |  | 25 | 57 | 2335 | 2.2 |
| &nbsp;&nbsp;&nbsp;RMBS | 1599 |  | 18 | 74 | 1543 | 1.4 |
| &nbsp;&nbsp;&nbsp;U.S. government | 2805 |  | 14 | 257 | 2562 | 2.4 |
| &nbsp;&nbsp;&nbsp;State and political subdivisions | 737 |  | 2 | 84 | 655 | 0.6 |
| &nbsp;&nbsp;&nbsp;Other foreign government | 6180 |  | 37 | 488 | 5729 | 5.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fixed maturity securities | $114976 | $232 | $1067 | $8483 | $107328 | 100.0% |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **December 31, 2025:** | Amortized Cost | Allowance for Credit Losses | Unrealized Gains | Unrealized Losses | Estimated <br>Fair Value | % of Total |
| Available-for-sale: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | $72736 | $189 | $1142 | $3952 | $69737 | 68.5% |
| &nbsp;&nbsp;&nbsp;Canadian government | 4920 |  | 286 | 106 | 5100 | 5.1 |
| &nbsp;&nbsp;&nbsp;Japanese government | 6516 |  | 1 | 1816 | 4701 | 4.6 |
| &nbsp;&nbsp;&nbsp;Korean government | 1407 |  | 1 | 96 | 1312 | 1.3 |
| &nbsp;&nbsp;&nbsp;ABS | 7478 | 21 | 69 | 157 | 7369 | 7.2 |
| &nbsp;&nbsp;&nbsp;CMBS | 2179 |  | 35 | 52 | 2162 | 2.1 |
| &nbsp;&nbsp;&nbsp;RMBS | 1615 |  | 26 | 72 | 1569 | 1.5 |
| &nbsp;&nbsp;&nbsp;U.S. government | 3508 |  | 27 | 248 | 3287 | 3.3 |
| &nbsp;&nbsp;&nbsp;State and political subdivisions | 737 |  | 2 | 79 | 660 | 0.6 |
| &nbsp;&nbsp;&nbsp;Other foreign government | 6168 |  | 83 | 379 | 5872 | 5.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fixed maturity securities | $107264 | $210 | $1672 | $6957 | $101769 | 100.0% |

---

The Company monitors its concentrations of financial instruments on an ongoing basis and mitigates credit risk by maintaining a diversified investment portfolio that limits exposure to any one issuer. The Company's exposure to concentrations of credit risk from single issuers, including certain agencies, greater than 10% of the Company's equity is disclosed below, as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 |
| | Amortized<br>Cost | Estimated <br>Fair Value | Amortized<br>Cost | Estimated <br>Fair Value |
| Fixed maturity securities guaranteed or issued by: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Japanese government | $9873 | $7817 | $6516 | $4701 |
| &nbsp;&nbsp;&nbsp;U.S. government | 2805 | 2562 | 3508 | 3287 |
| &nbsp;&nbsp;&nbsp;Canadian province of Quebec | 1632 | 1735 | 1642 | 1764 |

---

The amortized cost and estimated fair value of fixed maturity securities classified as available-for-sale as of March 31, 2026, are shown by contractual maturity in the table below (dollars in millions). Actual maturities can differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. Structured securities are shown separately in the table below as they are not due at a single maturity date.

---

| | | |
|:---|:---|:---|
| | Amortized Cost | Estimated Fair Value |
| Available-for-sale: |  |  |
| &nbsp;&nbsp;&nbsp;Due in one year or less | $2288 | $2222 |
| &nbsp;&nbsp;&nbsp;Due after one year through five years | 16429 | 16359 |
| &nbsp;&nbsp;&nbsp;Due after five years through ten years | 17100 | 16938 |
| &nbsp;&nbsp;&nbsp;Due after ten years | 67757 | 60650 |
| &nbsp;&nbsp;&nbsp;Structured securities | 11402 | 11159 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $114976 | $107328 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Corporate Fixed Maturity Securities*

The tables below show the major sectors of the Company's corporate fixed maturity holdings as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **March 31, 2026:** | Amortized Cost | Estimated Fair Value | % of Total |
| Finance | $22661 | $21270 | 29.0% |
| Industrial | 42019 | 39749 | 54.3 |
| Utility | 13056 | 12209 | 16.7 |
| &nbsp;&nbsp;&nbsp;Total | $77736 | $73228 | 100.0% |
| **December 31, 2025:** | Amortized Cost | Estimated Fair Value | % of Total |
| Finance | $21367 | $20489 | 29.4% |
| Industrial | 39381 | 37839 | 54.3 |
| Utility | 11988 | 11409 | 16.3 |
| &nbsp;&nbsp;&nbsp;Total | $72736 | $69737 | 100.0% |

---

*Allowance for Credit Losses and Impairments* – *Fixed Maturity Securities Available-for-Sale*

As discussed in Note 2 – "Significant Accounting Policies and Pronouncements" of the 2025 Annual Report, allowances for credit losses on fixed maturity securities are recognized in investment related gains (losses), net. The Company estimates the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security. Any remaining difference between the fair value and amortized cost is recognized in OCI.

The following tables present the rollforward of the allowance for credit losses in fixed maturity securities by type for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | | | | |
|  | Corporate | ABS | CMBS | Total |
| Balance, beginning of period | $189 | $21 | $— | $210 |
| &nbsp;&nbsp;&nbsp;Credit losses with no previous allowance | 64 |  |  | 64 |
| &nbsp;&nbsp;&nbsp;Securities disposed | (56) |  |  | (56) |
| &nbsp;&nbsp;&nbsp;Change in credit losses with a previous allowance | 14 |  |  | 14 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation |  |  |  |  |
| Balance, end of period | $211 | $21 | $— | $232 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | | | | |
|  | Corporate | ABS | CMBS | Total |
| Balance, beginning of period | $82 | $15 | $1 | $98 |
| &nbsp;&nbsp;&nbsp;Credit losses with no previous allowance | 10 |  |  | 10 |
| &nbsp;&nbsp;&nbsp;Securities disposed | (2) |  |  | (2) |
| &nbsp;&nbsp;&nbsp;Change in credit losses with a previous allowance | (1) |  | (1) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | (1) |  |  | (1) |
| Balance, end of period | $88 | $15 | $— | $103 |

---

*Unrealized Losses for Fixed Maturity Securities Available-for-Sale*

The Company's determination of whether a decline in value necessitates the recording of an allowance for credit losses includes an analysis of whether the issuer is current on its contractual payments, evaluating whether it is probable that the Company will be able to collect all amounts due according to the contractual terms of the security, and analyzing the overall ability of the Company to recover the amortized cost of the investment.

The following tables present the estimated fair value and gross unrealized losses for the 7,588 and 5,968 fixed maturity securities for which both the estimated fair value had declined and remained below amortized cost and an allowance for credit loss has not been recorded as of March 31, 2026 and December 31, 2025, respectively (dollars in millions). These investments are presented by class and grade of security, as well as the length of time the related fair value has continuously remained below amortized cost.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **March 31, 2026:** | Less than 12 months | Less than 12 months | 12 months or greater | 12 months or greater | Total | Total |
|  | Estimated Fair Value | Gross Unrealized Losses | Estimated Fair Value | Gross Unrealized Losses | Estimated Fair Value | Gross Unrealized Losses |
| Investment grade securities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | $26865 | $691 | $21780 | $4168 | $48645 | $4859 |
| &nbsp;&nbsp;&nbsp;Canadian government | 1488 | 37 | 650 | 96 | 2138 | 133 |
| &nbsp;&nbsp;&nbsp;Japanese government | 3586 | 71 | 4136 | 1985 | 7722 | 2056 |
| &nbsp;&nbsp;&nbsp;Korean government | 1043 | 178 | 74 | 5 | 1117 | 183 |
| &nbsp;&nbsp;&nbsp;ABS | 2962 | 28 | 1373 | 143 | 4335 | 171 |
| &nbsp;&nbsp;&nbsp;CMBS | 680 | 7 | 654 | 48 | 1334 | 55 |
| &nbsp;&nbsp;&nbsp;RMBS | 358 | 2 | 534 | 72 | 892 | 74 |
| &nbsp;&nbsp;&nbsp;U.S. government | 935 | 3 | 486 | 254 | 1421 | 257 |
| &nbsp;&nbsp;&nbsp;State and political subdivisions | 168 | 3 | 391 | 81 | 559 | 84 |
| &nbsp;&nbsp;&nbsp;Other foreign government | 2463 | 89 | 1712 | 396 | 4175 | 485 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investment grade securities | 40548 | 1109 | 31790 | 7248 | 72338 | 8357 |
| Below investment grade securities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | 1170 | 29 | 401 | 72 | 1571 | 101 |
| &nbsp;&nbsp;&nbsp;ABS | 207 | 4 | 19 | 1 | 226 | 5 |
| &nbsp;&nbsp;&nbsp;Other foreign government |  |  | 9 | 3 | 9 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total below investment grade securities | 1377 | 33 | 429 | 76 | 1806 | 109 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fixed maturity securities | $41925 | $1142 | $32219 | $7324 | $74144 | $8466 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **December 31, 2025:** | Less than 12 months | Less than 12 months | 12 months or greater | 12 months or greater | Total | Total |
|  | Estimated Fair Value | Gross Unrealized Losses | Estimated Fair Value | Gross Unrealized Losses | Estimated Fair Value | Gross Unrealized Losses |
| Investment grade securities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | $10591 | $255 | $22666 | $3635 | $33257 | $3890 |
| &nbsp;&nbsp;&nbsp;Canadian government | 1096 | 34 | 426 | 72 | 1522 | 106 |
| &nbsp;&nbsp;&nbsp;Japanese government | 1274 | 209 | 3351 | 1607 | 4625 | 1816 |
| &nbsp;&nbsp;&nbsp;Korean government | 1145 | 92 | 78 | 4 | 1223 | 96 |
| &nbsp;&nbsp;&nbsp;ABS | 2324 | 15 | 1149 | 141 | 3473 | 156 |
| &nbsp;&nbsp;&nbsp;CMBS |  |  | 705 | 50 | 705 | 50 |
| &nbsp;&nbsp;&nbsp;RMBS |  |  | 562 | 72 | 562 | 72 |
| &nbsp;&nbsp;&nbsp;U.S. government | 406 | 1 | 542 | 247 | 948 | 248 |
| &nbsp;&nbsp;&nbsp;State and political subdivisions | 73 | 1 | 451 | 78 | 524 | 79 |
| &nbsp;&nbsp;&nbsp;Other foreign government | 1382 | 26 | 1901 | 350 | 3283 | 376 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investment grade securities | 18291 | 633 | 31831 | 6256 | 50122 | 6889 |
| Below investment grade securities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | 652 | 25 | 258 | 31 | 910 | 56 |
| &nbsp;&nbsp;&nbsp;ABS | 19 | 1 |  |  | 19 | 1 |
| &nbsp;&nbsp;&nbsp;Other foreign government |  |  | 13 | 3 | 13 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total below investment grade securities | 671 | 26 | 271 | 34 | 942 | 60 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fixed maturity securities | $18962 | $659 | $32102 | $6290 | $51064 | $6949 |

---

The Company did not intend to sell, and more likely than not would not be required to sell, the securities outlined in the tables above, as of the dates presented. However, unforeseen facts and circumstances may cause the Company to sell fixed maturity securities in the ordinary course of managing its portfolio to meet certain diversification, credit quality and liquidity guidelines. Changes in unrealized losses are primarily due to changes in risk-free interest rates and credit spreads.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Net Investment Income*

Major categories of net investment income consist of the following (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Fixed maturity securities available-for-sale | $1369 | $1063 |
| Equity securities | 4 | 2 |
| Mortgage loans | 157 | 119 |
| Policy loans | 43 | 18 |
| Funds withheld at interest | 108 | 66 |
| Limited partnerships and real estate joint ventures | 54 | (15) |
| Short-term investments and cash and cash equivalents | 33 | 36 |
| Other invested assets | (1) | (5) |
| Investment income | 1767 | 1284 |
| &nbsp;&nbsp;&nbsp;Investment expense | (66) | (52) |
| Net investment income | $1701 | $1232 |

---

*Investment Related Gains (Losses), Net*

Investment related gains (losses), net consist of the following (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Fixed maturity securities available-for-sale: |  |  |
| &nbsp;&nbsp;&nbsp;Change in allowance for credit losses | $(22) | $(6) |
| &nbsp;&nbsp;&nbsp;Impairments on fixed maturity securities | (1) |  |
| &nbsp;&nbsp;&nbsp;Realized gains on investment activity | 59 | 36 |
| &nbsp;&nbsp;&nbsp;Realized losses on investment activity | (165) | (87) |
| Net losses on equity securities | (14) | (1) |
| Change in mortgage loan allowance for credit losses | 2 | 4 |
| Limited partnerships and real estate joint ventures impairment losses | (22) | (5) |
| Change in fair value of certain limited partnership investments | 6 | (7) |
| Net losses on freestanding derivatives | (57) | (2) |
| Net gains (losses) on embedded derivatives | 44 | (11) |
| Total investment related gains (losses), net | $(170) | $(79) |

---

*Collateral Arrangements*

The Company enters into various collateral arrangements with counterparties that require both the pledging and acceptance of invested assets as collateral. Pledged invested assets are included in the condensed consolidated balance sheets. Invested assets received as collateral are held in separate custodial accounts and are not recorded on the Company's condensed consolidated balance sheets. Subject to certain constraints, the Company is permitted by contract to sell or repledge collateral it receives; however, as of March 31, 2026 and December 31, 2025, none of the collateral received had been sold or repledged.

The Company also holds invested assets on deposit to meet regulatory requirements and holds assets in trust to satisfy collateral requirements under derivative transactions and certain third-party reinsurance treaties.

The following table includes invested assets on deposit, invested assets pledged and received as collateral, assets in trust held to satisfy collateral requirements and FHLB common stock restricted as to sale as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 |
| | Amortized<br>Cost | Estimated <br>Fair Value | Amortized<br>Cost | Estimated <br>Fair Value |
| Invested assets on deposit (regulatory deposits) | $10 | $9 | $10 | $9 |
| Invested assets pledged as collateral | 1880 | 1566 | 1739 | 1527 |
| Invested assets received as collateral | n/a | 2551 | n/a | 2620 |
| Assets in trust held to satisfy collateral requirements | 75687 | 71102 | 68241 | 65154 |
| FHLB common stock restricted as to sale | 68 | 68 | 68 | 68 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Securities Lending and Repurchase/Reverse Repurchase Agreements*

The following table provides the estimated fair value of securities relating to securities lending and repurchase/reverse repurchase agreements as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 | December 31, 2025 |
| | Securities Loaned <sup>(1)</sup> | Securities Borrowed <sup>(2)</sup> | Cash Collateral Received <sup>(3)</sup> | Securities Loaned <sup>(1)</sup> | Securities Borrowed <sup>(2)</sup> | Cash Collateral Received <sup>(3)</sup> |
| Securities lending transactions | $792 | $1054 | $— | $831 | $1058 | $— |
| Repurchase/reverse repurchase transactions | 2457 | 638 | 1645 | 2623 | 682 | 1783 |

---

(1)Securities loaned or pledged through securities lending transactions or sold to counterparties through repurchase transactions are included within fixed maturity securities. Collateral associated with certain securities lending transactions is not included within this table as the collateral pledged to the counterparty is the right to reinsurance treaty cash flows. Certain securities lending transactions do not require collateral.

(2)Securities borrowed or received as collateral through securities lending transactions or purchased from counterparties through reverse repurchase transactions are not reflected on the condensed consolidated balance sheets.

(3)A payable for the cash received by the Company is included within other liabilities.

The following table presents the estimated fair value of securities by the remaining contractual maturity of the Company's securities lending and repurchase agreements as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 |
| | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements | Remaining Contractual Maturity of the Agreements |
| | Overnight and Continuous | Up to 30 Days | 30 – 90 Days | Greater than 90 Days | Total | Overnight and Continuous | Up to 30 Days | 30 – 90 Days | Greater than 90 Days | Total |
| Securities lending transactions: |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | $— | $— | $211 | $205 | $416 | $— | $— | $357 | $71 | $428 |
| &nbsp;&nbsp;&nbsp;Japanese government |  | 149 |  | 150 | 299 |  |  |  | 310 | 310 |
| &nbsp;&nbsp;&nbsp;ABS |  |  | 13 | 3 | 16 |  |  | 25 |  | 25 |
| &nbsp;&nbsp;&nbsp;CMBS |  |  | 30 |  | 30 |  |  | 37 |  | 37 |
| &nbsp;&nbsp;&nbsp;RMBS |  |  | 10 |  | 10 |  |  | 10 |  | 10 |
| &nbsp;&nbsp;&nbsp;Other foreign government |  |  | 11 | 10 | 21 |  |  | 15 | 6 | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total |  | 149 | 275 | 368 | 792 |  |  | 444 | 387 | 831 |
| Repurchase/reverse repurchase transactions: |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate |  |  | 199 | 1098 | 1297 |  |  |  | 1336 | 1336 |
| &nbsp;&nbsp;&nbsp;Canadian government |  |  |  | 12 | 12 |  |  |  | 12 | 12 |
| &nbsp;&nbsp;&nbsp;Japanese government |  |  |  | 380 | 380 |  |  | 203 | 175 | 378 |
| &nbsp;&nbsp;&nbsp;ABS |  |  |  | 115 | 115 |  |  | 11 | 137 | 148 |
| &nbsp;&nbsp;&nbsp;CMBS |  |  |  | 225 | 225 |  |  | 49 | 227 | 276 |
| &nbsp;&nbsp;&nbsp;RMBS |  |  |  | 46 | 46 |  |  | 42 | 47 | 89 |
| &nbsp;&nbsp;&nbsp;U.S. government |  |  |  | 270 | 270 |  |  | 4 | 273 | 277 |
| &nbsp;&nbsp;&nbsp;Other foreign government |  |  |  | 112 | 112 |  |  |  | 107 | 107 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total |  |  | 199 | 2258 | 2457 |  |  | 309 | 2314 | 2623 |
| Total transactions | $— | $149 | $474 | $2626 | $3249 | $— | $— | $753 | $2701 | $3454 |

---

*Mortgage Loans*

The Company invests in both commercial and residential mortgage loans in the U.S. (91.7%), Canada (6.4%) and U.K. (1.9%). As of March 31, 2026, mortgage loans were geographically dispersed throughout the U.S. with the largest concentrations in California (11.7%), Texas (9.7%) and Utah (6.1%). The recorded investment in mortgage loans presented below is gross of unamortized deferred loan origination fees and expenses and allowance for credit losses.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The following table presents the distribution of the Company's recorded investment in mortgage loans by property type as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 |
| | Carrying Value | % of Total | Carrying Value | % of Total |
| Commercial: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Office | $1720 | 15.0% | $1800 | 16.0% |
| &nbsp;&nbsp;&nbsp;Retail | 3429 | 29.9 | 3455 | 30.7 |
| &nbsp;&nbsp;&nbsp;Industrial | 3724 | 32.4 | 3549 | 31.5 |
| &nbsp;&nbsp;&nbsp;Apartment | 1379 | 12.0 | 1356 | 12.0 |
| &nbsp;&nbsp;&nbsp;Hotel | 515 | 4.5 | 500 | 4.4 |
| &nbsp;&nbsp;&nbsp;Other commercial | 202 | 1.8 | 161 | 1.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commercial | 10969 | 95.6 | 10821 | 96.0 |
| Residential | 508 | 4.4 | 447 | 4.0 |
| Recorded investment | 11477 | 100.0% | 11268 | 100.0% |
| &nbsp;&nbsp;&nbsp;Unamortized loan origination fees and discount | (44) |  | (47) |  |
| &nbsp;&nbsp;&nbsp;Allowance for credit losses | (115) |  | (117) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total mortgage loans | $11318 |  | $11104 |  |

---

The following table presents the maturities of the Company's recorded investment in mortgage loans as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 |
| | Recorded<br>Investment | % of Total | Recorded<br>Investment | % of Total |
| Commercial: |  |  |  |  |
| Due within five years | $4620 | 42.1% | $4563 | 42.2% |
| Due after five years through ten years | 5432 | 49.5 | 5225 | 48.3 |
| Due after ten years | 917 | 8.4 | 1033 | 9.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commercial | $10969 | 100.0% | $10821 | 100.0% |
| Residential: |  |  |  |  |
| Due within five years | $190 | 37.4% | $184 | 41.2% |
| Due after five years through ten years |  |  |  |  |
| Due after ten years | 318 | 62.6 | 263 | 58.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total residential | $508 | 100.0% | $447 | 100.0% |

---

The following tables set forth certain key credit quality indicators of the Company's recorded investment in commercial mortgage loans as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment |
| | Debt Service Ratios | Debt Service Ratios | Debt Service Ratios | | |
| | >1.20x | 1.00x – 1.20x | <1.00x |<br>Total |% of Total |
| **March 31, 2026:** |  |  |  |  |  |
| **Loan-to-Value Ratio** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;0% – 59.99% | $4787 | $253 | $75 | $5115 | 46.6% |
| &nbsp;&nbsp;&nbsp;60% – 69.99% | 3143 | 266 | 57 | 3466 | 31.6 |
| &nbsp;&nbsp;&nbsp;70% – 79.99% | 1159 | 215 | 76 | 1450 | 13.2 |
| &nbsp;&nbsp;&nbsp;80% or greater | 637 | 174 | 127 | 938 | 8.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total commercial | $9726 | $908 | $335 | $10969 | 100.0% |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment |
| | Debt Service Ratios | Debt Service Ratios | Debt Service Ratios | | |
| | >1.20x | 1.00x – 1.20x | <1.00x |<br>Total |% of Total |
| **December 31, 2025:** |  |  |  |  |  |
| **Loan-to-Value Ratio** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;0% – 59.99% | $4799 | $162 | $79 | $5040 | 46.5% |
| &nbsp;&nbsp;&nbsp;60% – 69.99% | 3084 | 168 | 79 | 3331 | 30.8 |
| &nbsp;&nbsp;&nbsp;70% – 79.99% | 1126 | 232 | 99 | 1457 | 13.5 |
| &nbsp;&nbsp;&nbsp;80% or greater | 643 | 236 | 114 | 993 | 9.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total commercial | $9652 | $798 | $371 | $10821 | 100.0% |

---

The following tables set forth credit quality grades by year of origination of the Company's recorded investment in commercial mortgage loans as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment |
| | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | |
| | 2026 | 2025 | 2024 | 2023 | 2022 | Prior |<br>Total |
| **March 31, 2026:** |  |  |  |  |  |  |  |
| **Internal credit quality grade:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;High investment grade | $26 | $625 | $585 | $351 | $531 | $1950 | $4068 |
| &nbsp;&nbsp;&nbsp;Investment grade | 465 | 1906 | 1254 | 755 | 596 | 1396 | 6372 |
| &nbsp;&nbsp;&nbsp;Average |  |  |  | 71 | 107 | 208 | 386 |
| &nbsp;&nbsp;&nbsp;Watch list |  |  |  | 12 |  | 131 | 143 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total commercial | $491 | $2531 | $1839 | $1189 | $1234 | $3685 | $10969 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment |
| | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | |
| | 2025 | 2024 | 2023 | 2022 | 2021 | Prior |<br>Total |
| **December 31, 2025:** |  |  |  |  |  |  |  |
| **Internal credit quality grade:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;High investment grade | $636 | $587 | $352 | $539 | $458 | $1679 | $4251 |
| &nbsp;&nbsp;&nbsp;Investment grade | 1908 | 1257 | 788 | 617 | 481 | 973 | 6024 |
| &nbsp;&nbsp;&nbsp;Average |  |  | 83 | 107 | 36 | 195 | 421 |
| &nbsp;&nbsp;&nbsp;Watch list |  |  |  |  |  | 125 | 125 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total commercial | $2544 | $1844 | $1223 | $1263 | $975 | $2972 | $10821 |

---

The following tables set forth credit quality by year of origination of the Company's recorded investment in residential mortgage loans as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment |
| | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | |
| | 2026 | 2025 | 2024 | 2023 | 2022 | Prior |<br>Total |
| **March 31, 2026:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Performing | $21 | $357 | $40 | $8 | $20 | $58 | $504 |
| &nbsp;&nbsp;&nbsp;Non-performing |  | 4 |  |  |  |  | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total residential | $21 | $361 | $40 | $8 | $20 | $58 | $508 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment | Recorded Investment |
| | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | Year of Origination | |
| | 2025 | 2024 | 2023 | 2022 | 2021 | Prior |<br>Total |
| **December 31, 2025:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Performing | $310 | $47 | $9 | $21 | $54 | $6 | $447 |
| &nbsp;&nbsp;&nbsp;Non-performing |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total residential | $310 | $47 | $9 | $21 | $54 | $6 | $447 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The following table presents the current and past due composition of the Company's recorded investment in mortgage loans as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, 2026 | December 31, 2025 |
| Commercial: |  |  |
| Current | $10938 | $10805 |
| 31 – 60 days past due | 5 |  |
| 61 – 90 days past due | 26 |  |
| Greater than 90 days past due |  | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commercial | $10969 | $10821 |
| Residential: |  |  |
| Current | $503 | $444 |
| 31 – 60 days past due | 1 | 3 |
| 61 – 90 days past due |  |  |
| Greater than 90 days past due | 4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total residential | $508 | $447 |

---

The following table presents information regarding the Company's allowance for credit losses for mortgage loans for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | Commercial | Residential | Total |
| Balance, beginning of period | $112 | $5 | $117 |
| &nbsp;&nbsp;&nbsp;Provision (release) of credit losses | 4 | 1 | 5 |
| &nbsp;&nbsp;&nbsp;Write-offs, net of recoveries | (7) |  | (7) |
| Balance, end of period | $109 | $6 | $115 |
| **For the three months ended March 31, 2025:** |  |  |  |
| Balance, beginning of period | $93 | $— | $93 |
| &nbsp;&nbsp;&nbsp;Provision (release) of credit losses | (6) | 2 | (4) |
| &nbsp;&nbsp;&nbsp;Write-offs, net of recoveries |  |  |  |
| Balance, end of period | $87 | $2 | $89 |

---

During the three months ended March 31, 2026 and 2025, the Company modified one mortgage loan and three mortgage loans, respectively, for borrowers experiencing financial difficulty providing interest only payments, maturity extensions or payment deferrals. The total recorded investment before allowance for credit losses for the modified loans was $13 million and $19 million as of March 31, 2026 and 2025, respectively.

The Company had five residential mortgage loans in the amount of $4 million that were on nonaccrual status as of March 31, 2026. The Company had one commercial mortgage loan in the amount of $6 million that was on nonaccrual status as of March 31, 2025. The Company did not convert any mortgage loans to owned properties through a deed in lieu of foreclosure during the three months ended March 31, 2026 and 2025. The Company did not acquire any impaired mortgage loans during the three months ended March 31, 2026 and 2025.

*Policy Loans*

The majority of policy loans are associated with one client. These policy loans present no credit risk as the amount of the loan cannot exceed the obligation due to the ceding company upon the death of the insured or surrender of the underlying policy. The provisions of the treaties in force and the underlying policies determine the policy loan interest rates. The Company earns a spread between the interest rate earned on policy loans and the interest rate credited to corresponding liabilities.

*Funds Withheld at Interest*

For reinsurance agreements written on a modified coinsurance basis and certain agreements written on a coinsurance funds withheld basis, assets equal to the net statutory reserves are withheld and legally owned and managed by the ceding company. The Company reflects these assets on its consolidated balance sheets as funds withheld at interest.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Limited Partnerships and Real Estate Joint Ventures*

The carrying values of limited partnerships and real estate joint ventures as of March 31, 2026 and December 31, 2025 are as follows (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, 2026 | December 31, 2025 |
| Limited partnerships – equity method | $1878 | $1543 |
| Limited partnerships – fair value | 935 | 925 |
| Limited partnerships – cost method | 71 | 72 |
| Real estate joint ventures – equity method | 1193 | 1207 |
| Real estate joint ventures – fair value | 16 |  |
| &nbsp;&nbsp;&nbsp;Total limited partnerships and real estate joint ventures | $4093 | $3747 |

---

*Other Invested Assets*

Other invested assets include lifetime mortgages, derivative contracts and FHLB common stock. Other invested assets also include real estate held for investment, which is included in "Other" in the table below. As of March 31, 2026 and December 31, 2025, the allowance for credit losses for lifetime mortgages was not material. The carrying values of other invested assets as of March 31, 2026 and December 31, 2025 are as follows (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, 2026 | December 31, 2025 |
| Lifetime mortgages | $1219 | $1197 |
| Derivatives | 179 | 185 |
| FHLB common stock | 68 | 68 |
| Other | 59 | 64 |
| &nbsp;&nbsp;&nbsp;Total other invested assets | $1525 | $1514 |

---

NOTE 11 DERIVATIVE INSTRUMENTS

See Note 2 – "Significant Accounting Policies and Pronouncements" of the 2025 Annual Report for a detailed discussion of the accounting treatment for derivative instruments, including embedded derivatives. See Note 12 – "Fair Value of Assets and Liabilities" for additional disclosures related to the fair value hierarchy for derivative instruments, including embedded derivatives.

Commonly used derivative instruments include, but are not limited to: interest rate swaps, interest rate options, total return swaps, foreign currency swaps, foreign currency forwards, foreign currency options, equity options, equity futures, credit default swaps (single name and index), options on credit default index swaps, consumer price index ("CPI") swaps, forward bond purchase commitments, synthetic guaranteed investment contracts ("GICs"), other derivatives and embedded derivatives. For detailed information on these derivative instruments and the related strategies, see Note 12 – "Derivative Instruments" of the 2025 Annual Report.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Summary of Derivative Positions*

Freestanding derivatives, except for other swaps, are included in other invested assets or other liabilities, at fair value. Other swaps are included in other assets or other liabilities, at fair value. Embedded derivative assets and liabilities on modified coinsurance or funds withheld arrangements are included with the host contract in funds withheld at interest or funds withheld payable, at fair value. Embedded derivative liabilities on indexed products are included with the host contract in interest-sensitive contract liabilities, at fair value. The following table presents the notional amounts and gross fair value of derivative instruments prior to taking into account the netting effects of master netting agreements as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | March 31, 2026 | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 | December 31, 2025 |
| | Primary<br> Underlying Risk | | Carrying Value/Fair Value | Carrying Value/Fair Value | | Carrying Value/Fair Value | Carrying Value/Fair Value |
| | Primary<br> Underlying Risk | Notional<br>Amount | Assets | Liabilities | Notional<br>Amount | Assets | Liabilities |
| **Derivatives not designated as hedging instruments:** | **Derivatives not designated as hedging instruments:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest rate swaps | &nbsp;&nbsp;&nbsp;Interest rate | $2370 | $5 | $15 | $2088 | $5 | $14 |
| &nbsp;&nbsp;&nbsp;Interest rate options | &nbsp;&nbsp;&nbsp;Interest rate | 1000 | 1 |  | 750 |  |  |
| &nbsp;&nbsp;&nbsp;Total return swaps | &nbsp;&nbsp;&nbsp;Interest rate | 581 |  | 13 | 527 | 1 | 5 |
| &nbsp;&nbsp;&nbsp;Foreign currency swaps | &nbsp;&nbsp;&nbsp;Foreign currency | 150 | 48 |  | 150 | 48 |  |
| &nbsp;&nbsp;&nbsp;Foreign currency forwards | &nbsp;&nbsp;&nbsp;Foreign currency | 1451 | 2 | 49 | 1358 | 1 | 53 |
| &nbsp;&nbsp;&nbsp;Foreign currency options | &nbsp;&nbsp;&nbsp;Foreign currency | 305 |  |  | 305 |  |  |
| &nbsp;&nbsp;&nbsp;Equity options | &nbsp;&nbsp;&nbsp;Equity | 5988 | 285 | 123 | 5897 | 459 | 245 |
| &nbsp;&nbsp;&nbsp;Equity futures | &nbsp;&nbsp;&nbsp;Equity | 203 |  |  | 200 |  |  |
| &nbsp;&nbsp;&nbsp;Credit default swaps | &nbsp;&nbsp;&nbsp;Credit | 8073 | 16 | 14 | 6573 | 3 | 10 |
| &nbsp;&nbsp;&nbsp;Credit default index swaps options | &nbsp;&nbsp;&nbsp;Credit | 2000 |  |  | 1000 |  |  |
| &nbsp;&nbsp;&nbsp;Other swaps | &nbsp;&nbsp;&nbsp;Credit | 1165 | 2 | 2 | 1225 | 3 | 3 |
| &nbsp;&nbsp;&nbsp;CPI swaps | &nbsp;&nbsp;&nbsp;CPI | 389 | 7 | 3 | 395 | 2 | 7 |
| &nbsp;&nbsp;&nbsp;Synthetic GICs | &nbsp;&nbsp;&nbsp;Interest rate | 16923 |  |  | 17209 |  |  |
| &nbsp;&nbsp;&nbsp;Embedded derivatives in: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Modified coinsurance or funds withheld arrangements |  |  | 272 | 297 |  | 272 | 341 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indexed products |  |  |  | 397 |  |  | 470 |
| &nbsp;&nbsp;&nbsp;Total non-designated derivatives |  | 40598 | 638 | 913 | 37677 | 794 | 1148 |
| **Derivatives designated as hedging instruments:** | **Derivatives designated as hedging instruments:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest rate swaps | &nbsp;&nbsp;&nbsp;Interest rate | 3676 | 20 | 50 | 3641 | 31 | 56 |
| &nbsp;&nbsp;&nbsp;Forward bond purchase commitments | &nbsp;&nbsp;&nbsp;Interest rate | 4688 | 2 | 252 | 3058 | 5 | 227 |
| &nbsp;&nbsp;&nbsp;Foreign currency swaps | &nbsp;&nbsp;&nbsp;Foreign currency | 1954 | 8 | 360 | 2008 | 8 | 331 |
| &nbsp;&nbsp;&nbsp;Foreign currency forwards | &nbsp;&nbsp;&nbsp;Foreign currency | 2284 | 38 | 16 | 2270 | 12 | 38 |
| &nbsp;&nbsp;&nbsp;Total hedging derivatives |  | 12602 | 68 | 678 | 10977 | 56 | 652 |
| **Total derivatives** |  | $53200 | $706 | $1591 | $48654 | $850 | $1800 |

---

*Fair Value Hedges*

The Company designates and reports the following as fair value hedges when they meet the requirements of the general accounting principles for *Derivatives and Hedging:* interest rate swaps to convert fixed rate liabilities to floating rate liabilities. The gain or loss on the hedged item attributable to a change in interest rates and the offsetting gain or loss on the related interest rate swaps for the three months ended March 31, 2026 and 2025 are as follows (dollars in millions):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Derivative Type | Hedged Item | Claims and Other Policy<br>Benefits | Claims and Other Policy<br>Benefits | Interest Credited | Interest Credited |
|  |  | Derivatives | Hedged Items | Derivatives | Hedged Items |
| **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** |  |  |  |  |
| Interest rate swaps | Future policy benefits | $(2) | $4 | $— | $— |
| Interest rate swaps | Interest-sensitive contract liabilities |  |  | (8) | 9 |
| **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** |  |  |  |  |
| Interest rate swaps | Future policy benefits | $13 | $(13) | $— | $— |
| Interest rate swaps | Interest-sensitive contract liabilities |  |  | 20 | (25) |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| Hedged Item | Carrying Amount of <br>the Hedged Assets / (Liabilities) | Carrying Amount of <br>the Hedged Assets / (Liabilities) | Cumulative Fair Value Hedging Adjustments Included in the Carrying Amount of Hedged Assets / (Liabilities) <sup>(1)</sup> | Cumulative Fair Value Hedging Adjustments Included in the Carrying Amount of Hedged Assets / (Liabilities) <sup>(1)</sup> |
|  | March 31, 2026 | December 31, 2025 | March 31, 2026 | December 31, 2025 |
| Future policy benefits | $(585) | $(547) | $3 | $(1) |
| Interest-sensitive contract liabilities | (1468) | (1463) | 4 | (5) |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Includes $(8) million and $(6) million of cumulative adjustment on discontinued fair value hedging relationships at March 31, 2026 and December 31, 2025, respectively.

*Cash Flow Hedges*

Certain derivative instruments are designated as cash flow hedges when they meet the requirements of the general accounting principles for *Derivatives and Hedging*. The Company designates and accounts for the following as cash flow hedges: (i) certain interest rate swaps, in which the cash flows of assets are variable based on a benchmark rate; (ii) certain interest rate swaps, in which floating rate assets are converted to fixed rate assets; (iii) forward bond purchase commitments; and (iv) certain foreign currency swaps, in which the cash flows of assets are denominated in different currencies, commonly referred to as cross-currency swaps.

The following table presents the cash flow hedge components of AOCI, before income taxes, and where the gain or loss related to cash flow hedges is recognized on the condensed consolidated statement of income classification for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Balance, beginning of period | $(748) | $(495) |
| Gains (losses), net deferred in other comprehensive income (loss) | (88) | (6) |
| Amounts reclassified to net investment income | 18 | 18 |
| Amounts reclassified to interest expense | (1) | (2) |
| Balance, end of period | $(819) | $(485) |

---

As of March 31, 2026, approximately $72 million of before-tax deferred net losses on derivative instruments recorded in AOCI are expected to be reclassified to net investment income during the next twelve months. For the same time period, approximately $7 million of before-tax deferred net gains on derivative instruments recorded in AOCI are expected to be reclassified to interest expense during the next twelve months.

The following table presents the effect of derivatives in cash flow hedging relationships on the condensed consolidated statements of income for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| Derivative Type | Gains (Losses)<br> Deferred in OCI | Gains (Losses) Reclassified into Income from AOCI | Gains (Losses) Reclassified into Income from AOCI |
|  |  | Net Investment Income | Interest Expense |
| **For the three months ended March 31, 2026:** |  |  |  |
| Interest rate | $(38) | $— | $1 |
| Foreign currency | (50) | (18) |  |
| Total | $(88) | $(18) | $1 |
| **For the three months ended March 31, 2025:** |  |  |  |
| Interest rate | $12 | $(1) | $2 |
| Foreign currency | (18) | (17) |  |
| Total | $(6) | $(18) | $2 |

---

For the three months ended March 31, 2026 and 2025, there were no material amounts reclassified into earnings relating to instances in which the Company discontinued cash flow hedge accounting because the forecasted transaction did not occur by the anticipated date or within the additional time period permitted by the authoritative guidance for the accounting for derivatives and hedging.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Hedges of Net Investments in Foreign Operations*

The Company uses foreign currency forwards to hedge a portion of its net investment in certain foreign operations against adverse movements in exchange rates. The following table illustrates the Company's net investments in foreign operations ("NIFO") hedges and the gains (losses) deferred in OCI for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Derivative Gains (Losses) Deferred in OCI | Derivative Gains (Losses) Deferred in OCI |
| | For the three months ended March 31, | For the three months ended March 31, |
| Derivative Type | 2026 | 2025 |
| Foreign currency forwards | $39 | $(15) |

---

The cumulative foreign currency translation gain recorded in AOCI related to these hedges was $271 million and $232 million as of March 31, 2026 and December 31, 2025, respectively. If a hedged foreign operation was sold or substantially liquidated, the amounts in AOCI would be reclassified to the condensed consolidated statements of income. A pro rata portion would be reclassified upon partial sale of a hedged foreign operation. There were no sales or substantial liquidations of net investments in foreign operations that would have required the reclassification of gains or losses from AOCI into investment income during the periods presented.

*Non-qualifying Derivatives and Derivatives for Purposes Other Than Hedging*

The Company uses various other derivative instruments for risk management purposes that either do not qualify or have not been elected for hedge accounting treatment. The gain or loss related to the change in fair value for these derivative instruments is recognized in investment related gains (losses), net, except where otherwise noted.

A summary of the effect of non-qualifying derivatives, including embedded derivatives, on the Company's condensed consolidated statements of income for the three months ended March 31, 2026 and 2025 are as follows (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| | | Gains (Losses) for the three months ended March 31, | Gains (Losses) for the three months ended March 31, |
| Type of Non-qualifying Derivative | Income Statement <br>Location of Gains (Losses) | 2026 | 2025 |
| Interest rate swaps | Investment related gains (losses), net | $6 | $6 |
| Total return swaps | Investment related gains (losses), net | (6) | (6) |
| Foreign currency swaps | Investment related gains (losses), net | 1 | (3) |
| Foreign currency forwards | Investment related gains (losses), net | (25) | 22 |
| Foreign currency options | Investment related gains (losses), net | (1) | (1) |
| Equity options | Investment related gains (losses), net | (28) | (6) |
| Equity futures | Investment related gains (losses), net | 6 | 9 |
| Credit default swaps | Investment related gains (losses), net | (17) | (18) |
| CPI swaps | Investment related gains (losses), net | 7 | (5) |
| &nbsp;&nbsp;&nbsp;Subtotal |  | (57) | (2) |
| Embedded derivatives in: |  |  |  |
| &nbsp;&nbsp;&nbsp;Modified coinsurance or funds withheld arrangements | Investment related gains (losses), net | 44 | (11) |
| &nbsp;&nbsp;&nbsp;Indexed products | Interest credited | 30 | 24 |
| Total non-qualifying derivatives |  | $17 | $11 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Credit Derivatives*

The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of credit default swaps sold by the Company as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 | December 31, 2025 |
| Rating Agency Designation of Referenced Credit Obligations<sup>(1)</sup> | Estimated Fair<br>Value of Credit <br>Default Swaps | Maximum<br>Amount of Future<br>Payments under<br>Credit Default<br>Swaps <sup>(2)</sup> | Weighted<br>Average<br>Years to<br>Maturity <sup>(3)</sup> | Estimated Fair<br>Value of Credit <br>Default Swaps | Maximum<br>Amount of Future<br>Payments under<br>Credit Default<br>Swaps <sup>(2)</sup> | Weighted<br>Average<br>Years to<br>Maturity <sup>(3)</sup> |
| **AAA/AA/A** |  |  |  |  |  |  |
| Single name credit default swaps | $(13) | $490 | 13.9 | $(7) | $490 | 14.2 |
| **BBB** |  |  |  |  |  |  |
| Single name credit default swaps | 2 | 170 | 1.8 | 2 | 170 | 2.1 |
| Credit default swaps referencing indices | 13 | 7403 | 5.7 | (2) | 5903 | 5.5 |
| &nbsp;&nbsp;&nbsp;Subtotal | 15 | 7573 | 5.6 |  | 6073 | 5.4 |
| **BB** |  |  |  |  |  |  |
| Single name credit default swaps |  | 5 | 0.2 |  | 5 | 0.5 |
| **B** |  |  |  |  |  |  |
| Single name credit default swaps |  | 5 | 0.2 |  | 5 | 0.5 |
| Total | $2 | $8073 | 6.1 | $(7) | $6573 | 6.0 |

---

(1)Rating agency designations are based on ratings from Standard and Poor's ("S&P") when available. Other credited rating agencies or internal ratings may be used when S&P ratings are not available.

(2)Assumes the value of the referenced credit obligations is zero.

(3)The weighted average years to maturity of the credit default swaps is calculated based on weighted average notional amounts.

*Netting Arrangements and Credit Risk*

Certain of the Company's freestanding derivatives are subject to enforceable master netting arrangements and reported as a net asset or liability in the condensed consolidated balance sheets. The Company nets all derivatives that are subject to such arrangements.

The Company has elected to include all freestanding derivatives in the table below, irrespective of whether they are subject to an enforceable master netting arrangement or a similar agreement. See Note 10 – "Investments" for information regarding the Company's securities borrowing, lending and repurchase/reverse repurchase agreements.

The following table provides information relating to the netting of the Company's derivative instruments as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Gross Amounts <br>Recognized | Gross Amounts<br>Offset in the<br>Balance Sheet | Net Amounts<br>Presented in the<br>Balance Sheet | Financial<br>Instruments/Collateral <sup>(1)</sup> | Net Amount |
| **March 31, 2026:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivative assets | $434 | $(253) | $181 | $(181) | $— |
| &nbsp;&nbsp;&nbsp;Derivative liabilities | 897 | (253) | 644 | (644) |  |
| **December 31, 2025:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivative assets | $578 | $(390) | $188 | $(188) | $— |
| &nbsp;&nbsp;&nbsp;Derivative liabilities | 989 | (390) | 599 | (599) |  |

---

(1)Includes initial margin posted to a central clearing partner for financial instruments and excludes the excess of collateral received/pledged from/to the counterparty.

The Company may be exposed to credit-related losses in the event of non-performance by counterparties to derivative financial instruments. Generally, the credit exposure of the Company's derivative contracts is limited to the fair value and accrued interest of non-collateralized derivative contracts in an asset position at the reporting date. As of March 31, 2026, the Company had credit exposure of $16 million.

Derivatives may be exchange-traded or they may be privately negotiated contracts, which are referred to as over-the-counter ("OTC") derivatives. Certain of the Company's OTC derivatives are cleared and settled through central clearing counterparties ("OTC cleared") and others are bilateral contracts between two counterparties ("OTC bilateral"). The Company manages its credit risk related to OTC bilateral derivatives by entering into transactions with creditworthy counterparties, maintaining collateral arrangements and through the use of master netting agreements that provide for a single net payment to be made by one counterparty to another at each due date and upon termination. Additionally, the Company is required to pledge initial

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

margin for certain OTC bilateral derivatives subject to regulatory thresholds. The Company is only exposed to the default of the central clearing counterparties for OTC cleared derivatives, and these transactions require an initial and daily variation margin collateral postings. Exchange-traded derivatives are settled on a daily basis, thereby reducing the credit risk exposure in the event of non-performance by counterparties to such financial instruments.

NOTE 12 FAIR VALUE OF ASSETS AND LIABILITIES

*Fair Value Measurement*

General accounting principles for *Fair Value Measurements and Disclosures* define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. These principles also establish a three-level fair value hierarchy that requires an entity to maximize the use of observable inputs and to minimize the use of unobservable inputs when measuring fair value:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities. Active markets are defined through various characteristics for the measured asset/liability, such as having many transactions and narrow bid/ask spreads.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or market standard valuation techniques and assumptions that use significant inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the related assets or liabilities and include those whose value is determined using market standard valuation techniques described above. Prices are determined using valuation methodologies such as discounted cash flow models and other similar techniques that require management's judgment or estimation in developing inputs that are consistent with those other market participants would use when pricing similar assets and liabilities.

For a discussion of the Company's valuation methodologies for assets and liabilities measured at fair value and the fair value hierarchy, see Note 13 – "Fair Value of Assets and Liabilities" in the Notes to Consolidated Financial Statements included in the 2025 Annual Report.

See Note 7 – "Market Risk Benefits" for information about fair value measurement of market risk benefits.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Assets and Liabilities by Hierarchy Level*

Assets and liabilities measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 are summarized below (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **March 31, 2026:** |  | Fair Value Measurements Using: | Fair Value Measurements Using: | Fair Value Measurements Using: |
|  | Total | Level 1 | Level 2 | Level 3 |
| Assets: <sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fixed maturity securities available-for-sale: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate | $73228 | $— | $63154 | $10074 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canadian government | 5015 |  | 5015 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Japanese government | 7817 |  | 7817 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Korean government | 1163 |  | 1163 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ABS | 7281 |  | 3802 | 3479 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CMBS | 2335 |  | 2272 | 63 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RMBS | 1543 |  | 1543 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government | 2562 | 2353 | 206 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State and political subdivisions | 655 |  | 655 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other foreign government | 5729 |  | 5614 | 115 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fixed maturity securities available-for-sale | 107328 | 2353 | 91241 | 13734 |
| &nbsp;&nbsp;&nbsp;Equity securities | 300 | 209 |  | 91 |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest – embedded derivatives | (149) |  |  | (149) |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest | 63 |  |  | 63 |
| &nbsp;&nbsp;&nbsp;Real estate joint ventures – fair value | 16 |  |  | 16 |
| &nbsp;&nbsp;&nbsp;Cash equivalents | 3035 | 2945 | 90 |  |
| &nbsp;&nbsp;&nbsp;Short-term investments | 274 | 196 | 58 | 20 |
| &nbsp;&nbsp;&nbsp;Other invested assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivatives | 179 |  | 179 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 15 |  | 15 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other invested assets | 194 |  | 194 |  |
| &nbsp;&nbsp;Other assets – derivatives | 2 |  |  | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $111063 | $5703 | $91583 | $13777 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest-sensitive contract liabilities – embedded derivatives | $397 | $— | $— | $397 |
| &nbsp;&nbsp;&nbsp;Other liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Funds withheld at interest – embedded derivatives | (124) |  |  | (124) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivatives | 644 |  | 642 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $917 | $— | $642 | $275 |

---

(1)Excludes limited partnerships that are measured at estimated fair value using the NAV per share (or its equivalent) as a practical expedient. As of March 31, 2026, the fair value of such investments was $935 million.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| **December 31, 2025:** |  | Fair Value Measurements Using: | Fair Value Measurements Using: | Fair Value Measurements Using: |
|  | Total | Level 1 | Level 2 | Level 3 |
| Assets: <sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fixed maturity securities available-for-sale: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate | $69737 | $— | $59710 | $10027 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canadian government | 5100 |  | 5100 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Japanese government | 4701 |  | 4701 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Korean government | 1312 |  | 1312 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ABS | 7369 |  | 3831 | 3538 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CMBS | 2162 |  | 2099 | 63 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RMBS | 1569 |  | 1569 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government | 3287 | 3074 | 209 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State and political subdivisions | 660 |  | 660 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other foreign government | 5872 |  | 5752 | 120 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fixed maturity securities available-for-sale | 101769 | 3074 | 84943 | 13752 |
| &nbsp;&nbsp;&nbsp;Equity securities | 311 | 213 |  | 98 |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest – embedded derivatives | (128) |  |  | (128) |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest | 61 |  |  | 61 |
| &nbsp;&nbsp;&nbsp;Real estate joint ventures – fair value |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash equivalents | 2460 | 2460 |  |  |
| &nbsp;&nbsp;&nbsp;Short-term investments | 255 | 156 | 66 | 33 |
| &nbsp;&nbsp;&nbsp;Other invested assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivatives | 185 |  | 185 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 17 |  | 17 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other invested assets | 202 |  | 202 |  |
| &nbsp;&nbsp;Other assets – derivatives | 3 |  |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $104933 | $5903 | $85211 | $13819 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest-sensitive contract liabilities – embedded derivatives | $470 | $— | $— | $470 |
| &nbsp;&nbsp;&nbsp;Other liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Funds withheld at interest – embedded derivatives | (59) |  |  | (59) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivatives | 599 |  | 596 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $1010 | $— | $596 | $414 |

---

(1)Excludes limited partnerships that are measured at estimated fair value using the NAV per share (or its equivalent) as a practical expedient. As of December 31, 2025, the fair value of such investments was $925 million.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Quantitative Information Regarding Internally Priced Assets and Liabilities*

The following table presents quantitative information about significant unobservable inputs used in Level 3 fair value measurements that are developed internally by the Company as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Estimated Fair Value&nbsp;&nbsp;&nbsp;&nbsp; | Estimated Fair Value&nbsp;&nbsp;&nbsp;&nbsp; | Valuation Technique | Unobservable Input | Range (Weighted Average) | Range (Weighted Average) |
| | March 31, 2026 | December 31, 2025 | Valuation Technique | Unobservable Input | March 31, 2026 | December 31, 2025 |
| Assets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Corporate | $585 | $636 | Market comparable securities | Liquidity premium | 2%-4% (3%) | 0-4% (3%) |
|  |  |  |  | EBITDA Multiple | 6.0x-14.1x (8.0x) | 6.0x-14.8x (9.3x) |
| &nbsp;&nbsp;&nbsp;ABS | 1153 | 1329 | Market comparable securities | Liquidity premium | 0-67% (4%) | 0-20% (4%) |
| &nbsp;&nbsp;&nbsp;U.S. government | 3 | 4 | Market comparable securities | Liquidity premium | 1% | 1% |
| &nbsp;&nbsp;&nbsp;Equity securities | 30 | 41 | Market comparable securities | Liquidity premium | 4% | 4% |
|  |  |  |  | EBITDA Multiple | 7.5x-11.6x (9.0x) | 7.4x-13.3x (9.9x) |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest – embedded derivatives | 44 | 26 | Total return swap | Mortality | 0-100% (4%) | 0-100% (4%) |
|  |  |  |  | Lapse | 0-35% (16%) | 0-35% (17%) |
|  |  |  |  | Withdrawal | 0-10% (5%) | 0-10% (5%) |
|  |  |  |  | CVA | 0-5% (0%) | 0-5% (0%) |
|  |  |  |  | Crediting rate | 1-8% (2%) | 1%-8% (2%) |
| &nbsp;&nbsp;&nbsp;Other assets – derivatives | 2 | 3 | Credit default swap | Credit spread | 0-1% (0%) | 0-1% (0%) |
|  |  |  |  | Probability of default | 0-7% (1%) | 0-7% (1%) |
| Liabilities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest-sensitive contract liabilities – embedded derivatives – indexed products | 397 | 470 | Discounted cash flow | Mortality | 0-100% (3%) | 0-100% (3%) |
|  |  |  |  | Lapse | 0-35% (15%) | 0-35% (16%) |
|  |  |  |  | Withdrawal | 0-10% (5%) | 0-10% (4%) |
|  |  |  |  | Option budget projection | 1-8% (2%) | 1%-8% (2%) |
| &nbsp;&nbsp;&nbsp;Other liabilities – derivatives | 2 | 3 | Credit default swap | Credit spread | 0-1% (0%) | 0-1%(0%) |
|  |  |  |  | Probability of default | 0-7% (1%) | 0-7% (1%) |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Changes in Level 3 Assets and Liabilities*

Assets and liabilities transferred into Level 3 are due to a lack of observable market transactions and price information. Transfers out of Level 3 are primarily the result of the Company obtaining observable pricing information or a third-party pricing quotation that appropriately reflects the fair value of those assets and liabilities. The Company had Level 3 other swap assets and liabilities that on a gross and net basis were not material for the three months ended March 31, 2026.

For further information on the Company's valuation processes, see Note 13 – "Fair Value of Assets and Liabilities" in the Notes to Consolidated Financial Statements included in the 2025 Annual Report.

The reconciliations for all assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) are as follows (dollars in millions):

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | Fixed maturity securities available-for-sale | Fixed maturity securities available-for-sale | Fixed maturity securities available-for-sale | Fixed maturity securities available-for-sale |  | Real estate joint ventures – fair value |  | Funds <br>withheld at interest –embedded derivatives, net <sup>(1)</sup> | Funds <br>withheld at interest | Interest-sensitive contract <br>liabilities – embedded derivatives |
|  | Corporate | Foreign govt | Structured securities | U.S. and local govt | Equity securities | Real estate joint ventures – fair value | Short-term investments | Funds <br>withheld at interest –embedded derivatives, net <sup>(1)</sup> | Funds <br>withheld at interest | Interest-sensitive contract <br>liabilities – embedded derivatives |
| Fair value, beginning of period | $10027 | $120 | $3601 | $4 | $98 | $— | $33 | $(69) | $61 | $(470) |
| &nbsp;&nbsp;&nbsp;Total gains/losses (realized/unrealized) |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Included in earnings, net: |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income | 4 |  | (1) |  |  |  |  |  | 3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment related gains (losses), net | (30) |  |  |  | (10) |  |  | 44 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest credited |  |  |  |  |  |  |  |  |  | 30 |
| &nbsp;&nbsp;&nbsp;Included in other comprehensive income (loss) | (124) | (5) | (42) |  |  |  | (1) |  | (1) |  |
| &nbsp;&nbsp;Purchases <sup>(2)</sup> | 537 |  | 747 |  | 4 | 16 | 14 |  | 1 | (29) |
| &nbsp;&nbsp;Sales <sup>(2)</sup> | (130) |  | (37) |  | (1) |  | (2) |  |  |  |
| &nbsp;&nbsp;Settlements <sup>(2)</sup> | (182) |  | (691) | (1) |  |  | (18) |  | (1) | 72 |
| &nbsp;&nbsp;&nbsp;Transfers into Level 3 | 6 |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Transfers out of Level 3 | (34) |  | (35) |  |  |  | (6) |  |  |  |
| Fair value, end of period | $10074 | $115 | $3542 | $3 | $91 | $16 | $20 | $(25) | $63 | $(397) |
| Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period |
| Included in earnings, net: |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $3 | $— | $(1) | $— | $— | $— | $— | $— | $3 | $— |
| &nbsp;&nbsp;&nbsp;Investment related gains (losses), net | (35) |  |  |  | (10) |  |  | 44 |  |  |
| &nbsp;&nbsp;&nbsp;Interest credited |  |  |  |  |  |  |  |  |  | (42) |
| Included in other comprehensive income (loss) | (118) | (5) | (44) |  |  |  |  |  | (1) |  |

---

(1)Funds withheld at interest – embedded derivative assets and liabilities are presented net for purposes of the rollforward.

(2)The amount reported within purchases, sales and settlements is the purchase price (for purchases) and the sales/settlement proceeds (for sales and settlements) based upon the actual date purchased or sold/settled. Items purchased and sold/settled in the same period are excluded from the rollforward. The Company had no issuances during the period.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | Fixed maturity securities available-for-sale | Fixed maturity securities available-for-sale | Fixed maturity securities available-for-sale | Fixed maturity securities available-for-sale |  | Real estate joint ventures – fair value |  | Funds <br>withheld at interest –embedded derivatives, net <sup>(1)</sup> | Funds <br>withheld at interest | Interest-sensitive contract <br>liabilities – embedded derivatives |
|  | Corporate | Foreign govt | Structured securities | U.S. and local govt | Equity securities | Real estate joint ventures – fair value | Short-term investments | Funds <br>withheld at interest –embedded derivatives, net <sup>(1)</sup> | Funds <br>withheld at interest | Interest-sensitive contract <br>liabilities – embedded derivatives |
| Fair value, beginning of period | $6854 | $30 | $1799 | $5 | $88 | $— | $11 | $(55) | $56 | $(435) |
| &nbsp;&nbsp;&nbsp;Total gains/losses (realized/unrealized) |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Included in earnings, net: |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income | 4 |  | 2 |  |  |  |  |  | (1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment related gains (losses), net | (7) |  | 1 |  |  |  |  | (11) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest credited |  |  |  |  |  |  |  |  |  | 24 |
| &nbsp;&nbsp;&nbsp;Included in other comprehensive income (loss) | 39 |  | 20 |  |  |  |  |  | 2 |  |
| &nbsp;&nbsp;Purchases <sup>(2)</sup> | 1514 |  | 196 |  |  |  |  |  |  | 7 |
| &nbsp;&nbsp;Sales <sup>(2)</sup> | (44) |  |  |  | (1) |  |  |  |  |  |
| &nbsp;&nbsp;Settlements <sup>(2)</sup> | (140) |  | (114) | (1) |  |  | (6) |  |  | 21 |
| &nbsp;&nbsp;&nbsp;Transfers into Level 3 | 2 |  | 10 |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Transfers out of Level 3 |  |  | (6) |  |  |  | (2) |  |  |  |
| Fair value, end of period | $8222 | $30 | $1908 | $4 | $87 | $— | $3 | $(66) | $57 | $(383) |
| Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period |
| Included in earnings, net: |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $3 | $— | $1 | $— | $— | $— | $— | $— | $(1) | $— |
| &nbsp;&nbsp;&nbsp;Investment related gains (losses), net | (8) |  |  |  | 1 |  |  | (11) |  |  |
| &nbsp;&nbsp;&nbsp;Interest credited |  |  |  |  |  |  |  |  |  | 3 |
| Included in other comprehensive income (loss) | 40 |  | 21 |  |  |  |  |  | 2 |  |

---

(1)Funds withheld at interest – embedded derivative assets and liabilities are presented net for purposes of the rollforward.

(2)The amount reported within purchases, sales and settlements is the purchase price (for purchases) and the sales/settlement proceeds (for sales and settlements) based upon the actual date purchased or sold/settled. Items purchased and sold/settled in the same period are excluded from the rollforward. The Company had no issuances during the period.

*Nonrecurring Fair Value Measurements*

The Company has certain assets subject to measurement at fair value on a nonrecurring basis, in periods subsequent to their initial recognition if they are determined to be impaired. The following table presents information for assets measured at an estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (dollars in millions). The estimated fair values for these assets were determined using significant unobservable inputs (Level 3). For the three months ended March 31, 2025, the Company did not have any material assets that were measured at fair value on a nonrecurring basis due to impairment.

---

| | | |
|:---|:---|:---|
| | Carrying Value After Measurement | Carrying Value After Measurement |
| | At March 31, 2026 | At December 31, 2025 |
| Mortgage loans | $8 | $21 |
| Limited partnerships and real estate joint ventures | 10 | 46 |

---

---

| | |
|:---|:---|
| | Investment Related Gains (Losses), Net |
| | Three months ended March 31, 2026 |
| Mortgage loans | $(1) |
| Limited partnerships and real estate joint ventures | (6) |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Fair Value of Financial Instruments Carried at Other Than Fair Value*

The following table presents the carrying values and estimated fair values of the Company's financial instruments, which were not measured at fair value on a recurring basis, as of March 31, 2026 and December 31, 2025 (dollars in millions). For additional information regarding the methods and significant assumptions used by the Company to estimate these fair values, see Note 13 – "Fair Value of Assets and Liabilities" in the Notes to Consolidated Financial Statements included in the 2025 Annual Report. This table excludes any payables or receivables for collateral under repurchase/reverse repurchase agreements and other transactions. The estimated fair value of the excluded amounts approximates carrying value as they equal the amount of cash collateral received/paid.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **March 31, 2026:** | Carrying <br>Value <sup>(1)</sup> | Estimated <br>Fair Value | Fair Value Measurement Using: | Fair Value Measurement Using: | Fair Value Measurement Using: |
| **March 31, 2026:** | Carrying <br>Value <sup>(1)</sup> | Estimated <br>Fair Value | Level 1 | Level 2 | Level 3 |
| Assets: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Mortgage loans | $11318 | $11149 | $— | $— | $11149 |
| &nbsp;&nbsp;&nbsp;Policy loans | 3703 | 3703 |  | 3703 |  |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest | 8476 | 8285 |  |  | 8285 |
| &nbsp;&nbsp;&nbsp;Limited partnerships – cost method | 71 | 99 |  |  | 99 |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | 1958 | 1958 | 1958 |  |  |
| &nbsp;&nbsp;&nbsp;Short-term investments | 83 | 83 | 83 |  |  |
| &nbsp;&nbsp;&nbsp;Other invested assets | 1290 | 1063 | 1 | 68 | 994 |
| &nbsp;&nbsp;&nbsp;Accrued investment income | 1361 | 1361 |  | 1361 |  |
| &nbsp;&nbsp;&nbsp;Other asset | 1029 | 1039 |  |  | 1039 |
| Liabilities: |  |  |  |  |  |
| &nbsp;&nbsp;Interest-sensitive contract liabilities <sup>(2)</sup> | $31679 | $31579 | $— | $— | $31579 |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest | 6616 | 6441 |  |  | 6441 |
| &nbsp;&nbsp;&nbsp;Long-term debt | 6105 | 5951 |  |  | 5951 |
| **December 31, 2025:** |  |  |  |  |  |
| Assets: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Mortgage loans | $11104 | $11044 | $— | $— | $11044 |
| &nbsp;&nbsp;&nbsp;Policy loans | 3541 | 3541 |  | 3541 |  |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest | 8216 | 7970 |  |  | 7970 |
| &nbsp;&nbsp;&nbsp;Limited partnerships – cost method | 72 | 98 |  |  | 98 |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | 1708 | 1708 | 1708 |  |  |
| &nbsp;&nbsp;&nbsp;Short-term investments | 91 | 91 | 91 |  |  |
| &nbsp;&nbsp;&nbsp;Other invested assets | 1271 | 1051 | 2 | 68 | 981 |
| &nbsp;&nbsp;&nbsp;Accrued investment income | 1296 | 1296 |  | 1296 |  |
| &nbsp;&nbsp;&nbsp;Other asset | 1020 | 1071 |  |  | 1071 |
| Liabilities: |  |  |  |  |  |
| &nbsp;&nbsp;Interest-sensitive contract liabilities <sup>(2)</sup> | $31056 | $31013 | $— | $— | 31013 |
| &nbsp;&nbsp;&nbsp;Funds withheld at interest | 6863 | 6681 |  |  | 6681 |
| &nbsp;&nbsp;&nbsp;Long-term debt | 5710 | 5638 |  |  | 5638 |

---

(1)Carrying values presented herein may differ from those in the Company's condensed consolidated balance sheets because certain items within the respective financial statement captions may be measured at fair value on a recurring basis.

(2)Carrying values and estimated fair values presented herein include a reinsurance recoverable of $1.8 billion as of March 31, 2026 and $1.9 billion as of December 31, 2025.

NOTE 13 INCOME TAX

The effective tax rate for the three months ended March 31, 2026 was 24.9% on pre-tax income. The tax rate was higher than the U.S. statutory rate primarily due to income earned in foreign jurisdictions with statutory tax rates higher than in the U.S. as well as an increase to the valuation allowance on foreign tax credits. These increases were partially offset with benefits from additional foreign tax credits generated during the year. The effective tax rate for the three months ended March 31, 2025 was 22.2% on pre-tax income. The tax rate was higher than the U.S. statutory rate primarily due to income earned in foreign jurisdictions with higher statutory rates than the U.S., partially offset with benefits due to the adjustments to the valuation allowance and benefits received from taxes paid in foreign jurisdictions.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

NOTE 14 COMMITMENTS, CONTINGENCIES AND GUARANTEES

***Commitments***

*Funding of Investments*

The Company's commitments to fund investments as of March 31, 2026 and December 31, 2025, are presented in the following table (dollars in millions):

---

| | | |
|:---|:---|:---|
| | March 31, 2026 | December 31, 2025 |
| Limited partnerships and real estate joint ventures | $2247 | $2328 |
| Mortgage loans | 344 | 192 |
| Bank loans and private placements | 2702 | 2796 |
| Lifetime mortgages | 124 | 128 |

---

The Company anticipates that the majority of its current commitments will be invested over the next five years; however, these commitments could become due any time at the request of the counterparties. Bank loans and private placements are included in fixed maturity securities available-for-sale.

The Company has an immaterial liability, included in other liabilities, for current expected credit losses associated with unfunded commitments as of March 31, 2026 and December 31, 2025.

***Funding Agreements***

*Federal Home Loan Bank ("FHLB") of Des Moines*

The Company is a member of the FHLB and, through membership, has issued funding agreements to the FHLB in exchange for cash advances. As of March 31, 2026 and December 31, 2025, the Company had $1.3 billion of FHLB funding agreements outstanding. The Company is required to provide collateral in excess of the funding agreement amounts outstanding, considering any discounts to the securities posted and prepayment penalties.

*Funding Agreement Backed Notes*

The Company's FABN program allows RGA Global Funding, a special-purpose, unaffiliated statutory trust, to offer its senior secured medium-term notes to investors. RGA Global Funding uses the net proceeds from each sale to purchase one or more funding agreements from the Company. As of March 31, 2026 and December 31, 2025, the Company had $5.8 billion of FABN agreements outstanding, which are reflected in interest-sensitive contract liabilities.

***Contingencies***

*Litigation*

The Company is subject to litigation and regulatory investigations or actions from time to time. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters will have a material adverse effect on the financial condition, results of operations or cash flows of the Company. However, in light of the inherent uncertainties involved in future or pending legal, regulatory and governmental matters, some of which are beyond the Company's control, and indeterminate or potentially substantial amount of damages sought in any such matters, an adverse outcome could be material to the Company's financial condition, results of operations or cash flows for any particular reporting period. A legal reserve is established when the Company is notified of an arbitration demand, litigation or regulatory action or is notified that an arbitration demand, litigation or regulatory action is imminent, it is probable that the Company will incur a loss as a result and the amount of the probable loss is reasonably capable of being estimated.

***Guarantees***

*Statutory Reserve Support*

Certain RGA subsidiaries have committed to provide statutory reserve support to third parties, in exchange for a fee, by funding loans if certain defined events occur. Such statutory reserves are required under the U.S. Valuation of Life Policies Model Regulation (commonly referred to as Regulation XXX for term life insurance policies and Regulation A-XXX for universal life secondary guarantees). In addition, certain subsidiaries have also committed to provide capital support to a third party, in exchange for a fee, by agreeing to assume real estate leases in the event of a severe and prolonged decline in the commercial lease market. Upon assumption of a lease, the Company would recognize a right of use asset and lease obligation. As of March 31, 2026, the Company does not believe that it will be required to provide any funding under these commitments as the occurrence of the defined events is considered remote. The following table presents the maximum potential obligation for these commitments as of March 31, 2026 (dollars in millions):

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | |
|:---|:---|
| <u>Commitment Period</u> | Maximum Potential Obligation |
| 2034 | $1243 |
| 2035 | 1893 |
| 2036 | 2349 |
| 2037 | 5100 |
| 2038 | 1750 |
| 2039 | 8751 |
| 2041 | 720 |
| 2046 | 3000 |
| 2049 | 4750 |

---

***Support Agreements***

RGA, Inc. and several of its subsidiaries are obligors to various capital maintenance agreements with its subsidiaries. Under these agreements, the obligor guarantees for specified periods of time (depending on jurisdiction) that the applicable subsidiary will meet specified capital and surplus levels. Given the amount of business that has been and is expected to be written by the applicable subsidiaries benefiting from these agreements, the Company anticipates that the obligors will have sufficient liquidity and capital to meet any obligations under these agreements.

NOTE 15 SEGMENT INFORMATION

*Segments*

The Company has nine geographic-based and business-based operational segments including a Corporate and Other segment. Geographic-based operations are further segmented into traditional and financial solutions businesses. The Company's geographic based segments are U.S. and Latin America, Canada, Europe Middle East and Africa, and Asia Pacific.

Traditional reinsurance includes individual and group life and health, disability, long-term care and critical illness reinsurance. Financial Solutions includes asset-intensive reinsurance, longevity reinsurance, stable value products, pension risk transfer transactions and capital solutions products.

Corporate and Other revenues primarily include investment income from unallocated invested assets and service fees. Corporate and Other expenses consist of the offset to capital charges allocated to the operating segments within the policy acquisition costs and other insurance income line item, unallocated corporate overhead and executive costs, interest expense related to debt and service business expenses. Additionally, Corporate and Other includes results from the Company's FABNs issued prior to January 1, 2025. Effective January 1, 2025, newly issued FABNs are included in the U.S. Financial Solutions segment.

*Segment Accounting Policies*

The accounting policies of the segments are the same as those described in Note 2 – "Significant Accounting Policies and Pronouncements" in the Notes to Consolidated Financial Statements in the 2025 Annual Report.

The Company allocates capital to its segments based on an internally developed economic capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model considers the unique and specific nature of the risks inherent in the Company's businesses. As a result of the economic capital allocation process, a portion of investment income is attributed to the segments based on the level of allocated capital. In addition, the segments are charged for excess capital utilized above the allocated economic capital basis. This charge is included in policy acquisition costs and other insurance expenses.

There are no intersegment reinsurance transactions or revenues, and the Company does not have any material long-lived assets.

No individual client generated 10% or more of the Company's total gross premiums and other revenues on a consolidated basis for the three months ended March 31, 2026 and 2025. For the purpose of this disclosure, companies that are within the same insurance holding company structure are combined.

*Financial Measures*

The Company segment measure of profit or loss is adjusted operating income (loss) before income taxes. Adjusted operating income before income taxes does not equate to "Income (loss) before income taxes" as determined in accordance with U.S. GAAP but is the measure of segment profit or loss used by the Company's chief operating decision maker to evaluate segment performance and allocate resources and, consistent with authoritative guidance, is the measure of segment performance presented below. Adjusted operating income (loss) before income taxes is calculated as income before income taxes excluding, as applicable:

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Substantially all of the effects of net investment related gains and losses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the fair value of embedded derivatives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the fair value of contracts that provide market risk benefits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-economic losses at contract inception for direct pension risk transfer single premium business (which are amortized into adjusted operating income within adjusted claims and other policy benefits over the estimated lives of the contracts);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Any net gain or loss from discontinued operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The cumulative effect of any accounting changes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The impact of certain tax related items; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Any other items the Company believes are not indicative of the Company's ongoing operations.

The Company's significant expenses are (1) adjusted claims and other policy benefits which exclude the non-economic losses at contract inception for direct pension risk transfer single premium business, (2) future policy benefits remeasurement gains and losses, (3) adjusted interest credited, which excludes the change in fair value of embedded derivatives associated with indexed products and (4) interest expense.

The Company's Chief Operating Decision Maker ("CODM") is the President and Chief Executive Officer ("CEO"). The CEO uses segment adjusted operating income before income taxes to allocate resources (including employees and financial and capital resources) for each segment including consideration of future performance. The CEO considers performance on a monthly basis for segment adjusted operating income before income taxes when making decisions about allocating capital, personnel, evaluating market opportunities and future growth. The CEO also uses segment adjusted operating income before income taxes to assess the performance for each segment and for evaluating compensation of certain employees.

The Company does not report total assets by segment, as this metric is not used by the CODM to allocate resources or evaluate segment performance.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The following tables summarize the Company's reportable segment revenues, significant expenses, measure of profit and loss and reconciliations to the Company's consolidated totals (dollars in millions):

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | **For the three months ended March 31, 2026:** | | | | | | | | |
|  | U.S. and Latin America | U.S. and Latin America | Canada | Canada | Europe, Middle East and Africa | Europe, Middle East and Africa | Asia Pacific | Asia Pacific | Corporate and Other | Total |
|  | Traditional | Financial Solutions | Traditional | Financial Solutions | Traditional | Financial Solutions | Traditional | Financial Solutions | Corporate and Other | Total |
| Segment revenues | $2215 | $1147 | $403 | $109 | $646 | $495 | $950 | $495 | $179 | $6639 |
| *Reconciliation of revenues:* |  |  |  |  |  |  |  |  |  |  |
| Investment and derivative gains (losses) |  |  |  |  |  |  |  |  |  | (198) |
| Change in fair value of funds withheld embedded derivatives |  |  |  |  |  |  |  |  |  | 44 |
| Funds withheld gains (losses) – investment income |  |  |  |  |  |  |  |  |  | 4 |
| Investment income (loss) on unit-linked variable annuities |  |  |  |  |  |  |  |  |  | (1) |
| Other revenues <sup>(1)</sup> |  |  |  |  |  |  |  |  |  | 6 |
| &nbsp;&nbsp;Total consolidated revenues |  |  |  |  |  |  |  |  |  | $6494 |
| Less significant expenses <sup>(2)</sup>:  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Adjusted claims and other policy benefits | 1777 | 597 | 316 | 93 | 543 | 347 | 726 | 222 |  |  |
| &nbsp;&nbsp;Future policy benefits remeasurement (gains) losses | (6) | 14 | (1) | (1) | (10) | (11) | 9 | (1) |  |  |
| &nbsp;&nbsp;Adjusted interest credited | 22 | 264 |  |  |  | 8 |  | 140 | 44 |  |
| &nbsp;&nbsp;Interest expense |  |  |  |  |  |  |  |  | 98 |  |
| &nbsp;&nbsp;Other segment items <sup>(3)</sup> | 284 | 154 | 50 | 7 | 59 | 23 | 90 | 69 | 102 |  |
| Adjusted operating income (loss) before income taxes | $138 | $118 | $38 | $10 | $54 | $128 | $125 | $65 | $(65) | $611 |
| *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* |  |  |  |  |  |  |  |
| Investment and derivative gains (losses) | Investment and derivative gains (losses) | Investment and derivative gains (losses) | Investment and derivative gains (losses) |  |  |  |  |  |  | (198) |
| Market risk benefits remeasurement gains (losses) | Market risk benefits remeasurement gains (losses) | Market risk benefits remeasurement gains (losses) | Market risk benefits remeasurement gains (losses) |  |  |  |  |  |  | (22) |
| Change in fair value of funds withheld embedded derivatives | Change in fair value of funds withheld embedded derivatives | Change in fair value of funds withheld embedded derivatives | Change in fair value of funds withheld embedded derivatives |  |  |  |  |  |  | 44 |
| Funds withheld gains (losses) – investment income | Funds withheld gains (losses) – investment income | Funds withheld gains (losses) – investment income | Funds withheld gains (losses) – investment income |  |  |  |  |  |  | 4 |
| Derivatives – interest credited | Derivatives – interest credited | Derivatives – interest credited | Derivatives – interest credited |  |  |  |  |  |  | (3) |
| Investment income (loss) on unit-linked variable annuities | Investment income (loss) on unit-linked variable annuities | Investment income (loss) on unit-linked variable annuities | Investment income (loss) on unit-linked variable annuities |  |  |  |  |  |  | (1) |
| Interest credited on unit-linked variable annuities | Interest credited on unit-linked variable annuities | Interest credited on unit-linked variable annuities | Interest credited on unit-linked variable annuities |  |  |  |  |  |  | 1 |
| Interest expense on uncertain tax positions | Interest expense on uncertain tax positions | Interest expense on uncertain tax positions | Interest expense on uncertain tax positions |  |  |  |  |  |  | (1) |
| Other reconciling items <sup>(4)</sup> | Other reconciling items <sup>(4)</sup> | Other reconciling items <sup>(4)</sup> | Other reconciling items <sup>(4)</sup> |  |  |  |  |  |  | 6 |
| &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income |  |  |  |  |  | $441 |

---

(1)Includes market valuation adjustments on surrender charges and other immaterial items.

(2)The significant expense categories and amounts align with the segment level information that is regularly provided to the CEO. Intersegment expenses are included within the amounts above.

(3)Includes policy acquisition costs and other insurance expenses and other operating expenses.

(4)Includes market valuation adjustments on surrender charges, pension risk transfer initial loss and other immaterial items.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | **For the three months ended March 31, 2025:** | | | | | | | | |
|  | U.S. and Latin America | U.S. and Latin America | Canada | Canada | Europe, Middle East and Africa | Europe, Middle East and Africa | Asia Pacific | Asia Pacific | Corporate and Other | Total |
|  | Traditional | Financial Solutions | Traditional | Financial Solutions | Traditional | Financial Solutions | Traditional | Financial Solutions | Corporate and Other | Total |
| Segment revenues | $2191 | $496 | $384 | $107 | $572 | $282 | $850 | $321 | $137 | $5340 |
| *Reconciliation of revenues:* |  |  |  |  |  |  |  |  |  |  |
| Investment and derivative gains (losses) |  |  |  |  |  |  |  |  |  | (71) |
| Change in fair value of funds withheld embedded derivatives |  |  |  |  |  |  |  |  |  | (11) |
| Funds withheld gains (losses) – investment income |  |  |  |  |  |  |  |  |  |  |
| Investment income (loss) on unit-linked variable annuities |  |  |  |  |  |  |  |  |  |  |
| Other revenues <sup>(1)</sup> |  |  |  |  |  |  |  |  |  | 2 |
| &nbsp;&nbsp;Total consolidated revenues |  |  |  |  |  |  |  |  |  | $5260 |
| Less significant expenses <sup>(2)</sup>:  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Adjusted claims and other policy benefits | 1773 | 200 | 295 | 91 | 483 | 167 | 671 | 145 |  |  |
| &nbsp;&nbsp;Future policy benefits remeasurement (gains) losses | (25) | (2) | 3 |  | (8) | (3) | (18) | (3) |  |  |
| &nbsp;&nbsp;Adjusted interest credited | 29 | 123 |  |  |  | 6 |  | 84 | 47 |  |
| &nbsp;&nbsp;Interest expense |  |  |  |  |  |  |  |  | 80 |  |
| &nbsp;&nbsp;Other segment items <sup>(3)</sup> | 274 | 108 | 54 | 5 | 47 | 22 | 91 | 36 | 80 |  |
| Adjusted operating income (loss) before income taxes | $140 | $67 | $32 | $11 | $50 | $90 | $106 | $59 | $(70) | $485 |
| *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* | *Reconciliation of adjusted operating income (loss) before income taxes* |  |  |  |  |  |
| Investment and derivative gains (losses) | Investment and derivative gains (losses) | Investment and derivative gains (losses) | Investment and derivative gains (losses) |  |  |  |  |  |  | (71) |
| Market risk benefits remeasurement gains (losses) | Market risk benefits remeasurement gains (losses) | Market risk benefits remeasurement gains (losses) | Market risk benefits remeasurement gains (losses) |  |  |  |  |  |  | (29) |
| Change in fair value of funds withheld embedded derivatives | Change in fair value of funds withheld embedded derivatives | Change in fair value of funds withheld embedded derivatives | Change in fair value of funds withheld embedded derivatives |  |  |  |  |  |  | (11) |
| Funds withheld gains (losses) – investment income | Funds withheld gains (losses) – investment income | Funds withheld gains (losses) – investment income | Funds withheld gains (losses) – investment income |  |  |  |  |  |  |  |
| Derivatives – interest credited | Derivatives – interest credited | Derivatives – interest credited | Derivatives – interest credited |  |  |  |  |  |  | (10) |
| Investment income (loss) on unit-linked variable annuities | Investment income (loss) on unit-linked variable annuities | Investment income (loss) on unit-linked variable annuities | Investment income (loss) on unit-linked variable annuities |  |  |  |  |  |  |  |
| Interest credited on unit-linked variable annuities | Interest credited on unit-linked variable annuities | Interest credited on unit-linked variable annuities | Interest credited on unit-linked variable annuities |  |  |  |  |  |  |  |
| Interest expense on uncertain tax positions | Interest expense on uncertain tax positions | Interest expense on uncertain tax positions | Interest expense on uncertain tax positions |  |  |  |  |  |  |  |
| Other reconciling items <sup>(4)</sup> | Other reconciling items <sup>(4)</sup> | Other reconciling items <sup>(4)</sup> | Other reconciling items <sup>(4)</sup> |  |  |  |  |  |  | 5 |
| &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income | &nbsp;&nbsp;Income before income taxes per condensed consolidated statements of income |  |  |  |  |  | $369 |

---

(1)Includes market valuation adjustments on surrender charges and other immaterial items.

(2)The significant expense categories and amounts align with the segment level information that is regularly provided to the CEO. Intersegment expenses are included within the amounts above.

(3)Includes policy acquisition costs and other insurance expenses and other operating expenses.

(4)Includes market valuation adjustments on surrender charges, pension risk transfer initial loss and other immaterial items.

NOTE 16 FINANCING ACTIVITIES

*2026 Subordinated Debt Issuances*

On March 3, 2026, the Company issued 6.375% fixed-rate reset subordinated debentures due 2056 with a face amount of $400 million and used the net proceeds for general corporate purposes. Capitalized issuance costs are estimated to be $5 million.

*2056 Subordinated Debt Redemption*

On May 1, 2026, a notice of redemption was issued to the holders of all of the Company's outstanding $400 million aggregate principal amount 5.75% Fixed-to-Floating Rate Subordinated Debentures due 2056 (the "2056 Debentures") in accordance with the terms of the indenture governing the 2056 Debentures. The 2056 Debentures will be redeemed in full on June 15, 2026, at a redemption price equal to 100% of the outstanding principal amount thereof, plus accrued and unpaid interest thereon.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

NOTE 17 NEW ACCOUNTING STANDARDS

Changes to the general accounting principles are established by the Financial Accounting Standards Board ("FASB") in the form of accounting standards updates to the FASB Accounting Standards Codification™. Accounting standards updates not listed below were assessed and determined to be not applicable or expected to have a minimal impact on the Company's condensed consolidated financial statements.

---

| | | |
|:---|:---|:---|
| **Description** | **Anticipated Date of Adoption** | **Effect on the Consolidated Financial Statements** |
| **Standards not yet adopted:** | | |
| *Disaggregation of Income Statement Expenses*<br>This standard requires disclosure, in the notes to the financial statements, of specific information about certain costs and expenses. Early adoption is permitted. | December 31, 2027 | The adoption of the new standard will be applied retrospectively to all periods presented in the year of adoption. The adoption of the new standard will expand the Company's disclosures but will have no impact on its results of operations or financial position. |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**<u>Cautionary Note Regarding Forward-Looking Statements</u>**

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and federal securities laws including, among others, statements relating to projections of the future operations, strategies, earnings, revenues, income or loss, ratios, financial performance, and growth potential of Reinsurance Group of America, Incorporated (the "Company"). Forward-looking statements often contain words and phrases such as "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "if," "intend," "likely," "may," "plan," "potential," "pro forma," "project," "should," "will," "would," and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. Forward-looking statements are based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. Forward-looking statements are not a guarantee of future performance and are subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results, performance, and achievements could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Factors that could also cause results or events to differ, possibly materially, from those expressed or implied by forward-looking statements, include, among others: (1) changes in mortality, morbidity, policyholder behavior, claims experience, investment returns, interest rates, expenses and other factors as compared to our pricing assumptions; (2) investment results, whether from changes in economic, capital- and credit-market conditions, asset selection, or otherwise, and their impact on the Company's investment securities, liquidity, portfolio yields, credit quality, access to capital, cost of capital, and amount of capital required for regulatory and contractual purposes; (3) changes in the Company's financial strength and credit ratings and the effect of such changes on the Company; (4) the availability, amount, cost, and market value of collateral necessary for regulatory reserves, capital, and client obligations; (5) changes in laws and regulations, tax policy and rates, accounting standards, and privacy, data security and cybersecurity regulations applicable to the Company, and actions by regulators with authority over the Company's operations, as well as regulatory restrictions on the ability of Company subsidiaries to pay dividends to the Company; (6) the impact of general economic conditions in the U.S. and globally, including as a result of inflation, interest rate levels, geopolitical instability, and impacts from the imposition of, or changes in tariffs, as well as the stability of and actions by governments, central banks, and economies in jurisdictions where the Company operates, affecting interest rates, markets generally, or the demand for insurance and reinsurance; (7) the stability and financial performance of clients, reinsurers, third-party investment managers and other institutions and the effects of the Company's dependence on such third parties; (8) the effectiveness of the Company's risk management strategy, policy, and procedures, whether relating to reinsurance, investment strategy, operations, or otherwise; (9) the impact of impairments of the value of the Company's investment securities on the Company's capital requirements and the fact that the determination of allowances and impairments taken on the Company's investments is highly subjective; (10) the threat of catastrophic events such as pandemics, epidemics, other major health issues, natural disasters, war, military actions (including conflicts in the Middle East), and terrorism or other acts of violence; (11) competitive factors and competitors' responses to the Company's initiatives; (12) development and introduction of new products and distribution opportunities and entry into new lines of business and markets; (13) the impact of the development and adoption of artificial intelligence; (14) the effect of acquisitions and other significant transactions, including risks related to the integration of acquired blocks of business and entities and the Company's ability to achieve the expected benefits of such transactions, including the transaction entered into with subsidiaries of Equitable Holdings, Inc. on July 31, 2025; (15) interruption or failure of the Company's telecommunication, information technology, or other operational systems, or the Company's failure to maintain adequate security to protect the confidentiality or privacy of personal or sensitive data and intellectual property stored on such systems; (16) adverse developments with respect to litigation, arbitration, or regulatory investigations or actions; (17) risks associated with our international operations, including related to fluctuation in foreign currency exchange rates; and (18) other risks and uncertainties described in this document and in the Company's other filings with the Securities and Exchange Commission ("SEC").

Forward-looking statements should be evaluated together with the many risks and uncertainties that affect the Company's business, including those mentioned in this document and described in the periodic reports the Company files with the SEC. These forward-looking statements speak only as of the date on which they are made. The Company does not undertake any obligation to update these forward-looking statements, even though the Company's situation may change in the future, except as required under applicable securities law. For a discussion of the risks and uncertainties that could cause actual results to differ materially from those contained in the forward-looking statements, you are advised to see Item 1A – "Risk Factors" in the 2025 Annual Report, as may be supplemented by Item 1A – "Risk Factors" in the Company's subsequent Quarterly Reports on Form 10-Q and in the Company's other periodic and current reports filed with the SEC.

**<u>Overview</u>**

The Company is among the leading global providers of life reinsurance and financial solutions, with $4.3 trillion of life reinsurance in force and assets of $164.1 billion as of March 31, 2026. Traditional reinsurance includes individual and group

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

life and health, disability and critical illness reinsurance. Financial solutions includes longevity reinsurance, asset-intensive reinsurance, pension risk transfer, capital solutions, including financial reinsurance and stable value products. The Company derives revenues primarily from renewal premiums from existing reinsurance treaties, new business premiums from existing or new reinsurance treaties, fee income from financial solutions business and income earned on invested assets.

The Company's Traditional reinsurance business involves reinsuring life insurance policies that are often in force for the remaining lifetime of the underlying individuals insured, with premiums earned typically over a period of 10 to 30 years or longer. To a lesser extent, the Company also reinsures certain health business, typically, for one to three years. Each year, however, a portion of the business under existing treaties terminates due to, among other things, lapses or voluntary surrenders of underlying policies, deaths of the insured, and the exercise of recapture options by ceding companies. The Company's Financial Solutions business, including significant asset-intensive and longevity risk transactions, allows its clients to take advantage of growth opportunities and manage their capital, longevity and investment risk. The Company also works with partners to provide pension solutions that enable plan sponsors to diversify and protect the benefits provided to the annuitants.

For its Traditional business, the Company's profitability largely depends on the volume and amount of death- and health-related claims incurred and the ability to adequately price the risks it assumes. While death claims are reasonably predictable over a period of many years, claims are less predictable over shorter periods and are subject to significant fluctuation from quarter to quarter and year to year. For longevity business, the Company's profitability depends on the lifespan of the underlying contract holders and the investment performance for certain contracts. Additionally, the Company generates profits on investment spreads associated with the reinsurance of investment type contracts and generates fees from financial reinsurance transactions, which are typically shorter duration than its traditional life reinsurance business. The Company believes that its sources of liquidity are sufficient to cover potential claims payments on both a short-term and long-term basis.

As is customary in the reinsurance business, clients continually update, refine and revise reinsurance information provided to the Company. Such revised information is used by the Company in preparation of its condensed consolidated financial statements and the financial effects resulting from the incorporation of revised data are reflected in the current period.

*Segment Presentation*

The Company has geographic-based and business-based operational segments. Geographic-based operations are further segmented into Traditional and Financial Solutions businesses. The Company allocates capital to its segments based on an internally developed economic capital model, the purpose of which is to measure the risk in the business and to provide a consistent basis upon which capital is deployed. The economic capital model considers the unique and specific nature of the risks inherent in RGA's businesses.

As a result of the economic capital allocation process, a portion of investment income is credited to the segments based on the level of allocated capital. In addition, the segments are charged for excess capital utilized above the allocated economic capital basis. This charge is included in policy acquisition costs and other insurance expenses. Segment investment performance varies with the composition of investments and the relative allocation of capital to the operating segments.

Segment revenue levels can be significantly influenced by currency fluctuations, large transactions, mix of business and reporting practices of ceding companies, and therefore may fluctuate from period to period. Although reasonably predictable over a period of years, segment claims experience can be volatile over shorter periods. See "Results of Operations by Segment" below for further information about the Company's segments.

**<u>Consolidated Results of Operations</u>**

A discussion of the Company's financial condition and results of operations for the three months ended March 31, 2026 and 2025 are presented below.

***Consolidated income before income taxes***

The following table summarizes the changes in net income for the periods presented (dollars in millions, except per share data):

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Revenues** |  |  |  |
| Net premiums | $4595 | $4019 | $576 |
| Net investment income | 1701 | 1232 | 469 |
| Investment related losses, net | (170) | (79) | (91) |
| Other revenues | 368 | 88 | 280 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 6494 | 5260 | 1234 |
| **Benefits and expenses** |  |  |  |
| Claims and other policy benefits | 4621 | 3822 | 799 |
| Future policy benefits remeasurement gains | (7) | (56) | 49 |
| Market risk benefits remeasurement (gains) losses | 22 | 29 | (7) |
| Interest credited | 480 | 299 | 181 |
| Policy acquisition costs and other insurance expenses | 512 | 417 | 95 |
| Other operating expenses | 326 | 300 | 26 |
| Interest expense | 99 | 80 | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total benefits and expenses | 6053 | 4891 | 1162 |
| **Income (loss) before income taxes** | 441 | 369 | 72 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 110 | 81 | 29 |
| **Net income (loss)** | $331 | $288 | $43 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interest | 1 | 2 | (1) |
| **Net income available to RGA, Inc. shareholders** | $330 | $286 | $44 |
| **Earnings per share** |  |  |  |
| Basic earnings per share | $5.04 | $4.33 | $0.71 |
| Diluted earnings per share | $4.98 | $4.27 | $0.71 |

---

*Consolidated results*

The increase in net income and income before income taxes for the three months ended March 31, 2026, was primarily the result of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The execution of reinsurance contracts with subsidiaries of Equitable Holdings, Inc. ("Equitable Holdings") on July 31, 2025. Pursuant to these agreements, the Company's U.S. Financial Solutions segment assumed a 75% quota share of Equitable Holdings' in force individual life insurance liabilities on a coinsurance and modified coinsurance basis, consisting of a diversified mix of life products and account value liabilities, with total liabilities of approximately $12 billion. This transaction increased income before income taxes by $39 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An increase in net investment income due to an increase in invested assets and an increase in variable investment income, partially offset by an increase in interest credited.

The increase in income was partially offset by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An increase in investment related losses, net, resulting from higher realized losses from portfolio repositioning, a decrease in the fair value of freestanding derivatives and an increase in impairments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An increase in policy acquisition costs and other insurance expenses due to an increase in new business volume.

*Fluctuations in foreign currency to U.S. dollar exchange rates*

Foreign currency fluctuations can result in variances in the financial statement line items. Foreign currency fluctuations increased income before income taxes by $20 million primarily due to the strengthening of the British pound Canadian dollar and Euro as compared to the U.S. dollar. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Investment related gains and losses*

The increase in investment related losses, net is attributable to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• During 2026 and 2025, the Company repositioned its investment portfolio to generate higher yields, which led to net capital losses of $106 million and $51 million, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the fair value of freestanding derivatives increased investment related losses, net by $57 million in 2026, compared to $2 million in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company incurred $43 million and $8 million of changes in allowance for credit losses and impairments during the three months ended March 31, 2026 and 2025, respectively.

The increase in investment related losses, net was partially offset by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the fair value of embedded derivatives associated with modified coinsurance/funds withheld treaties, decreased investment related losses, net by $44 million in 2026.

See the Investment section within Management Discussion and Analysis, Note 10 – "Investments" and Note 11 – "Derivative Instruments" in the Notes to Condensed Consolidated Financial Statements for additional information on the changes in allowance for credit losses, impairment losses and derivatives.

*Market risk benefits*

Market risk benefits consist of guaranteed minimum benefits associated with the Company's reinsurance of variable and indexed annuities. The change in fair value of the freestanding derivatives purchased by the Company to hedge the liability is reflected in investment related gains (losses), net. The change in fair value of market risk benefits for guaranteed minimum benefits, after allowing for changes in the associated freestanding derivatives, decreased income before income taxes by $13 million and $3 million in 2026 and 2025, respectively.

*Non-economic changes in insurance liabilities*

Non-economic changes in insurance liabilities include the initial loss on PRT transactions, net of amortization and changes in the fair value of embedded derivatives associated with the Company's reinsurance of indexed products. The initial loss at inception of a PRT transaction is the difference between the single premium received and the valuation of the initial reserve based on interest rates prescribed by U.S. GAAP. During 2026 and 2025, the Company incurred non-economic losses of $3 million and $6 million, respectively.

*Income taxes*

The effective tax rate was 24.9% and 22.2% for 2026 and 2025, respectively. See Note 13 – "Income Tax" in the Notes to Condensed Consolidated Financial Statements for additional information.

***Consolidated adjusted operating income before income taxes***

Non-GAAP Measure – Consolidated adjusted operating income before income taxes is not determined in accordance with U.S. GAAP. The Company principally uses consolidated adjusted operating income before income taxes in evaluating performance because the Company believes that such measure, when reviewed in conjunction with relevant U.S. GAAP measure (i.e., income before income taxes), presents a clearer picture of its operating performance and assist the Company in the allocation of its resources. The Company believes that this non-GAAP financial measure provides investors and other third parties with a better understanding of the Company's results of operations, financial statements and the underlying profitability drivers and trends of the Company's businesses by excluding specified items which may not be indicative of the Company's ongoing operating performance and may fluctuate significantly from period to period. This measure should be considered supplementary to the Company's financial results that are presented in accordance with U.S. GAAP and should not be viewed as a substitute for U.S. GAAP measures. Other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way the Company calculates such measures. Consequently, the Company's non-GAAP financial measures may not be comparable to similar measures used by other companies.

Adjusted operating income (loss) before income taxes is calculated as income (loss) before income taxes excluding, as applicable:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Substantially all of the effect of net investment related gains and losses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the fair value of embedded derivatives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the fair value of contracts that provide market risk benefits;

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-economic losses at contract inception for direct pension risk transfer single premium business (which are amortized into adjusted operating income within claims and other policy benefits over the estimated lives of the contracts);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Any net gain or loss from discontinued operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The cumulative effect of any accounting changes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The impact of certain tax related items; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Any other items the Company believes are not indicative of the Company's ongoing operations.

See "Segment Accounting Policies" within Note 15 – "Segment Information" in the Notes to Condensed Consolidated Financial Statements for additional information regarding the presentation of segment results and the Company's definition of adjusted operating income.

*Reconciliation of income before income taxes to adjusted operating income (loss) before income taxes* 

The reconciliation of consolidated income before income taxes to consolidated adjusted operating income before income taxes is shown below for the periods presented (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| Income before income taxes | $441 | $369 | $72 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment and derivative (gains) losses | 198 | 71 | 127 |
| &nbsp;&nbsp;&nbsp;&nbsp;Market risk benefits remeasurement gains (losses) | 22 | 29 | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of funds withheld embedded derivatives | (44) | 11 | (55) |
| &nbsp;&nbsp;&nbsp;&nbsp;Funds withheld (gains) losses – investment income | (4) |  | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives – interest credited | 3 | 10 | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment income on unit-linked variable annuities | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest credited on unit-linked variable annuities | (1) |  | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense on uncertain tax positions | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (6) | (5) | (1) |
| Adjusted operating income before income taxes | $611 | $485 | $126 |

---

*Three months ended March 31, 2026, compared to the three months ended March 31, 2025*

The increase in adjusted operating income before income taxes was primarily the result of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An increase in net investment income attributable to an increase in invested assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Variable investment income, excluding spread related business, was $26 million for the three months ended March 31, 2026, compared to a loss of $6 million in the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contribution from the transaction with Equitable Holdings completed in the third quarter of 2025.

See "Results of Operations by Segment" for additional discussion of current and prior period results of operations.

*Fluctuations in foreign currency to U.S. dollar exchange rates*

Foreign currency fluctuations can result in variances in the financial statement line items. Foreign currency fluctuations increased adjusted operating income before income taxes by $17 million due to the strengthening of the British pound, Canadian dollar and Euro as compared to the U.S. dollar. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations.

*Premiums and business growth*

The increase in premiums was primarily due to organic growth on existing treaties and new business production, measured by the face amount of reinsurance in force, of $150.6 billion during 2026 compared to $131.7 billion during 2025. Consolidated assumed life reinsurance in force increased to $4.3 trillion as of March 31, 2026, from $4.0 trillion as of March 31, 2025, due to new business production and changes in foreign exchange rates.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Net investment income* 

The increase in net investment income was primarily due to an increase in the average invested asset base and an increase in variable investment income associated with joint venture and limited partnership investments. The following summarizes the primary drivers contributing to the increase in net investment income for the three months ended March 31, 2026 and 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The average invested assets at amortized cost, excluding spread related business, totaled $49.5 billion and $44.0 billion in 2026 and 2025, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The average yield earned on investments, excluding spread related business, was 4.93% and 4.64% in 2026 and 2025, respectively. The increase in investment yield for the three months ended March 31, 2026, in comparison with the same period in the prior year, was primarily due to increased variable income from limited partnerships and real estate joint ventures.

The average yield will vary from year to year depending on several variables, including the prevailing risk-free interest rate and credit spread environment, prepayment fees and make-whole premiums, changes in the mix of the underlying investments and cash and cash equivalents balances. Variable investment income from joint ventures and limited partnerships will also vary from year to year and is highly dependent on the timing of dividends and distributions on certain investments. Investment income is allocated to the operating segments based upon average assets and related capital levels deemed appropriate to support segment operations.

**Results of Operations by Segment**

As noted above, adjusted operating income (loss) before income taxes, when presented at a segment level, is a measure reported to the Company's management for purposes of making decisions about allocating resources to the Company's business segments and assessing the performance of the business segments and is presented in the Company's financial statement footnotes in accordance with U.S. GAAP. The Company's significant segment expenses are (1) adjusted claims and other policy benefits, which exclude the non-economic losses at contract inception for direct pension risk transfer single premium business, (2) future policy benefits remeasurement gains and losses, (3) adjusted interest credited, which excludes the change in the fair value of embedded derivatives associated with indexed products and (4) interest expense. See Note 15 – "Segment Information" in the Notes to Consolidated Financial Statements for additional information regarding the presentation of segment results and the Company's definition of adjusted operating income.

**<u>U.S. and Latin America Operations</u>** 

The U.S. and Latin America operations consist of two major segments: Traditional and Financial Solutions. The Traditional segment primarily specializes in the reinsurance of individual mortality-risk, long-term care, universal life products and, to a lesser extent, group reinsurance. The Financial Solutions segment consists of Asset-Intensive and Capital Solutions. Asset-Intensive within the Financial Solutions segment includes coinsurance of products which primarily exhibit interest rate and market risks such as annuities, corporate-owned life insurance policies, PRT group annuity contracts and, to a lesser extent, fee-based synthetic guaranteed investment contracts, indexed and variable life insurance, investment only and stable value contracts. Effective, January 1, 2025, newly issued FABN issuances are included in the U.S. Financial Solutions segment. Capital Solutions within the Financial Solutions segment primarily involves assisting ceding companies in meeting applicable regulatory requirements by enhancing the ceding companies' financial strength and regulatory surplus position through relatively low risk reinsurance and other transactions. Typically, these transactions do not qualify as reinsurance under GAAP due to the low-risk nature of the transactions; therefore only the related net fees are reflected in other revenues.

On July 31, 2025, the Company executed reinsurance contracts with subsidiaries of Equitable Holdings. Pursuant to these agreements, the Company's U.S. Financial Solutions segment assumed a 75% quota share of Equitable Holdings' in force individual life insurance liabilities on a coinsurance and modified coinsurance basis, consisting of a diversified mix of life products and account value liabilities, with total liabilities of approximately $12 billion.

The following table sets forth the U.S. and Latin America operating results for the periods indicated (dollars in millions). See additional information in the Traditional and Financial Solutions sections.

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| Total segment revenues | $3362 | $2687 | $675 |
| Total adjusted benefits and expenses | 3106 | 2480 | 626 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $256 | $207 | $49 |

---

The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to the contribution from the transaction with Equitable Holdings executed on July 31, 2025, and an increase in variable investment income in the current period.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*<u>Traditional Reinsurance</u>*

The following table sets forth the U.S. and Latin America Traditional segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $1932 | $1921 | $11 |
| Net investment income | 288 | 268 | 20 |
| Investment related losses, net | (12) | (6) | (6) |
| Other revenues | 7 | 8 | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 2215 | 2191 | 24 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 1777 | 1773 | 4 |
| Future policy benefits remeasurement gains | (6) | (25) | 19 |
| Adjusted interest credited | 22 | 29 | (7) |
| Policy acquisition costs and other insurance expenses | 223 | 219 | 4 |
| Other operating expenses | 61 | 55 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 2077 | 2051 | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $138 | $140 | $(2) |
| **Key metrics** |  |  |  |
| Life reinsurance in force | $1,900.2 billion | $1,840.6 billion |  |
| Future policy benefits remeasurement gains |  |  |  |
| &nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;Effect of actual variances from expected experience | $(6) | $(25) |  |
| Loss ratio <sup>(1)</sup> | 91.7% | 91.0% |  |
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 11.5% | 11.4% |  |
| Other operating expenses as a percentage of net premiums | 3.2% | 2.9% |  |

---

(1)Includes adjusted claims and other policy benefits and future policy benefits remeasurement gains.

The decrease in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to less favorable claims experience in the current period, mostly offset by the impact of rate increases and favorable variable investment income.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net premiums was primarily due to new business growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net investment income was primarily due to favorable variable investment income and a higher asset base supporting the business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The segment added new life business production, measured by face amount of life reinsurance in force, of $47.8 billion and $36.3 billion during the first three months of 2026 and 2025, respectively.

*Adjusted benefits and expenses*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The reduction in future policy benefits remeasurement gains was due to less favorable claims experience in the current period.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*<u>Financial Solutions</u>*

The following table sets forth the U.S. and Latin America Financial Solutions segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $320 | $109 | $211 |
| Net investment income | 564 | 337 | 227 |
| Investment related gains (losses), net | (16) |  | (16) |
| Other revenues | 279 | 50 | 229 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 1147 | 496 | 651 |
| **Benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 597 | 200 | 397 |
| Future policy benefits remeasurement (gains) losses | 14 | (2) | 16 |
| Adjusted interest credited | 264 | 123 | 141 |
| Policy acquisition costs and other insurance expenses | 131 | 84 | 47 |
| Other operating expenses | 23 | 24 | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 1029 | 429 | 600 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $118 | $67 | $51 |
| **Key metrics** |  |  |  |
| Future policy benefits remeasurement (gains) losses |  |  |  |
| &nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;Effect of actual variances from expected experience | $14 | $(2) |  |

---

The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to the transaction with Equitable Holdings and favorable variable investment income.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net premiums was primarily due to premiums received on the transaction with Equitable Holdings in the current year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net investment income was primarily due to an increase in the invested asset base supporting asset intensive transactions and an increase in variable investment income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ The book value of the invested asset base supporting asset-intensive transactions increased to $37.2 billion as of March 31, 2026, from $25.8 billion as of March 31, 2025, resulting in an increase in investment income. As of March 31, 2026 and March 31, 2025, $3.1 billion and $3.2 billion, respectively, of the invested assets were funds withheld at interest, of which 90% or greater was associated with two clients.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ The increase in the asset base was primarily due to $13.6 billion from new transactions and growth from treaties open to new business, offset by $0.8 billion in run-off of existing in force transactions and $1.5 billion associated with an external retrocession transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in other revenues was primarily due to policy charges on universal life-type policies associated with the transaction with Equitable Holdings.

*Adjusted benefits and expenses*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in adjusted claims and other policy benefits, adjusted interest credited and policy acquisition costs and other insurance expenses was primarily due to the transaction with Equitable Holdings.

*Reinsurance of separate accounts*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Certain of the Company's reinsurance contracts, including the Equitable Holdings transaction, reinsure the ceding company's separate account liabilities on a modified coinsurance basis. Under the terms of these arrangements, the ceding company retains the assets supporting the separate account liabilities. The Company receives a fee based on the policyholder's account value and is not directly exposed to the investment performance of the separate account assets. Periodic settlements between the Company and the ceding company are net settled. The Company, having the right of offset, has offset assumed separate account assets and liabilities in its consolidated balance sheet. As of March 31, 2026 and December 31, 2025, the Company assumed $16.1 billion and $16.7 billion of separate account liabilities.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**<u>Canada Operations</u>**

The Canada operations are primarily engaged in traditional reinsurance, which consists mainly of traditional individual life reinsurance, and to a lesser extent, creditor, group life and health, critical illness and disability reinsurance. Creditor insurance covers the outstanding balance on personal, mortgage or commercial loans in the event of death, disability or critical illness and is generally shorter in duration than traditional individual life insurance. The Canada Financial Solutions segment consists of longevity, asset-intensive and capital solutions.

The following table sets forth the Canada operating results for the periods indicated (dollars in millions). See additional information in the Traditional and Financial Solutions sections.

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| Total segment revenues | $512 | $491 | $21 |
| Total adjusted benefits and expenses | 464 | 448 | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $48 | $43 | $5 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to more favorable experience on Traditional business and favorable foreign currency fluctuations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency fluctuations can result in variances in the financial statement line items. Foreign currency fluctuations in the Canadian dollar resulted in a $2 million increase in adjusted operating income before income taxes for the three months ended March 31, 2026. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations.

*<u>Traditional Reinsurance</u>*

The following table sets forth the Canada Traditional segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $339 | $319 | $20 |
| Net investment income | 62 | 65 | (3) |
| Investment related gains, net | 1 | 1 |  |
| Other revenues | 1 | (1) | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 403 | 384 | 19 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 316 | 295 | 21 |
| Future policy benefits remeasurement (gains) losses | (1) | 3 | (4) |
| Adjusted interest credited |  |  |  |
| Policy acquisition costs and other insurance expenses | 36 | 41 | (5) |
| Other operating expenses | 14 | 13 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 365 | 352 | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $38 | $32 | $6 |
| **Key metrics** |  |  |  |
| Life reinsurance in force | $522.6 billion | $478.6 billion |  |
| Future policy benefits remeasurement (gains) losses |  |  |  |
| &nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | $(1) | $3 |  |
| Loss ratio <sup>(1)</sup> | 92.9% | 93.4% |  |
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 10.6% | 12.9% |  |
| Other operating expenses as a percentage of net premiums | 4.1% | 4.1% |  |

---

(1)Includes adjusted claims and other policy benefits and future policy benefits remeasurement (gains) losses.

The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to more favorable experience across all lines of business and favorable foreign currency fluctuations.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The increase in net premiums was primarily due to organic growth and favorable foreign currency fluctuations.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The segment added new life business production, measured by face amount of life reinsurance in force, of $13.1 billion and $13.2 billion during the first three months of 2026 and 2025, respectively.

*Adjusted benefits and expenses*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The decrease in the loss ratio for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to favorable experience across all lines of business in 2026.

*<u>Financial Solutions</u>*

The following table sets forth the Canada Financial Solutions segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $45 | $52 | $(7) |
| Net investment income | 62 | 51 | 11 |
| Investment related gains (losses), net | (1) |  | (1) |
| Other revenues | 3 | 4 | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 109 | 107 | 2 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 93 | 91 | 2 |
| Future policy benefits remeasurement (gains) losses | (1) |  | (1) |
| Adjusted interest credited |  |  |  |
| Policy acquisition costs and other insurance expenses | 6 | 5 | 1 |
| Other operating expenses | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 99 | 96 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $10 | $11 | $(1) |
| **Key metrics** |  |  |  |
| Future policy benefits remeasurement (gains) losses |  |  |  |
| &nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | $(1) | $— |  |

---

Adjusted operating income before income taxes for the three months ended March 31, 2026, was comparable to the same period in 2025.

**<u>Europe, Middle East and Africa Operations</u>** 

The Europe, Middle East and Africa ("EMEA") operations consist of two major segments: Traditional and Financial Solutions. The Traditional segment primarily provides reinsurance through yearly renewable term and coinsurance agreements on a variety of life, health and critical illness products. Reinsurance agreements may be facultative or automatic agreements covering primarily individual risks and, in some markets, group risks. The Financial Solutions segment consists of reinsurance and other transactions associated with longevity closed blocks, payout annuities, capital management solutions and financial reinsurance.

The following table sets forth the EMEA operating results for the periods indicated (dollars in millions). See additional information in the Traditional and Financial Solutions sections.

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| Total segment revenues | $1141 | $854 | $287 |
| Total adjusted benefits and expenses | 959 | 714 | 245 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $182 | $140 | $42 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to increased net premiums and an increase in net investment income, partially offset by increased adjusted claims and other policy benefits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency fluctuations can result in variances in the financial statement line items. Foreign currency fluctuations resulted in a $13 million increase in adjusted operating income before income taxes for the three months ended March 31, 2026. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*<u>Traditional Reinsurance</u>*

The following table sets forth the EMEA Traditional segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $605 | $540 | $65 |
| Net investment income | 35 | 30 | 5 |
| Investment related gains (losses), net |  |  |  |
| Other revenues | 6 | 2 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 646 | 572 | 74 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 543 | 483 | 60 |
| Future policy benefits remeasurement gains | (10) | (8) | (2) |
| Adjusted interest credited |  |  |  |
| Policy acquisition costs and other insurance expenses | 35 | 20 | 15 |
| Other operating expenses | 24 | 27 | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 592 | 522 | 70 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $54 | $50 | $4 |
| **Key metrics** |  |  |  |
| Life reinsurance in force | $1,074.4 billion | $1,036.7 billion |  |
| Future policy benefits remeasurement gains |  |  |  |
| &nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | $(10) | $(8) |  |
| Loss ratio <sup>(1)</sup> | 88.1% | 88.0% |  |
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 5.8% | 3.7% |  |
| Other operating expenses as a percentage of net premiums | 4.0% | 5.0% |  |

---

(1)Includes adjusted claims and other policy benefits and future policy benefits remeasurement gains.

The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to increased net premiums, offset by an increase in adjusted claims and other policy benefits.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The increase in net premiums was due to increased business volume on new and existing treaties in the first three months of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The segment added new life business production, measured by face amount of life reinsurance in force, of $35.6 billion and $63.4 billion during the three months ended March 31, 2026, and the same period in 2025, respectively.

*Adjusted benefits and expenses*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in policy acquisition costs and other insurance expenses as a percentage of net premiums was largely due to differences in allowance levels and the mix of business across the region.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*<u>Financial Solutions</u>*

The following table sets forth the EMEA Financial Solutions segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $344 | $189 | $155 |
| Net investment income | 137 | 85 | 52 |
| Investment related losses, net | (1) | (1) |  |
| Other revenues | 15 | 9 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 495 | 282 | 213 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 347 | 167 | 180 |
| Future policy benefits remeasurement (gains) losses | (11) | (3) | (8) |
| Adjusted interest credited | 8 | 6 | 2 |
| Policy acquisition costs and other insurance expenses | 3 | 1 | 2 |
| Other operating expenses | 20 | 21 | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 367 | 192 | 175 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $128 | $90 | $38 |
| **Key metrics** |  |  |  |
| Future policy benefits remeasurement (gains) losses |  |  |  |
| &nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | $(11) | $(3) |  |

---

The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to increased net investment income and increased net premiums, partially offset by an increase in adjusted claims and other policy benefits related to closed longevity blocks.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The increase in net premiums was primarily due to increased volumes of closed longevity block transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net investment income was primarily due to an increase in invested assets supporting the segment.

*Adjusted benefits and expenses* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The increase in adjusted claims and other policy benefits was the result of increased volumes of closed block longevity and asset-intensive transactions.

**<u>Asia Pacific Operations</u>**

Asia Pacific operations include business generated by the Company's offices throughout Asia and Australia. The Traditional segment's principal types of reinsurance include individual and group life and health, critical illness, disability and superannuation. Reinsurance agreements may be facultative or automatic agreements covering primarily individual risks, and in some markets, group risks. Superannuation is the Australian government mandated compulsory retirement savings program. Superannuation funds accumulate retirement funds for employees, and, in addition, typically offer life and disability insurance coverage. The Financial Solutions segment includes financial reinsurance, asset-intensive and certain disability and life blocks.

The following table sets forth the Asia Pacific operating results for the periods indicated (dollars in millions). See additional information in the Traditional and Financial Solutions sections.

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| Total segment revenues | $1445 | $1171 | $274 |
| Total adjusted benefits and expenses | 1255 | 1006 | 249 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $190 | $165 | $25 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to an increase in net investment income and business growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency fluctuations can result in variances in the financial statement line items. Foreign currency movements had no material impact on adjusted operating income before income taxes during the three months ended March 31, 2026. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*<u>Traditional Reinsurance</u>*

The following table sets forth the Asia Pacific Traditional segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $860 | $777 | $83 |
| Net investment income | 82 | 71 | 11 |
| Investment related gains losses, net |  | (1) | 1 |
| Other revenues | 8 | 3 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 950 | 850 | 100 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 726 | 671 | 55 |
| Future policy benefits remeasurement (gains) losses | 9 | (18) | 27 |
| Adjusted interest credited |  |  |  |
| Policy acquisition costs and other insurance expenses | 35 | 39 | (4) |
| Other operating expenses | 55 | 52 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 825 | 744 | 81 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $125 | $106 | $19 |
| **Key metrics** |  |  |  |
| Life reinsurance in force | $581.7 billion | $561.1 billion |  |
| Future policy benefits remeasurement (gains) losses |  |  |  |
| &nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | $9 | $(18) |  |
| Loss ratio <sup>(1)</sup> | 85.5% | 84.0% |  |
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 4.1% | 5.0% |  |
| Other operating expenses as a percentage of net premiums | 6.4% | 6.7% |  |

---

(1)Includes adjusted claims and other policy benefits and future policy benefits remeasurement (gains) losses.

The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to an increase in net premiums and net investment income, partially offset by an increase in adjusted claims and other policy benefits and future policy benefits remeasurement losses.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The increase in net premiums was primarily due to continued business growth in the segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The segment added new life business production, measured by face amount of life reinsurance in force, of $40.0 billion and $14.3 billion during the three months ended March 31, 2026 and 2025, respectively, due to new business production.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net investment income was due to higher investment yield and an increase in invested assets.

*Adjusted benefits and expenses*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The increase in the loss ratio for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to less favorable claims experience across the segment.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*<u>Financial Solutions</u>*

The following table sets forth the Asia Pacific Financial Solutions segment operating results for the periods indicated (dollars in millions):

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $150 | $112 | $38 |
| Net investment income | 319 | 196 | 123 |
| Investment related gains, net | 12 | 7 | 5 |
| Other revenues | 14 | 6 | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 495 | 321 | 174 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits | 222 | 145 | 77 |
| Future policy benefits remeasurement gains | (1) | (3) | 2 |
| Adjusted interest credited | 140 | 84 | 56 |
| Policy acquisition costs and other insurance expenses | 58 | 27 | 31 |
| Other operating expenses | 11 | 9 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 430 | 262 | 168 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating income before income taxes | $65 | $59 | $6 |
| **Key metrics** |  |  |  |
| Future policy benefits remeasurement gains |  |  |  |
| &nbsp;&nbsp;&nbsp;Effect of changes in cash flow assumptions | $— | $— |  |
| &nbsp;&nbsp;&nbsp;Effect of actual variances from expected experience | $(1) | $(3) |  |

---

The increase in adjusted operating income before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to an increase in net premiums and net investment income, partially offset by an increase in adjusted claims and other policy benefits, adjusted interest credited and policy acquisition costs and other insurance expenses.

The invested asset base supporting asset-intensive transactions increased to $38.0 billion as of March 31, 2026, from $25.0 billion as of March 31, 2025. The increase in the asset base compared to March 31, 2025, was primarily due to approximately $7.8 billion from transactions executed in the quarter and net organic growth of $5.2 billion from existing in force blocks. The amount of reinsurance assumed from client companies, as measured by pre-tax statutory surplus, risk based capital and other financial reinsurance structures, was $2.5 billion and $2.1 billion for the three months ended March 31, 2026 and 2025, respectively. Fees earned from this business can vary significantly depending on the size, complexity and timing of the transactions and, therefore, can fluctuate from period to period.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net premiums was due to increased contributions from several existing in force blocks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in net investment income was due to a growing asset base and higher variable investment income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in other revenues was due to higher initial income and surrender charges from transactions during the period.

*Adjusted benefits and expenses*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increases in adjusted claims and other policy benefits and adjusted interest credited were due to new asset-intensive transactions.

**<u>Corporate and Other</u>**

Corporate and Other revenues primarily include investment income from unallocated invested assets and service fees. Corporate and Other expenses consist of the offset to capital charges allocated to the operating segments within the policy acquisition costs and other insurance income line item, unallocated overhead and executive costs, interest expense related to debt and service business expenses. Additionally, Corporate and Other includes results from the Company's FABNs issued prior to January 1, 2025. Effective, January 1, 2025, newly issued FABN issuances are included in the U.S. Financial Solutions segment.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | |
|:---|:---|:---|:---|
| **For the three months ended March 31,** | | | |
|  | 2026 | 2025 | 2026 vs 2025 |
| **Segment revenues** |  |  |  |
| Net premiums | $— | $— | $— |
| Net investment income | 149 | 129 | 20 |
| Investment related gains, net | 1 | 3 | (2) |
| Other revenues | 29 | 5 | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total segment revenues | 179 | 137 | 42 |
| **Adjusted benefits and expenses** |  |  |  |
| Adjusted claims and other policy benefits |  |  |  |
| Future policy benefits remeasurement (gains) losses |  |  |  |
| Adjusted interest credited | 44 | 47 | (3) |
| Policy acquisition costs and other insurance expenses | (15) | (19) | 4 |
| Other operating expenses | 117 | 99 | 18 |
| Interest expense | 98 | 80 | 18 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted benefits and expenses | 244 | 207 | 37 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted operating loss before income taxes | $(65) | $(70) | $5 |

---

The decrease in adjusted operating loss before income taxes for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to an increase in net investment income and other revenues, partially offset by an increase in other operating expenses and interest expense.

*Segment revenues*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The increase in net investment income was primarily due to an increase in yield.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in other revenues was primarily due to income earned on a note receivable.

*Adjusted benefits and expenses*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in other operating expenses was primarily due to higher compensation expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The increase in interest expense was primarily due to an increase in outstanding debt.

**Liquidity and Capital Resources**

**<u>Overview</u>**

The Company believes that cash flows from the source of funds available to it will provide sufficient cash flows for the next twelve months and the foreseeable future thereafter to satisfy the current liquidity requirements of the Company under various scenarios that include the potential risk of early recapture of reinsurance treaties, market events and higher than expected claims. The Company performs periodic liquidity stress testing to ensure that its asset portfolio includes sufficient high quality liquid assets that could be utilized to bolster its liquidity position under stress scenarios. These assets could be utilized as collateral for secured borrowing transactions with various third parties or by selling the securities in the open market if needed. The Company's liquidity requirements have been and will continue to be funded through net cash flows from operations. However, in the event of significant unanticipated cash requirements beyond normal liquidity needs, the Company has multiple liquidity alternatives available based on market conditions and the amount and timing of the liquidity need. These alternatives include the sale of invested assets subject to market conditions, borrowings under committed credit facilities, secured borrowings, and if necessary, issuing long-term debt, preferred securities or common equity.

**<u>Current Market Environment</u>**

The Company's average investment yield, excluding spread related business, for the three months ended March 31, 2026, was 4.93%, 29 basis points higher than the same period in 2025. The average yield will vary from year to year depending on several variables, including the prevailing risk-free interest rate and credit spread environment, prepayment fees and make-whole premiums, changes in the mix of the underlying investments and cash and cash equivalents balances. Variable investment income from joint ventures and limited partnerships will also vary from year to year and is highly dependent on the timing of dividends and distributions on certain investments. Gross unrealized gains on fixed maturity securities available-for-sale decreased from $1.7 billion at December 31, 2025, to $1.1 billion at March 31, 2026. Gross unrealized losses increased from $7.0 billion at December 31, 2025 to $8.5 billion at March 31, 2026.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The Company continues to be in a position to hold any investment security showing an unrealized loss until recovery, provided it remains comfortable with the credit of the issuer. The Company does not rely on short-term funding or commercial paper and, to date, has experienced no liquidity pressure and does not anticipate such pressure in the foreseeable future.

The Company projects its reserves to be sufficient and does not expect to be required to take any actions to augment capital, even if interest rates remain at current levels for the next five years, assuming all other factors remain constant. To mitigate disintermediation risk, the Company purchased swaptions to protect against a material increase in interest rates. While the Company has felt the pressures of sustained low interest rates, followed by the recent significant increase in risk-free rates, and volatile equity markets, its business and results of operations are not overly sensitive to these risks. Mortality and morbidity risks continue to be the most significant risk for the Company. Although management believes that the Company's current capital base is adequate to support its business at current operating levels, it continues to monitor new business opportunities and any associated new capital needs that could arise from the changing financial landscape.

**<u>The Holding Company</u>**

RGA is an insurance holding company whose primary uses of liquidity include, but are not limited to, the immediate capital needs of its operating companies, dividends paid to its shareholders, repurchase of common stock and interest payments on its indebtedness. The primary sources of RGA's liquidity include proceeds from its capital-raising efforts, interest income on undeployed corporate investments, interest income received on surplus notes with RGA Reinsurance Company ("RGA Reinsurance"), RGA Life and Annuity Insurance Company ("RGA Life and Annuity") and Rockwood Reinsurance Company ("Rockwood Re"), and dividends from operating subsidiaries. As the Company continues to operate its business and manage capital, RGA will continue to be dependent upon these sources of liquidity. The following tables provide comparative information for RGA (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Interest and dividend income | $40 | $33 |
| Interest expense | 73 | 63 |
| Capital contributions to subsidiaries | 8 | 10 |
| Issuance of unaffiliated debt | 400 | 700 |
| Dividends to shareholders | 61 | 59 |

---

---

| | | |
|:---|:---|:---|
| | March 31, 2026 | December 31, 2025 |
| Cash and invested assets | $1574 | $1360 |

---

See Item 15, Schedule II – "Condensed Financial Information of the Registrant" in the 2025 Annual Report for additional financial information related to RGA.

The undistributed earnings of substantially all of the Company's foreign subsidiaries have been reinvested indefinitely in those non-U.S. operations, as described in Note 14 – "Income Tax" in the Notes to Consolidated Financial Statements in the 2025 Annual Report. As U.S. Tax Reform generally eliminates U.S. federal income taxes on dividends from foreign subsidiaries, the Company does not expect to incur material income taxes if these funds are repatriated.

RGA endeavors to maintain a capital structure that provides financial and operational flexibility to its subsidiaries, credit ratings that support its competitive position in the financial services marketplace, and shareholder returns. As part of the Company's capital deployment strategy, it has repurchased shares of RGA common stock and paid dividends to RGA shareholders, as authorized by the board of directors.

On January 29, 2026, RGA's board of directors authorized a share repurchase program for up to $500 million of RGA's outstanding common stock. The authorization was effective immediately and does not have an expiration date. During the three months ended March 31, 2026, the Company repurchased 225,638 shares of common stock under this program. As of March 31, 2026, the aggregate amount remaining under the Company's share repurchase authorization was approximately $450 million.

Repurchases will be made in accordance with applicable securities laws, through market transactions, block trades, privately negotiated transactions or other means, or a combination of these methods, with the timing and number of shares repurchased dependent on a variety of factors, including share price, corporate and regulatory requirements, and market and business conditions. Repurchases may be commenced or suspended from time to time without prior notice.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

Details underlying dividend and share repurchase program activity were as follows (in millions, except share data):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Dividends to shareholders | $61 | $59 |
| Purchase of common stock <sup>(1)</sup> | 50 |  |
| Total amount paid to shareholders | $111 | $59 |
| Number of common shares purchased <sup>(1)</sup> | 225638 |  |
| Average price per share | $221.59 | $— |

---

(1)Excludes shares utilized to execute and settle certain stock incentive awards.

In April 2026, RGA's board of directors declared a quarterly dividend of $0.93 per share. All future payments of dividends are at the discretion of RGA's board of directors and will depend on the Company's earnings, capital requirements, insurance regulatory conditions, operating conditions and other such factors as the board of directors may deem relevant. The amount of dividends that RGA can pay will depend in part on the operations of its reinsurance subsidiaries. See Note 3 – "Equity" in the Notes to Condensed Consolidated Financial Statements for information on the Company's share repurchase program.

**<u>Debt</u>**

Certain of the Company's debt agreements contain financial covenant restrictions related to, among others, liens, the issuance and disposition of stock of restricted subsidiaries, minimum requirements of consolidated net worth, maximum ratios of debt to capitalization and change of control provisions. On March 13, 2023, the Company entered into a syndicated revolving credit facility with a five-year term and an overall capacity of $850 million. As of March 31, 2026, the Company had no cash borrowings outstanding and no letters of credit issued under this facility. Under the terms of this facility, the Company is required to maintain a minimum consolidated net worth of $5.8 billion. Also, consolidated indebtedness, calculated as of the last day of each fiscal quarter, cannot exceed 35% of the sum of the Company's consolidated indebtedness plus adjusted RGA Inc.'s shareholders' equity. A material ongoing covenant default could require immediate payment of the amount due, including principal, under the Company's various debt agreements. Additionally, the Company's debt agreements contain cross-acceleration covenants, which would make outstanding borrowings immediately payable in the event of a material uncured covenant default under any of the agreements, including, but not limited to, non-payment of indebtedness when due for an amount in excess of the amounts set forth in those agreements, bankruptcy proceedings, or any other event that results in the acceleration of the maturity of indebtedness.

As of March 31, 2026 and December 31, 2025, the Company had $6.2 billion and $5.8 billion, respectively, in outstanding borrowings under its debt agreements and was in compliance with all covenants under those agreements. As of March 31, 2026 and December 31, 2025, the average interest rate on long-term debt outstanding was 5.40% and 5.33%, respectively. The ability of the Company to make debt principal and interest payments depends on the earnings and surplus of subsidiaries, investment earnings on undeployed capital proceeds, available liquidity at the holding company and the Company's ability to raise additional funds.

The Company enters into derivative agreements with counterparties that reference either the Company's debt rating or its financial strength rating. If either rating is downgraded in the future, it could trigger certain terms in the Company's derivative agreements, which could negatively affect overall liquidity. For the majority of the Company's derivative agreements, there is a termination event should the long-term senior debt ratings drop below either BBB+ (S&P) or Baa1 (Moody's) or the financial strength ratings drop below either A- (S&P) or A3 (Moody's).

On March 3, 2026, the Company issued 6.375% fixed-rate reset subordinated debentures due 2056 with a face amount of $400 million and used the net proceeds for general corporate purposes. Capitalized issuance costs are estimated to be $5 million.

On May 1, 2026, a notice of redemption was issued to the holders of all of the Company's outstanding $400 million aggregate principal amount 5.75% Fixed-to-Floating Rate Subordinated Debentures due 2056 (the "2056 Debentures") in accordance with the terms of the indenture governing the 2056 Debentures. The 2056 Debentures will be redeemed in full on June 15, 2026, at a redemption price equal to 100% of the outstanding principal amount thereof, plus accrued and unpaid interest thereon.

Based on the historic cash flows and the current financial results of the Company, management believes that RGA's cash flows will be sufficient to enable RGA to meet its obligations for at least the next twelve months.

**<u>Credit and Committed Facilities</u>**

The Company has obtained bank letters of credit in favor of various affiliated and unaffiliated insurance companies from which the Company assumes business. These letters of credit represent guarantees of performance under the reinsurance agreements and allow ceding companies to take statutory reserve credits. Certain of these letters of credit contain financial covenant

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

restrictions similar to those described in the "Debt" discussion above. At March 31, 2026, there were approximately $313 million of outstanding bank letters of credit in favor of third parties. Additionally, in accordance with applicable regulations, the Company utilizes letters of credit to secure statutory reserve credits when it retrocedes business to its affiliated subsidiaries. The Company retrocedes business to its affiliates to help reduce the amount of regulatory capital required in certain jurisdictions, such as the U.S., Canada and the U.K. The Company believes that the capital required to support the business retroceded to its affiliates reflects more realistic expectations than the original jurisdiction in which the business was written, where capital requirements are often considered to be quite conservative. As of March 31, 2026, $1.2 billion in letters of credit from various banks were outstanding, but undrawn, backing reinsurance between the various subsidiaries of the Company.

**<u>Cash Flows</u>**

The Company's principal cash inflows from its reinsurance operations include premiums and deposit funds received from ceding companies. The primary liquidity concerns with respect to these cash flows are early recapture of the reinsurance contract by the ceding company and lapses of annuity products reinsured by the Company. The Company's principal cash inflows from its invested assets result from investment income and the maturity and sales of invested assets. The primary liquidity concerns with respect to these cash inflows relates to the risk of default by debtors and interest rate volatility. The Company manages these risks very closely. See "Investments" below.

Additional sources of liquidity to meet unexpected cash outflows in excess of operating cash inflows and current cash and equivalents on hand includes drawing funds under a revolving credit facility, under which the Company had availability of $850 million as of March 31, 2026. The Company also had $302 million of funds available through collateralized borrowings from the FHLB as of March 31, 2026. In addition to these facilities, the Company's subsidiaries, RGA Reinsurance Company ("RGA Re") and RGA Americas Reinsurance Company, Ltd. ("RGA Americas"), maintain a $200 million committed credit facility to provide contingent capital to RGA Re and RGA Americas. As of March 31, 2026, the Company could have borrowed these additional amounts without violating any of its existing debt covenants.

The Company's principal cash outflows relate to the payment of claims liabilities, interest credited, operating expenses, income taxes, dividends to shareholders, purchases of treasury stock and principal and interest under debt and other financing obligations. The Company seeks to limit its exposure to loss on any single insured and to recover a portion of benefits paid by ceding reinsurance to other insurance enterprises or reinsurers under excess coverage and coinsurance contracts. See Note 2 – "Significant Accounting Policies and Pronouncements" in the Notes to Consolidated Financial Statements in the 2025 Annual Report. The Company performs annual financial reviews of its retrocessionaires to evaluate financial stability and performance. The Company has never experienced a material default in connection with retrocession arrangements, nor has it experienced any difficulty in collecting claims recoverable from retrocessionaires; however, no assurance can be given as to the future performance of such retrocessionaires or the recoverability of future claims. The Company's management believes that its cash and cash equivalents as well as its current sources of liquidity are adequate to meet its cash requirements for the next 12 months.

*Summary of Primary Sources and Uses of Liquidity and Capital*

The Company's primary sources and uses of liquidity and capital for the three months ended March 31, 2026 and 2025 are summarized as follows (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| | 2026 | 2025 |
| Sources: |  |  |
| Net cash provided by operating activities | $2873 | $1429 |
| Proceeds from long-term debt issuance, net | 395 | 691 |
| Treasury stock reissued | 5 |  |
| Change in deposit asset on reinsurance | 43 | 50 |
| Net deposits to investment-type policies and contracts | 1578 | 1432 |
| Effect of exchange rate changes on cash |  | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total sources | 4894 | 3626 |
| Uses: |  |  |
| Net cash used in investing activities | 3697 | 1695 |
| Dividends to shareholders | 61 | 59 |
| Principal payments of long-term debt | 1 | 1 |
| Purchases of treasury stock | 94 | 38 |
| Change in cash collateral for derivatives and repurchase/reverse repurchase agreements | 199 | 8 |
| Effect of exchange rate changes on cash | 17 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total uses | 4069 | 1801 |
| Net change in cash and cash equivalents | $825 | $1825 |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Cash Flows from Operations* – The principal cash inflows from the Company's reinsurance activities come from premiums, investment and fee income, annuity considerations and deposit funds. The principal cash outflows relate to the liabilities associated with various life and health insurance, annuity and disability products, operating expenses, income tax payments and interest on outstanding debt obligations. The primary liquidity concern with respect to these cash flows is the risk of shortfalls in premiums and investment income, particularly in periods with abnormally high claims levels.

*Cash Flows from Investments* – The principal cash inflows from the Company's investment activities come from repayments of principal on invested assets, proceeds from maturities of invested assets, sales of invested assets and settlements of freestanding derivatives. The principal cash outflows relate to purchases of investments, issuances of policy loans and settlements of freestanding derivatives. The Company typically has a net cash outflow from investing activities because cash inflows from insurance operations are reinvested in accordance with its asset/liability management discipline to fund insurance liabilities. The Company closely monitors and manages these risks through its credit risk management process. The primary liquidity concerns with respect to these cash flows are the risk of default by debtors and market disruption, which could make it difficult for the Company to sell investments.

*Financing Cash Flows* – The principal cash inflows from the Company's financing activities come from issuances of RGA debt and equity securities, and deposit funds associated with universal life and other investment type policies and contracts. The principal cash outflows come from repayments of debt, payments of dividends to shareholders, purchases of treasury stock, and withdrawals associated with universal life and other investment type policies and contracts. A primary liquidity concern with respect to these cash flows is the risk of early contractholder and policyholder withdrawal.

**<u>Contractual Obligations</u>**

There were no material changes in the Company's contractual obligations from those reported in the 2025 Annual Report, except for the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company's contractual obligations associated with long-term debt, including interest, increased at March 31, 2026, due to the Company's issuance of $400 million in subordinated debentures on March 3, 2026. See Note 16 – "Financing Activities" for further information.

**<u>Asset / Liability Management</u>**

The Company actively manages its cash and invested assets using an approach that is intended to balance quality, diversification, asset/liability matching, liquidity and investment return. The goals of the investment process are to optimize after-tax, risk-adjusted investment income and after-tax, risk-adjusted total return while managing the assets and liabilities on a cash flow and duration basis.

The Company has established target asset portfolios for its operating segments, which represent the investment strategies intended to profitably fund its liabilities within acceptable risk parameters. These strategies include objectives and limits for effective duration, yield curve sensitivity and convexity, liquidity, asset sector concentration and credit quality.

The Company's asset-intensive products are primarily supported by investments in fixed maturity securities reflected on the Company's balance sheet and under funds withheld arrangements with the ceding company. Investment guidelines are established to structure the investment portfolio based upon the type, duration and behavior of products in the liability portfolio so as to achieve targeted levels of profitability. The Company manages the asset-intensive business to provide a targeted spread between the interest rate earned on investments and the interest rate credited to the underlying interest-sensitive contract liabilities. The Company periodically reviews models projecting different interest rate scenarios and their effect on profitability. Certain of these asset-intensive agreements, primarily in the U.S. and Latin America Financial Solutions operating segment, are generally funded by fixed maturity securities that are withheld by the ceding company.

The Company's liquidity position (cash and cash equivalents and short-term investments) was $5.4 billion and $4.5 billion at March 31, 2026 and December 31, 2025, respectively. Liquidity needs are determined from valuation analyses conducted by operational units and are driven by product portfolios. Periodic evaluations of demand liabilities and short-term liquid assets are designed to adjust specific portfolios, as well as their durations and maturities, in response to anticipated liquidity needs.

See "Securities Borrowing, Lending and Repurchase/Reverse Repurchase Agreements" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for information related to the Company's securities borrowing, lending and repurchase/reverse repurchase programs. In addition to the Company's security agreements with third parties, certain RGA subsidiaries have entered into intercompany securities lending agreements to more efficiently source securities for lending to third parties and to provide for more efficient regulatory capital management.

The Company is a member of the FHLB and holds $68 million of FHLB common stock, which is included in other invested assets on the Company's condensed consolidated balance sheets. The Company has entered into funding agreements with the FHLB under guaranteed investment contracts whereby the Company has issued the funding agreements in exchange for cash and for which the FHLB has been granted a blanket lien on the Company's commercial and residential mortgage-backed

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

securities and commercial mortgage loans used to collateralize the Company's obligations under the funding agreements. The Company maintains control over these pledged assets, and may use, commingle, encumber or dispose of any portion of the collateral as long as there is no event of default and the remaining qualified collateral is sufficient to satisfy the collateral maintenance level. The funding agreements and the related security agreements represented by this blanket lien provide that upon any event of default by the Company, the FHLB's recovery is limited to the amount of the Company's liability under the outstanding funding agreements. The amount of the Company's liability for the funding agreements with the FHLB was $1.3 billion at March 31, 2026 and December 31, 2025, which is included in interest-sensitive contract liabilities on the Company's condensed consolidated balance sheets. The advances on these agreements are collateralized primarily by commercial and residential mortgage-backed securities, commercial mortgage loans and U.S. Treasury and government agency securities. The amount of collateral exceeds the liability and is dependent on the type of assets collateralizing the guaranteed investment contracts.

**<u>Investments</u>**

*Management of Investments*

The Company's investment and derivative strategies involve matching the characteristics of its reinsurance products and other obligations. The Company seeks to closely approximate the interest rate sensitivity of the assets with estimated interest rate sensitivity of the reinsurance liabilities. The Company achieves its income objectives through strategic and tactical asset allocations, applying security and derivative strategies within asset/liability and disciplined risk management frameworks. Derivative strategies are employed within the Company's risk management framework to help manage duration, currency and other risks in assets and/or liabilities and to replicate the credit characteristics of certain assets.

The Company's portfolio management groups work with the Enterprise Risk Management function to develop the investment policies for the assets of the Company's domestic and international investment portfolios. All investments held by the Company, directly or in a funds withheld at interest reinsurance arrangement, are monitored for conformance with the Company's stated investment policy limits as well as any limits prescribed by the applicable jurisdiction's insurance laws and regulations. See Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for additional information regarding the Company's investments.

*Portfolio Composition*

The Company had total cash and invested assets of $142.0 billion and $134.6 billion as of March 31, 2026 and December 31, 2025, respectively, as illustrated below (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | % of Total | December 31, 2025 | % of Total |
| Fixed maturity securities available-for-sale - public | $94438 | 66.4% | $88993 | 66.2% |
| Fixed maturity securities available-for-sale - private | 12890 | 9.1 | 12776 | 9.5 |
| Equity securities | 300 | 0.2 | 311 | 0.2 |
| Mortgage loans | 11318 | 8.0 | 11104 | 8.2 |
| Policy loans | 3703 | 2.6 | 3541 | 2.6 |
| Funds withheld at interest | 8390 | 5.9 | 8149 | 6.1 |
| Limited partnerships and real estate joint ventures | 4093 | 2.9 | 3747 | 2.8 |
| Short-term investments | 357 | 0.3 | 346 | 0.3 |
| Other invested assets | 1525 | 1.1 | 1514 | 1.1 |
| Cash and cash equivalents | 4993 | 3.5 | 4168 | 3.0 |
| &nbsp;&nbsp;&nbsp;Total cash and invested assets | $142007 | 100.0% | $134649 | 100.0% |

---

*Investment Yield* – *Excluding Spread Related Business*

The following table presents consolidated average invested assets at amortized cost, net investment income, investment yield, variable investment income ("VII") and investment yield excluding VII, which can vary significantly from period to period (dollars in millions). The table excludes spread related business. Spread related business is primarily associated with contracts on which the Company earns an interest rate spread between assets and liabilities. To varying degrees, fluctuations in the yield on other spread related business are generally subject to corresponding adjustments to the interest credited on the liabilities.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | | | |
|:---|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 | &nbsp;&nbsp;&nbsp;&nbsp;Increase / <br> (Decrease) |
| Average invested assets at amortized cost | $49549 | $44016 | $5533 |
| Net investment income | $599 | $502 | $97 |
| Annualized investment yield (ratio of net investment income to average invested assets at amortized cost) | 4.93% | 4.64% | 29 bps |
| VII (included in net investment income) | $26 | $(6) | $32 |
| Annualized investment yield excluding VII (ratio of net investment income, excluding VII, to average invested assets, excluding assets with only VII, at amortized cost) | 4.85% | 4.90% | (5) bps |

---

Investment yield increased for the three months ended March 31, 2026, in comparison to the same period in the prior year, primarily due to increased variable income from limited partnerships and real estate joint ventures slightly offset by lower yield on cash and cash equivalents.

*Fixed Maturity Securities Available-for-Sale*

See "Fixed Maturity Securities Available-for-Sale" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for tables that provide the amortized cost, allowance for credit losses, unrealized gains and losses and estimated fair value of these securities by type as of March 31, 2026 and December 31, 2025.

Important factors in the selection of investments include diversification, quality, yield, call protection and total rate of return potential. The relative importance of these factors is determined by market conditions and the underlying reinsurance liability and existing portfolio characteristics. As of March 31, 2026 and December 31, 2025, approximately 94.3% of total fixed maturity securities were investment grade.

The Company owns floating rate securities that represented approximately 8.7% and 8.9% of total fixed maturity securities as of March 31, 2026 and December 31, 2025, respectively. These investments have a higher degree of income variability than the other fixed income holdings in the portfolio due to fluctuations in interest payments. The Company holds floating rate investments to enhance asset management strategies and match certain interest-sensitive contract liabilities.

The largest asset class in which fixed maturity securities were invested was corporate securities, which represented approximately 68.2% and 68.5% of total fixed maturity securities as of March 31, 2026 and December 31, 2025, respectively. See "Corporate Fixed Maturity Securities" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for tables showing the major sector types, which comprise the corporate fixed maturity holdings as of March 31, 2026 and December 31, 2025.

As of March 31, 2026 and December 31, 2025, the Company's investments in Canadian government securities represented 4.7% and 5.1%, respectively, of total fixed maturity securities. These assets are primarily high quality, long duration provincial strip bonds, the valuation of which is closely linked to the interest rate curve. These assets are longer in duration and held primarily for asset/liability management to meet Canadian regulatory requirements.

As of March 31, 2026 and December 31, 2025, the Company's investments in Japanese government securities represented 7.3% and 4.6%, respectively, of total fixed maturity securities. These assets are primarily long duration government bonds matching the liability profile of the Company's Japanese business.

The Company references rating agency designations in some of its investments disclosures. These designations are based on the ratings from nationally recognized statistical rating organizations, primarily Moody's, S&P and Fitch. Structured securities held by the Company's insurance subsidiaries that maintain the NAIC statutory basis of accounting utilize the NAIC rating methodology. The NAIC assigns designations to publicly traded as well as privately placed securities. The designations assigned by the NAIC range from class 1 to class 6, with designations in classes 1 and 2 generally considered investment grade (BBB or higher rating agency designation). NAIC designations in classes 3 through 6 are generally considered below investment grade (BB or lower rating agency designation). If no rating is available from a rating agency or the NAIC, then an internally developed rating is used.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The quality of the Company's available-for-sale fixed maturity securities portfolio, as measured at fair value and by the percentage of fixed maturity securities invested in various ratings categories, relative to the entire available-for-sale fixed maturity securities portfolio, as of March 31, 2026 and December 31, 2025 was as follows (dollars in millions):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | March 31, 2026 | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 | December 31, 2025 |
| NAIC<br> Designation | Rating Agency<br>Designation | Amortized Cost | Estimated<br>Fair Value | % of Total&nbsp;&nbsp;&nbsp;&nbsp; | Amortized Cost | Estimated<br>Fair Value | % of Total&nbsp;&nbsp;&nbsp;&nbsp; |
| 1 | AAA/AA/A | $75437 | $69596 | 64.8% | $69007 | $64571 | 63.4% |
| 2 | BBB | 33252 | 31702 | 29.5 | 32330 | 31423 | 30.9 |
| 3 | BB | 4436 | 4371 | 4.1 | 4815 | 4823 | 4.8 |
| 4 | B | 1334 | 1269 | 1.2 | 714 | 632 | 0.6 |
| 5 | CCC and lower | 393 | 318 | 0.3 | 356 | 294 | 0.3 |
| 6 | In or near default | 124 | 72 | 0.1 | 42 | 26 |  |
|  | &nbsp;&nbsp;&nbsp;Total | $114976 | $107328 | 100.0% | $107264 | $101769 | 100.0% |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

The Company's fixed maturity portfolio includes structured securities. The following table shows the types of structured securities the Company held as of March 31, 2026 and December 31, 2025 (dollars in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 | December 31, 2025 |
| | Amortized Cost | Estimated<br>Fair Value | % of Total | Amortized Cost | Estimated<br>Fair Value | % of Total |
| ABS: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Collateralized loan obligations ("CLOs") | $2462 | $2449 | 21.9% | $2486 | $2481 | 22.4% |
| &nbsp;&nbsp;&nbsp;ABS, excluding CLOs | 4974 | 4832 | 43.3 | 4992 | 4888 | 44.0 |
| Total ABS | 7436 | 7281 | 65.2 | 7478 | 7369 | 66.4 |
| CMBS | 2367 | 2335 | 20.9 | 2179 | 2162 | 19.5 |
| RMBS: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Agency | 351 | 314 | 2.9 | 359 | 324 | 2.9 |
| &nbsp;&nbsp;&nbsp;Non-agency | 1248 | 1229 | 11.0 | 1256 | 1245 | 11.2 |
| Total RMBS | 1599 | 1543 | 13.9 | 1615 | 1569 | 14.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $11402 | $11159 | 100.0% | $11272 | $11100 | 100.0% |

---

The Company's ABS portfolio primarily consists of CLOs, aircraft and rated note feeders. The principal risks in holding ABS are structural, credit, capital market and interest rate risks. Structural risks include the securities' cash flow priority in the capital structure and the inherent prepayment sensitivity of the underlying collateral. Credit risks include the adequacy and ability to realize proceeds from the collateral. Credit risks are mitigated by credit enhancements that include excess spread, over-collateralization and subordination. Capital market risks include general level of interest rates and the liquidity for these securities in the marketplace.

The Company's CMBS portfolio primarily consists of large pool securitizations that are diverse by property type, borrower and geographic dispersion. The principal risks in holding CMBS are structural and credit risks. Structural risks include the securities' cash flow priority in the capital structure and the inherent prepayment sensitivity of the underlying collateral. Credit risks include the adequacy and ability to realize proceeds from the collateral. The Company focuses on investment grade rated tranches that provide additional credit support beyond the equity protection in the underlying loans. These assets are viewed as an attractive alternative to other fixed income asset classes.

The Company's RMBS portfolio includes agency-issued pass-through securities and collateralized mortgage obligations. Agency-issued pass-through securities are guaranteed or otherwise supported by the Federal Home Loan Mortgage Corporation, Federal National Mortgage Association, or the Government National Mortgage Association. The principal risks in holding RMBS are prepayment and extension risks, which will affect the timing of when cash will be received and are dependent on the level of mortgage interest rates. Prepayment risk is the unexpected increase in principal payments from the expected, primarily as a result of owner refinancing. Extension risk relates to the unexpected slowdown in principal payments from the expected. In addition, non-agency RMBS face credit risk should the borrower be unable to pay the contractual interest or principal on their obligation. The Company monitors its mortgage-backed securities to mitigate exposure to the cash flow uncertainties associated with these risks.

As of March 31, 2026 and December 31, 2025, the Company classified approximately 12.8% and 13.5%, respectively, of its fixed maturity securities in the Level 3 category. Refer to Note 12 – "Fair Value of Assets and Liabilities" in the Notes to Condensed Consolidated Financial Statements for additional information. These securities primarily consist of private placement corporate and asset-backed securities.

See "Securities Lending and Repurchase/Reverse Repurchase Agreements" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for information related to the Company's securities lending and repurchase/reverse repurchase agreements.

*Mortgage Loans*

The Company's mortgage loan portfolio consists of U.S., Canada and U.K. based investments primarily in retail locations, light industrial properties, and commercial offices. The mortgage loan portfolio is diversified by geographic region and property type as discussed further under "Mortgage Loans" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements. Mortgage loans in the Company's portfolio range in size up to $57 million, with an average mortgage loan investment as of March 31, 2026, of $7 million.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

As of March 31, 2026 and December 31, 2025, the Company's recorded investments in mortgage loans, gross of unamortized deferred loan origination fees and expenses, discounts and allowance for credit losses, were distributed geographically as follows (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 |
| | Recorded<br>Investment | % of Total | Recorded<br>Investment | % of Total |
| U.S. Region: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;West | $4167 | 36.3% | $4119 | 36.6% |
| &nbsp;&nbsp;&nbsp;South | 3844 | 33.5 | 3689 | 32.7 |
| &nbsp;&nbsp;&nbsp;Midwest | 1758 | 15.3 | 1677 | 14.9 |
| &nbsp;&nbsp;&nbsp;Northeast | 759 | 6.6 | 793 | 7.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal – U.S. | 10528 | 91.7 | 10278 | 91.2 |
| Canada | 736 | 6.4 | 758 | 6.7 |
| United Kingdom | 213 | 1.9 | 232 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $11477 | 100.0% | $11268 | 100.0% |

---

See "Allowance for Credit Losses and Impairments" in Note 2 – "Significant Accounting Policies and Pronouncements" of the 2025 Annual Report and "Mortgage Loans" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for information regarding the Company's policy for allowance for credit losses on mortgage loans.

*Allowance for Credit Losses and Impairments*

The table below summarizes investment related gains (losses), net, related to allowances for credit losses and impairments for the three months ended March 31, 2026 and 2025 (dollars in millions):

---

| | | |
|:---|:---|:---|
| | Three months ended March 31, | Three months ended March 31, |
| | 2026 | 2025 |
| Change in allowance for credit losses on fixed maturity securities | $(22) | $(6) |
| Impairments on fixed maturity securities | (1) | $— |
| Change in mortgage loan allowance for credit losses | 2 | 4 |
| Limited partnership and real estate joint ventures impairment losses | (22) | (5) |
| Other impairment losses |  | (1) |
| &nbsp;&nbsp;&nbsp;Total | $(43) | $(8) |

---

The Company's determination of whether a decline in value necessitates the recording of an allowance for credit losses includes an analysis of whether the issuer is current on its contractual payments, evaluating whether it is probable that the Company will be able to collect all amounts due according to the contractual terms of the security and analyzing the overall ability of the Company to recover the amortized cost of the investment. See "Allowance for Credit Losses and Impairments" in Note 2 – "Significant Accounting Policies and Pronouncements" of the Company's 2025 Annual Report for additional information.

As of March 31, 2026 and December 31, 2025, the Company had $8.5 billion and $7.0 billion, respectively, of gross unrealized losses related to its fixed maturity securities. The Company monitors its fixed maturity securities to determine impairments in value and evaluates factors such as financial condition of the issuer, payment performance, compliance with covenants, general market and industry sector conditions, current intent and ability to hold securities, and various other subjective factors. Based on management's judgment, an allowance for credit losses in the amount that fair value is less than the amortized cost is recorded for securities determined to have expected credit losses.

See "Unrealized Losses for Fixed Maturity Securities Available-for-Sale" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for tables that present the estimated fair value and gross unrealized losses for securities that have estimated fair values below amortized cost by class and grade, as well as the length of time the related estimated fair value has remained below amortized cost as of March 31, 2026 and December 31, 2025.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

*Funds Withheld at Interest*

For reinsurance agreements written on a modified coinsurance basis and certain agreements written on a coinsurance basis, assets equal to the net statutory reserves are withheld by the ceding company and are legally owned by the ceding company. The Company reflects these assets on its balance sheet as funds withheld at interest. Interest accrues on the total funds withheld at rates defined by the terms of the applicable reinsurance agreement. The Company is subject to the investment performance on such assets, although the Company does not directly control them because such assets are legally owned by the ceding company. To mitigate this risk, investment guidelines are commonly set in the reinsurance agreements which restrict the ceding company's investment activity with respect to such assets. The Company monitors the ceding company's compliance with these contractual restrictions. These assets are primarily fixed maturity investment securities and pose investment risks similar to the fixed maturity securities owned by the Company. Ceding companies with funds withheld at interest had an average financial strength rating of "A" as of March 31, 2026 and December 31, 2025. Certain ceding companies maintain segregated portfolios for the benefit of the Company.

*Other Invested Assets*

Other invested assets primarily include lifetime mortgages, derivative contracts, FHLB common stock and real estate held for investment. See "Other Invested Assets" in Note 10 – "Investments" in the Notes to Condensed Consolidated Financial Statements for a table that presents the carrying value of the Company's other invested assets by type as of March 31, 2026 and December 31, 2025.

The Company utilizes derivative financial instruments to protect the Company against possible changes in the fair value of its investment portfolio as a result of interest rate changes, to hedge against risk of changes in the purchase price of securities, to hedge liabilities associated with the reinsurance of variable annuities with guaranteed living benefits and to manage the portfolio's effective yield, maturity and duration. In addition, the Company utilizes derivative financial instruments to reduce the risk associated with fluctuations in foreign currency exchange rates. The Company uses exchange-traded, centrally cleared, and customized over-the-counter derivative financial instruments.

See Note 11 – "Derivative Instruments" in the Notes to Condensed Consolidated Financial Statements for a table that presents the notional amounts and fair value of investment related derivative instruments held as of March 31, 2026 and December 31, 2025.

The Company may be exposed to credit-related losses in the event of non-performance by counterparties to derivative financial instruments. Generally, the credit exposure of the Company's derivative contracts is limited to the fair value and accrued interest of non-collateralized derivative contracts in an asset position at the reporting date. As of March 31, 2026, the Company had credit exposure of $16 million.

The Company manages its credit risk related to over-the-counter derivatives by entering into transactions with creditworthy counterparties, maintaining collateral arrangements and through the use of master agreements that provide for a single net payment to be made by one counterparty to another at each due date and upon termination. As exchange-traded futures are affected through regulated exchanges, and positions are marked to market on a daily basis, the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties. See Note 11 – "Derivative Instruments" in the Notes to Condensed Consolidated Financial Statements for more information regarding the Company's derivative instruments.

The Company holds $1,219 million and $1,197 million of beneficial interest in lifetime mortgages in the U.K., net of allowance for credit losses, as of March 31, 2026 and December 31, 2025, respectively. Investment income includes $16 million and $13 million in interest income earned on lifetime mortgages for the three months ended March 31, 2026 and 2025, respectively. Lifetime mortgages represent loans provided to individuals 55 years of age and older secured by the borrower's residence. Lifetime mortgages are comparable to a home equity loan by allowing the borrower to utilize the equity in their home as collateral. The amount of the loan is dependent on the appraised value of the home at the time of origination, the borrower's age and interest rate. Unlike a home equity loan, no payment of principal or interest is required until the death of the borrower or sale of the home. Lifetime mortgages may also be either fully funded at origination, or the borrower can request periodic funding similar to a line of credit. Lifetime mortgages are subject to risks, including market, credit, interest rate, liquidity, operational, reputational and legal risks.

**<u>New Accounting Standards</u>**

Changes to the general accounting principles are established by the Financial Accounting Standards Board ("FASB") in the form of accounting standards updates to the FASB Accounting Standards Codification<sup>TM</sup>.

See Note 17 – "New Accounting Standards" in the Notes to Condensed Consolidated Financial Statements for information on new accounting pronouncements and their impact, if any, on the Company's results of operations and financial position.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**ITEM 3. Quantitative and Qualitative Disclosures About Market Risk**

Market risk is the risk of fluctuations in the value of financial instruments as a result of absolute or relative changes in interest rates, foreign currency exchange rates, equity prices or commodity prices. To varying degrees, the Company products and services, and the investment activities supporting them, generate exposure to market risk. The market risk incurred, and the Company's strategies for managing this risk, vary by product. As of March 31, 2026, there have been no material changes in the Company's economic exposure to market risk or the Company's Enterprise Risk Management function from December 31, 2025, a description of which may be found in its Annual Report on Form 10-K, for the year ended December 31, 2025, Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," filed with the Securities and Exchange Commission.

**ITEM 4. Controls and Procedures**

The Chief Executive Officer and the Chief Financial Officer have evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that these disclosure controls and procedures were effective.

There was no change in the Company's internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the quarter ended March 31, 2026, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**<u>PART II - OTHER INFORMATION</u>**

**ITEM 1. Legal Proceedings**

The Company is subject to litigation and regulatory investigations or actions from time to time. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters will have a material adverse effect on the financial condition, results of operations or cash flows of the Company. However, in light of the inherent uncertainties involved in future or pending legal, regulatory and governmental matters, some of which are beyond the Company's control, and indeterminate or potentially substantial amount of damages sought in any such matters, an adverse outcome could be material to the Company's financial condition, results of operations or cash flows for any particular reporting period. A legal reserve is established when the Company is notified of an arbitration demand, litigation or regulatory action or is notified that an arbitration demand, litigation or regulatory action is imminent, it is probable that the Company will incur a loss as a result and the amount of the probable loss is reasonably capable of being estimated.

**ITEM 1A. Risk Factors**

There have been no material changes from the risk factors previously disclosed in the 2025 Annual Report.

 **ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds**

<u>Issuer Purchases of Equity Securities</u>

The following table summarizes the Company's repurchase activity of its common stock during the quarter ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Total Number of Shares<br>Purchased <sup>(1)</sup> | Average Price Paid per <br>Share | Total Number of Shares<br>Purchased as Part of<br>Publicly Announced Plans<br>or Programs <sup>(1)</sup> | Maximum Number (or<br>Approximate Dollar<br>Value) of Shares that May<br>Yet Be Purchased Under<br>the Plan or Program |
| January 1, 2026 – January 31, 2026 | 50132 | $196.91 |  | $500000000 |
| February 1, 2026 – February 28, 2026 | 241879 | $221.35 | 225638 | $450000136 |
| March 1, 2026 – March 31, 2026 | 150032 | $205.01 |  | $450000136 |

---

(1)The Company repurchased 225,638 shares of common stock under its share repurchase program in February 2026. The Company net settled – issuing 148,948, 68,162 and 270,503 shares from treasury and repurchasing from recipients 50,132, 16,241 and 150,032 shares in January, February and March 2026, respectively, in settlement of income tax withholding requirements incurred by the recipients of equity incentive awards.

On January 29, 2026, the board of directors authorized a share repurchase program for up to $500 million of RGA's outstanding common stock. The authorization was effective immediately and does not have an expiration date. During the three months ended March 31, 2026, the Company repurchased 225,638 shares of common stock under this program. As of March 31, 2026, the aggregate amount remaining under the Company's share repurchase authorization was approximately $450 million.

Repurchases will be made in accordance with applicable securities laws, through market transactions, block trades, privately negotiated transactions or other means, or a combination of these methods, with the timing and number of shares repurchased dependent on a variety of factors, including share price, corporate and regulatory requirements, and market and business conditions. Repurchases may be commenced or suspended from time to time without prior notice.

**ITEM 5. Other Information**

During the three months ended March 31, 2026, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement."

**ITEM 6. Exhibits**

See index to exhibits.

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| <u>Exhibit<br>Number</u> | <u>Description</u> |
| [3.1](https://www.sec.gov/Archives/edgar/data/0000898174/000119312520150241/d929891dex31i.htm) | [Amended and Restated Articles of Incorporation, effective May 21, 2020, incorporated by reference to Exhibit 3.1(i) to Current Report on Form 8-K filed May 22, 2020](https://www.sec.gov/Archives/edgar/data/0000898174/000119312520150241/d929891dex31i.htm) |
| [3.2](https://www.sec.gov/Archives/edgar/data/898174/000119312522309205/d438101dex31.htm) | [Amended and Restated Bylaws, effective December 20, 2022, incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed December 20, 2022](https://www.sec.gov/Archives/edgar/data/898174/000119312522309205/d438101dex31.htm) |
| [4.1](https://www.sec.gov/Archives/edgar/data/898174/000119312526088164/d50383dex42.htm) | [Twelfth Supplemental Indenture, dated March 3, 2026, between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee, regarding the Debentures, incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed March 3, 2026](https://www.sec.gov/Archives/edgar/data/898174/000119312526088164/d50383dex42.htm) |
| [10.1](ex1012026q110-q.htm) | [Form of Performance Contingent Share Agreement under RGA Flexible Stock Plan, as amended and restated effective May 21, 2025 (the "RGA Flexible Stock Plan") for awards with a grant date beginning on or after March 19, 2026\*](ex1012026q110-q.htm) |
| [10.2](ex1022026q110-q.htm) | [Form of Stock Appreciation Right Award Agreement under RGA Flexible Stock Plan for awards with a grant date beginning on or after March 19, 2026\*](ex1022026q110-q.htm) |
| [10.3](ex1032026q110-q.htm) | [Form of Restricted Stock Unit Agreement under RGA Flexible Stock Plan for awards with a grant date beginning on or after March 19, 2026\*](ex1032026q110-q.htm) |
| [31.1](ex3112026q110-q.htm) | [Certification of Chief Executive Officer](ex3112026q110-q.htm)[, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002](ex3112026q110-q.htm) |
| [31.2](ex3122026q110-q.htm) | [Certification of Chief Financial Officer](ex3122026q110-q.htm)[, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002](ex3122026q110-q.htm) |
| [32.1](ex3212026q110-q.htm) | [Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002](ex3212026q110-q.htm) |
| [32.2](ex3222026q110-q.htm) | [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002](ex3222026q110-q.htm) |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| [101.SCH](rga-20260331.htm) | [XBRL Taxonomy Extension Schema Document](rga-20260331.htm) |
| [101.CAL](rga-20260331_cal.xml) | [XBRL Taxonomy Extension Calculation Linkbase Document](rga-20260331_cal.xml) |
| [101.LAB](rga-20260331_lab.xml) | [XBRL Taxonomy Extension Label Linkbase Document](rga-20260331_lab.xml) |
| [101.PRE](rga-20260331_pre.xml) | [XBRL Taxonomy Extension Presentation Linkbase Document](rga-20260331_pre.xml) |
| [101.DEF](rga-20260331_def.xml) | [XBRL Taxonomy Extension Definition Linkbase Document](rga-20260331_def.xml) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101). |

---

\* Represents a management contract or compensatory plan or arrangement

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**GLOSSARY OF SELECTED TERMS**

Throughout this quarterly report on Form 10-Q, the Company may use certain abbreviations, acronyms and terms which are defined below.

**Entities**

---

| | |
|:---|:---|
| **Term or Acronym** | **Definition** |
| RGA Reinsurance | RGA Reinsurance Company |
| Rockwood Re | Rockwood Reinsurance Company |
| Castlewood Re | Castlewood Reinsurance Company |
| Chesterfield Re | Chesterfield Reinsurance Company |
| RGA Life and Annuity | RGA Life and Annuity Insurance Company |
| RGA Canada | RGA Life Reinsurance Company of Canada |
| RGA Barbados | RGA Reinsurance Company (Barbados) Ltd. |
| RGA Americas | RGA Americas Reinsurance Company, Ltd. |
| Manor Re | Manor Reinsurance, Ltd. |
| RGA Worldwide | RGA Worldwide Reinsurance Company, Ltd. |
| RGA Global | RGA Global Reinsurance Company, Ltd. |
| RGA Australia | RGA Reinsurance Company of Australia Limited |
| RGA International | RGA International Reinsurance Company dac |
| Aurora National | Aurora National Life Assurance Company |
| Omnilife | Omnilife Insurance Company, Limited |
| Papara | Papara Financing LLC |

---

**Certain Terms and Acronyms**

---

| | |
|:---|:---|
| **Term or Acronym** | **Definition** |
| A.M. Best | A.M. Best Company |
| ABS | Asset-backed securities |
| Actuary | A specialist in the mathematics of risk, especially as it relates to insurance calculations such as premiums, reserves, dividends, insurance rates and annuity rates. |
| Allowance | An amount paid by the reinsurer to the ceding company to help cover the ceding company's acquisition and other costs, especially commissions. Allowances are usually calculated as a large percentage (often 100%) of first-year premiums reinsured and smaller percentages of renewal premiums reinsured. |
| AOCI | Accumulated other comprehensive income (loss) |
| Asset-Intensive Reinsurance | A transaction (usually coinsurance or funds withheld and often involving reinsurance of annuities) where performance of the underlying assets, more so than any mortality risk, is a key element. |
| Assumed reinsurance | Insurance risk that a reinsurer accepts (assumes) from a ceding company. |
| ASU | Accounting Standards Update |
| ASU 2018-12 | Financial Accounting Standards Board's Accounting Standards Update No. 2018-12, "Targeted Improvements to the Accounting for Long-Duration Contracts" and related amendments. Also referred to as LDTI. |
| Automatic Reinsurance | Reinsurance arrangement whereby the ceding company and reinsurer agree that all business of a certain description will be ceded to the reinsurer. Under this arrangement, the ceding company performs underwriting decision-making within agreed-upon parameters for all business reinsured. |
| Bermuda Insurance Act | Bermuda's Insurance Act 1978 which distinguishes between insurers carrying on long-term business, insurers carrying on special purpose business and insurers carrying on general business. |
| BMA | Bermuda Monetary Authority |
| BSCR | Bermuda Solvency Capital Requirement |
| CCPA | California Consumer Privacy Act of 2018 |
| Capital-motivated reinsurance | Reinsurance, including financial reinsurance, whose primary purpose is to enhance the cedant's capital position. |
| Captive insurer | An insurance or reinsurance entity designed to provide insurance or reinsurance coverage for risks of the entity or entities by which it is owned or to which it is affiliated. |
| CECL | Accounting for current expected credit losses using the model based on expected losses rather than incurred losses. |
| Ceding company (also known as cedant) | An insurer that transfers, or cedes, risk to a reinsurer |
| CEO | RGA's Chief Executive Officer |
| Cession | The insurance risk associated with a policy that is reinsured from an insurer to a reinsurer. |
| CFO | RGA's Chief Financial Officer |
| CIO | RGA's Chief Information Officer |
| CISO | RGA's Global Chief Information Security and Privacy officer |
| CLOs | Collateralized loan obligations |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | |
|:---|:---|
| CMBS | Commercial mortgage-backed securities, a part of our investment portfolio that consists of securities made up of commercial mortgages stated on our balance sheet at fair value. |
| Coinsurance (also known as original terms reinsurance) | A form of reinsurance under which the ceding company shares its premiums, death claims, surrender benefits, dividends and policy loans with the reinsurer, and the reinsurer pays expense allowances to reimburse the ceding company for a share of its expenses. |
| Coinsurance funds-withheld | A variant on coinsurance, in which the ceding company withholds assets equal to reserves and shares investment income on those assets with the reinsurer. |
| Counterparty | A party to a contract requiring or offering the exchange of risk. |
| Counterparty risk | The risk that a party to an agreement will be unable to fulfill its contractual obligations |
| CPI | Consumer price index |
| Critical illness (CI) insurance (also known as dread disease insurance) | Insurance that provides a guaranteed fixed sum upon diagnosis of a specified illness or condition such as cancer, heart disease, or permanent total disability. The coverage can be offered on a stand-alone basis or as an add-on to a life insurance policy. |
| CRO | RGA's Chief Risk Officer |
| CVA | Credit valuation adjustment |
| DAC | Deferred policy acquisition costs: Costs of acquiring new business, which vary with and are directly related to the production of new business, have been deferred to the extent that such costs are deemed recoverable from future premiums or gross profits. |
| "Directors Plan" | Flexible Stock Plan for Directors |
| EBITDA | Earnings before interest, taxes, depreciation and amortization |
| EBS | Economic balance sheet framework as part of the Bermuda Solvency Capital Requirement that forms the basis for an insurer's enhanced capital requirements. |
| ECR | Enhanced capital requirement in accordance with the provisions of the Bermuda Insurance Act. |
| EEA | European Economic Area |
| EMEA | Europe, Middle East and Africa geographic segment |
| Enterprise Risk Management (ERM) | An enterprise-wide framework used by a firm to assess all risks facing the organization, manage mitigation strategies, monitor ongoing risks and report to interested audiences. |
| ESG | Environmental, social and governance |
| EU | European Union |
| Expected mortality | Number of deaths predicted to occur in a defined group of people. |
| FABN | Funding Agreement Backed Notes |
| Face amount | Amount payable at the death of the insured or at the maturity of the policy. |
| Facultative reinsurance | A type of reinsurance in which the reinsurer underwrites an individual risk submitted by the ceding company for a risk that is unusual, large, highly substandard or not covered by an automatic reinsurance treaty. Such risks are typically submitted to multiple reinsurers for competitive offers. |
| FASB | Financial Accounting Standards Board |
| FCA | Financial Conduct Authority |
| FHLB | Federal Home Loan Bank |
| FIA | Fixed indexed annuities |
| Financial reinsurance (also known as financially-motivated reinsurance) | A form of capital-motivated reinsurance that satisfies all regulatory requirements for risk transfer and is often designed to produce very predictable reinsurer profits as a percentage of the capital provided. |
| FSB | Financial Stability Board which consists of representatives of national financial authorities of the G20 nations. |
| FVO | Fair value option |
| GAAP | U.S. generally accepted accounting principles |
| GDPR | General Data Protection Regulation which establishes uniform data privacy laws across the European Union. |
| GICs | Guaranteed investment contracts |
| GILTI | Global intangible low-taxed income; a provision of U.S. Tax Reform that generally eliminates U.S. Federal income tax deferral on earnings of foreign subsidiaries. |
| GloBE | Model Global Anti-Base Erosion rules developed by the Organization for Economic Cooperation and Development |
| GMAB | Guaranteed minimum accumulation benefits; a feature of some variable annuities that the Company reinsures |
| GMDB | Guaranteed minimum death benefits; a feature of some variable annuities that the Company reinsures |
| GMIB | Guaranteed minimum income benefits; a feature of some variable annuities that the Company reinsures |
| GMWB | Guaranteed minimum withdrawal benefits; a feature of some variable annuities that the Company reinsures |
| Group life insurance | Insurance policy under which the lives of a group of people, most commonly employees of a single company, are insured in accordance with the terms of one master contract. |
| Guaranteed issue life insurance | Insurance products that are guaranteed upon application, regardless of past health conditions. |
| IAIG | Internationally Active Insurance Group |
| IAIS | International Association of Insurance Supervisors |
| IBNR | Incurred but not reported; a liability on claims that are based on historical reporting patterns, but have not yet been reported. |
| Individual life insurance | An insurance policy that insures the life of usually one and sometimes two or more related individuals, rather than a group of people. |
| In-force sum insured | A measure of insurance in effect at a specific date. |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | |
|:---|:---|
| Initial public offering (IPO) | The first sale to the public of shares of common stock issued by a private company. IPOs often are issued by smaller companies seeking the capital to expand, but they also can be used by large mutual or privately owned companies seeking to become publicly traded. |
| International Financial Reporting Standards (IFRS) | Standards and interpretations adopted by the International Accounting Standards Board (IASB) |
| ISO | International Organization Standardization |
| LDTI | Financial Accounting Standards Board's Accounting Standards Update No. 2018-12, "Targeted Improvements to the Accounting for Long-Duration Contracts" and related amendments. Also referred to as ASU 2018-12. |
| Liquidity position | Combination of the Company's cash equivalents and short-term investments |
| Longevity product | An insurance product that mitigates longevity risk by providing a stream of income for the duration of the policyholder's life. |
| Loss ratio | Claims and other policy benefits and Future policy benefits remeasurement (gains) losses as a percentage of net premiums |
| Market risk benefits (MRB) | Contracts or contract features that provide protection to the policyholder from capital market risk and expose the Company to other-than-nominal capital market risk and are measured at fair value |
| MDCI | Missouri Department of Commerce and Insurance |
| MMS | Minimum margin of solvency required to be maintained by the Company's Bermuda subsidiaries. |
| Modified coinsurance | A variant on coinsurance in which the ceding company retains all the reserves, as well as assets backing reserves, and pays the reinsurer interest on the reinsurer's share of the reserves. |
| Moody's | Moody's Investors Service |
| Morbidity | A measure of the incidence of sickness or disease within a specific population group. |
| Mortality experience | Actual number of deaths occurring in a defined group of people. |
| Mortality risk reinsurance | Reinsurance that focuses primarily on transfer of mortality risk through coinsurance of term products or YRT. |
| NAIC | National Association of Insurance Commissioners |
| NAIC SAP | NAIC statutory accounting practices |
| NAV | Net asset value |
| Net Premium Ratio (NPR) | The NPR equals the present value of benefits divided by the present value of gross premiums |
| NIFO | Net investments in foreign operations |
| NIST | National Institute of Standards and Technology |
| NOL | Net operating loss |
| Non-traditional reinsurance | Usually synonymous with capital-motivated reinsurance, but includes any reinsurance of non-biometrical risks |
| Novation | The act of replacing one participating member of a contract with another, with all rights, duties and terms being transferred to the new party upon consent of all parties affected. |
| NYSE | New York Stock Exchange: the exchange where RGA is traded under the symbol "RGA" |
| OAS | Option-adjusted spread |
| OCI | Other comprehensive income (loss) |
| OTC | Derivatives that are privately negotiated contracts, which are known as over-the-counter derivatives |
| OTC Cleared | OTC derivatives that are cleared and settled through central clearing counterparties. |
| PBR | Principles-based reserves |
| PCAOB | Public Company Accounting Oversight Board (United States) |
| Pension Plans | The Company's sponsored or administrated qualified and non-qualified defined benefit pension plans |
| Portfolio | The totality of risks assumed by an insurer or reinsurer. |
| Preferred risk coverage | Coverage designed for applicants who represent a better-than-average risk to an insurer. |
| Premium | Amount paid to insure a risk. |
| Primary insurance (also known as direct insurance) | Insurance business relating to contracts directly between insurers and policyholders. The insurance company is directly responsible to the policyholder. |
| Production | New business produced during a specified period. |
| PRT | Pension risk transfer |
| PSU | Performance Share Units |
| Quota share (also known as 'first dollar' quota share) | A reinsurance arrangement in which the reinsurer receives a certain percentage of each risk reinsured. |
| RBC | Risk based capital, which are guidelines promulgated by the NAIC and identify minimum capital requirements based upon business levels and asset mix. |
| Recapture | The right of the ceding company to cancel reinsurance under certain conditions. |
| Regulation XXX/Regulation A-XXX | U.S. Valuation of Life Policies Model Regulation implemented beginning in 2002 for various types of life insurance business, significantly increased the level of reserves that U.S. life insurance and life reinsurance companies must hold on their statutory financial statements for various types of life insurance business, primarily certain level premium term life products. |
| Reinsurance | The transfer of insurance risk from one reinsurer, referred to as the ceding company, to a reinsurer, in conjunction with the payment of a reinsurance premium. Through reinsurance, a reinsurer 'insures' an insurer. |
| Reserves | The amount required to be carried as a liability in the financial statement of an insurer or reinsurer to provide for future commitments under outstanding policies and contracts. |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

---

| | |
|:---|:---|
| Retakaful | A form of reinsurance that is acceptable within Islamic law. See Takaful. |
| Retention limit | The maximum amount of risk a company will insure on one life. |
| Retrocession | A transfer of reinsurance risk from a reinsurer to another reinsurer, referred to as the retrocessionaire, in conjunction with the payment of a retrocession premium. Through retrocession, a retrocessionaire reinsures a reinsurer. |
| Retrocessionaire | A reinsurer that reinsures another reinsurer; see Retrocession. |
| RMBS | Residential mortgage-backed securities, a part of our investment portfolio that consists of securities made up of residential mortgages. Stated on our balance sheet at fair value. |
| RMSC | The Company's Risk Management Steering Committee |
| RSUs | Restricted Stock Units |
| S&P | Standard & Poor's |
| SARs | Stock Appreciation Rights |
| SEC | Securities and Exchange Commission |
| Securitization | The structuring of financial assets as collateral against which securities can be issued to investors. |
| Simplified issue life insurance | Insurance products with limited face amounts that require no or minimal underwriting. |
| SOFR | Secured Overnight Financing Rate |
| SPLRC | Special Purpose Life Reinsurance Captives |
| Statutory capital | The excess of statutory assets over statutory reserves, both of which are calculated in accordance with standards established by insurance regulators. |
| "Stock Plans" | The RGA flexible stock plan and the Flexible Stock Plan for Directors, collectively |
| Takaful | A form of insurance that is acceptable within Islamic law, and that is devised upon the principles of mutual advantage and group security. |
| TDR | Troubled Debt Restructuring |
| Tele-underwriting | A telephone interview process, during which an applicant's qualifications to be insured are assessed. |
| The "County" | The County of St. Louis, Missouri |
| The "Plan" | RGA Flexible Stock Plan |
| The Board | RGA's board of directors |
| The Companies Act | The Bermuda's Companies Act of 1981 |
| The Company | Reinsurance Group of America, Incorporated and its subsidiaries, all of which are wholly owned, collectively |
| Treaty (also known as a contract) | A reinsurance agreement between a reinsurer and a ceding company. The three most common types of reinsurance treaties are YRT (yearly renewable term), coinsurance and modified coinsurance. The three most common methods of accepting reinsurance are automatic, facultative and facultative-obligatory. |
| TVaR | Tail Value-at-Risk used for calculated capital requirement for Bermuda subsidiaries. |
| U.S. Tax Reform | The U.S. Tax Cuts and Jobs Act of 2017 |
| UAE | United Arab Emirates |
| U.K. | United Kingdom |
| UL | Universal life insurance |
| Underwriting | The process that assesses the risk inherent in an application for insurance prior to acceptance of the policy. |
| Valuation | The periodic calculation of reserves, the funds that insurance companies are required to hold in order satisfy all future insurance obligations. |
| Variable life insurance | A form of whole life insurance under which the death benefit and the cash value of the policy fluctuate according to the performance of an investment fund. Most variable life insurance policies guarantee that the death benefit will not fall below a specified minimum. |
| VII | Variable investment income |
| VOCRA | Value of customer relationships acquired which represents the present value of the expected future profits associated with the expected future business acquired through existing customers of the acquired company or business. |
| VODA | Value of distribution agreements which represents the present value of future profits associated with the expected future business derived from distribution agreements. |
| Webcasts | Presentation of information broadcast over the Internet. |
| Yearly Renewable Term (YRT) | A type of reinsurance which covers only mortality risk, with each year's premium based on the current amount of risk. |

---

------

<u>[**Table of Contents**](#i308ff4d2adb242a0b9b47d3fd0f5b98c_7)</u>

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | Reinsurance Group of America, Incorporated | Reinsurance Group of America, Incorporated |
| &nbsp;&nbsp;&nbsp;&nbsp;Date: May 8, 2026 | By: | <u>/s/ Tony Cheng</u> |
|  |  | Tony Cheng |
|  |  | President and Chief Executive Officer |
|  |  | (Principal Executive Officer) |
| &nbsp;&nbsp;&nbsp;&nbsp;Date: May 8, 2026 | By: | <u>/s/ Axel André</u> |
|  |  | Axel André |
|  |  | Executive Vice President and Chief Financial Officer |
|  |  | (Principal Financial and Accounting Officer) |

---

## Exhibit 10.1

**REINSURANCE GROUP OF AMERICA, INCORPORATED**

**FLEXIBLE STOCK PLAN**

**<u>PERFORMANCE CONTINGENT SHARE AGREEMENT</u>**

Reinsurance Group of America, Incorporated, a Missouri corporation (the "Company"), and ("Employee"), hereby agree as follows:

**SECTION 1**

**<u>GRANT OF PERFORMANCE SHARES</u>**

Pursuant to the Reinsurance Group of America, Incorporated Flexible Stock Plan as amended and restated effective May 21, 2025 (the "Plan"), and pursuant to action of the Committee charged with the Plan's administration, the Company has granted to Employee, effective March [_], 2026 (the "Date of Grant"), subject to the terms, conditions and limitations stated in this Performance Contingent Share Agreement (this "Agreement"), the Plan and the Company's executive compensation recoupment policies (as discussed in Section 8(c)), an award of performance contingent shares with respect to <shares_awarded> shares of Common Stock (the "Award"). The performance contingent shares awarded to Employee in this Agreement are referred to herein as "Performance Shares."

**SECTION 2**

**<u>TERMS OF THE PLAN</u>**

This Award is granted under and is expressly subject to all the terms and provisions of the Plan, which terms are incorporated herein by reference. This Agreement and the Plan contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings with respect to such subject matter. The Plan and this Agreement are administered by the Committee. Any determination under the Plan or this Agreement made by the Committee shall be at the Committee's sole discretion. Capitalized terms used and not otherwise defined in this Agreement shall have the same meanings ascribed to them in the Plan.

**SECTION 3**

**<u>TERMS OF GRANT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Performance Period</u>. The performance period for this Award is the three year period beginning on January 1 of the year of the Date of Grant and ending December 31 of the second year following the year of the Date of Grant (i.e., year 3) (the "Performance Period").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Payment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)<u>Performance Shares Payable In Common Stock</u>. Subject to Sections 5, 6 and 7 below, if Employee is continuously employed by the Company and its Affiliates through the end of the Performance Period, (i) by March 15 of the calendar year following the end of the Performance Period, or as soon as administratively practicable

663868&nbsp;&nbsp;&nbsp;&nbsp;

------

thereafter, the Committee shall determine the number of Performance Shares that shall become earned and vested pursuant to this Award based on the Committee's determination of the level of achievement with respect to the performance criteria for the Performance Period in accordance with Section 4 below, and (ii) not later than April 30 of the calendar year in which the Committee determines the number of Performance Shares that so vest, the Company shall issue to Employee one share of the Company's Common Stock (each, a "Share") for each Performance Share earned under this Agreement in settlement of this Award; provided, however, that any fractional Performance Share may be paid in fractional Shares or in cash equal to such fraction of the Fair Market Value of a Share of Common Stock on the date of payment (as determined by the Committee); provided, further, that the Committee shall have the discretion to reduce or eliminate the number of Shares deliverable hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)<u>Dividend Equivalents</u>. Performance Shares shall not include dividend equivalent payments or dividend credit rights.

**SECTION 4**

**<u>PERFORMANCE CRITERIA AND ADJUSTMENTS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Performance Criteria</u>. The measures and weights for the grant of Performance Shares subject to this Agreement are set forth in a memorandum (the "Memorandum") provided to Employee by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Adjustment of Award</u>. As specified in the Memorandum, the number of Performance Shares subject to this Award will be adjusted following the end of the Performance Period as determined by the Committee as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Fifty percent (50.0%) of the number of Performance Shares subject to this Award will increase or decrease based upon the Company's Average ROE over the Performance Period;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Fifty percent (50.0%) of the number of Performance Shares subject to this Award will increase or decrease based upon the Company's BVPS Growth over the Performance Period (the adjustments described in Sections 4(b)(1) and 4(b)(2) shall be collectively referred to as the "Initial Adjustments"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The final number of Performance Shares in the Award will increase or decrease by multiplying (i) the number of Performance Shares after calculating the Initial Adjustments, and (ii) the rTSR Factor as set forth in the Memorandum.

In no event will Employee be entitled to receive a total number of shares of Common Stock with respect to Performance Shares in excess of 200% of the Award, even if the Company's Average ROE, BVPS Growth, and/or rTSR Percentile Ranking during the Performance Period exceeds the maximum values established for any such measure(s).

&nbsp;&nbsp;&nbsp;&nbsp;2

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Average ROE</u>. "Average ROE" means the average adjusted operating return, excluding standard adjustments, on equity, excluding AOCI and cumulative change in fair value of funds withheld embedded derivatives, for the trailing twelve-month period for each of the three years of the Performance Period. Standard adjustments identified are actuarial assumption reviews (e.g., mortality, morbidity, and lapse assumption changes and their impact on reserves and the carrying value of deferred acquisition costs), variable investment income outside of a range of -50% to +50% of income on these investments included in the three-year plan, and integration costs or other adjustments related to merger and acquisition activity. Standard adjustments represent a positive or negative impact to adjusted operating income. Adjusted operating return on equity is a non-GAAP financial measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>BVPS Growth</u>. "BVPS Growth" means the average of the annual growth rates in book value per share, excluding AOCI and cumulative change in fair value of funds withheld embedded derivatives, for each year in the Performance Period. BVPS Growth is a non-GAAP financial measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Potential Adjustments</u>. Each of Average ROE and BVPS Growth are Performance Goals which may be adjusted by the Committee from time to time following the date of this Agreement, including to account for the effects of unusual or non-recurring accounting impacts or changes in accounting standards or treatment or any other unusual or extraordinary items as determined by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Peer Group</u>. "Peer Group" shall mean the group of competitor companies as determined by the Committee from time to time and as provided separately to Employee. If the Committee determines in its informed judgment that a significant event has occurred that the Committee expects to have, or the Committee determines has had, a substantial effect on the business or Total Shareholder Return (as defined below) of any company in the Peer Group, including by way of example events such as bankruptcies, insolvencies, delisting, and divestitures, mergers, acquisitions, or similar transactions in each case that significantly change the major markets or operational scope of the peer company's business, it will remove that peer company from the Peer Group. A company that is removed from the Peer Group before the end of the Performance Period will be excluded from the calculation of rTSR Percentile Ranking.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Total Shareholder Return</u>. "Total Shareholder Return" shall mean total shareholder return as applied to the Company or any company in the Peer Group, determined by comparing the average of the applicable company's closing stock prices over the 20 trading days immediately preceding the first day of the Performance Period with the average of the applicable company's closing stock prices over the last 20 trading days of the Performance Period, including dividends (if any) when actually paid on Shares or peer company common stock, as applicable, on a reinvested basis during the applicable period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>rTSR Percentile Ranking</u>. "rTSR Percentile Ranking" shall mean the relative ranking of the Company's Total Shareholder Return as compared to the Total Shareholder Returns of the Peer Group companies, expressed as a percentile ranking.

**SECTION 5**

&nbsp;&nbsp;&nbsp;&nbsp;3

------

**<u>CONDITIONS AND LIMITATIONS ON RIGHT TO RECEIVE</u>**

**<u>COMMON SHARES</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Demotion or Transfer</u>. If Employee is demoted or transferred to a position with the Company or any of its Affiliates in which Employee is no longer eligible to participate in the Plan prior to the expiration of the Performance Period, as determined by the Committee, the Performance Shares awarded to Employee hereunder shall be forfeited unless otherwise determined by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Death</u>. If Employee ceases to be employed by the Company or any of its Affiliates prior to the expiration of the Performance Period due to his or her death, the Company shall issue to the legal representative of Employee's estate, Employee's revocable living trust or any beneficiary designated in accordance with Section 8(e) below (as applicable, the "Beneficiary") a pro rata portion of the Shares that would have been issued to Employee under this Agreement in settlement of this Award had Employee remained in continuous employment with the Company or its Affiliates through the end of the Performance Period, assuming achievement at a 100% performance level (such target number of shares issuable in connection with such assumed achievement at a 100% performance level, the "Target Grant") or such other number of Shares as determined by the Committee. Such pro rata portion of the Target Grant shall be determined by multiplying the Target Grant by a fraction, the numerator of which is the number of calendar months in the Performance Period prior to Employee's death, and the denominator of which is 36. Employment for any portion of a calendar month during the Performance Period shall be deemed employment for that calendar month. Such settlement shall occur as soon as reasonably practicable, and in any event no later than the 60th day following the Company's receipt of notice of Employee's death from the Beneficiary. Any Performance Shares subject to this Award in excess of the pro rata portion to be issued pursuant to this Section 5(b) shall be cancelled effective as of Employee's termination of employment on account of Disability, and Employee shall have no further rights with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Disability</u>. If Employee ceases to be employed by the Company or any of its Affiliates prior to the expiration of the Performance Period due to his or her Disability, the Company shall issue to Employee a pro rata portion of the Target Grant that would have been issued to Employee under this Agreement in settlement of this Award or such other number of Shares as determined by the Committee. Such pro rata portion of the Target Grant shall be determined by multiplying the Target Grant by a fraction, the numerator of which is the number of calendar months in the Performance Period prior to Employee's termination of employment due to Disability, and the denominator of which is 36. Employment for any portion of a calendar month during the Performance Period shall be deemed employment for that calendar month. Such settlement shall occur at such time as provided in Section 3(b)(1) of this Agreement. For purposes of this Agreement, "Disability" shall mean disability as defined in any long-term disability plan maintained by the Company or an Affiliate which covers Employee or, in the absence of any such plan, a physical or mental condition of Employee arising during the Performance Period which prevents Employee from continuing employment with the Company and its Affiliates, all as determined by the Committee in its discretion. Any Performance Shares subject to this Award in excess of the pro rata portion to be issued pursuant to this Section 5(c)

&nbsp;&nbsp;&nbsp;&nbsp;4

------

shall be cancelled effective as of Employee's termination of employment on account of Disability, and Employee shall have no further rights with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Retirement</u>. If Employee ceases to be a full-time employee of the Company or any of its Affiliates (as may be determined by the Company or such Affiliate from time to time) at any time during the first year of the Performance Period (the last date of the first year of the Performance Period, the "Retirement Forfeiture End Date") due to Retirement, all of the Performance Shares awarded to Employee hereunder shall be forfeited, unless otherwise determined by the Committee.

If Employee ceases to be employed by the Company or any of its Affiliates at any time during the Performance Period after the Retirement Forfeiture End Date, the Company shall settle the Performance Shares subject to this Award (subject to Sections 6 and 7) following the end of the Performance Period by issuing to Employee (or, upon Employee's death following Retirement, the Beneficiary) the Shares that would have been issued to Employee in settlement of this Award had Employee remained in continuous employment with the Company or its Affiliates (following adjustment based on the ultimate level of achievement during the Performance Period as provided in Section 4 above). Such settlement shall occur as provided in Section 3(b)(1) of this Agreement.

For purposes of this Agreement, "Retirement" shall mean Employee's termination of employment with the Company and its Affiliates after Employee has attained a combination of age and years of service that equals at least 65; provided that, (A) Employee has been employed by the Company and its Affiliates for at least five years and (B) the maximum number of years of service credited for purposes of this calculation shall be ten.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Termination</u>. Except as otherwise provided in this Section 5, if Employee's continuous employment with the Company and its Affiliates is terminated prior to the end of the Performance Period, whether voluntarily or involuntarily, for any reason other than death, Disability or Retirement, this Agreement will terminate and be of no further force or effect and the Performance Shares awarded to Employee hereunder shall be forfeited, unless otherwise determined by the Committee.

**SECTION 6**

**<u>CHANGE OF CONTROL</u>**

Notwithstanding anything contained herein to the contrary, upon the consummation of any Change of Control during the Performance Period prior to the vesting or forfeiture of the Performance Shares subject to this Award in accordance with Sections 3 and 5 above, the provisions of Article IX of the Plan will apply.

Subject to the foregoing, following any Change of Control in respect of which the Performance Shares subject to this Award continue to remain outstanding and/or are assumed or for which an award is substituted (a "Substitute Award") in accordance with Article IX of the Plan, the original terms of this Award shall continue in effect, except that upon any involuntary termination of Employee's employment by the Company or an Affiliate (including for purposes

&nbsp;&nbsp;&nbsp;&nbsp;5

------

of this Section 6, any successor thereof resulting from the Change of Control) following such Change of Control other than for Cause, the Performance Shares subject to this Award shall immediately thereupon vest at an assumed 100% performance level and be settled as soon as reasonably practicable following the date of such involuntary termination, and in any event no later than the 60th day following such involuntary termination. For purposes of this Section 6, "Cause" shall mean (a) any conduct, act or omission that is contrary to Employee's duties as an officer or employee of the Company or any of its Affiliates, or that is inimical or in any way contrary to the best interests of the Company or any of its Affiliates, or (b) any violation of any terms of the restrictive covenants set forth in Section 7 of this Agreement (the "Restrictive Covenants"), in each case as determined by the Committee.

**SECTION 7**

**<u>RESTRICTIVE COVENANTS</u>**

In exchange for the consideration provided to Employee pursuant to this Agreement, which Employee acknowledges is in addition to any compensation for services performed, Employee agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Non-Compete</u>. For the duration of Employee's employment with the Company or any of its affiliates or subsidiaries, including, but not limited to, RGA Enterprise Services Company, and for a period of 12 months following the termination of Employee's employment, Employee shall not, directly or indirectly, be employed by or provide any services for any person, business, firm, company, or other entity engaged in the same or similar lines of business as the Company or that competes with the Company in any way, without the written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Non-Solicit</u>. For the duration of Employee's employment with the Company or any of its affiliates or subsidiaries, including, but not limited to, RGA Enterprise Services Company, and for a period of 12 months following the termination of Employee's employment, Employee shall not, directly or indirectly, solicit, induce, persuade, or advise, or attempt to or encourage another person or entity to solicit, induce, persuade, or advise, any person employed by the Company or any person retained by the Company as an independent contractor or contingent worker, to terminate their employment or contract relationship with the Company, or to obtain employment or commence a contract relationship with another person or entity, without the written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Confidentiality</u>. Employee shall keep in strict confidence all confidential and/or proprietary information of the Company, its affiliates, and subsidiaries in accordance with applicable Company policies and procedures. Confidential and/or proprietary information includes, but is not limited to, any trade secrets, processes, formulas, data, know-how, inventions, improvements, techniques, training methods, business management methods, financial data, technical data and documentation, contracts, strategic planning, product/service specifications, communication systems, marketing plans, forecasts, customer and supplier lists and contacts, price and cost lists, prototypes, computer programs, databases, drawings, models, marketing data, projections, client and employee information, books, records, accounts, data

&nbsp;&nbsp;&nbsp;&nbsp;6

------

processing information, or any document in any form in Employee's possession which refers or relates to the Company's business and affairs. Confidential and proprietary information shall not include information that was, is, or becomes generally available to the public through no fault of the Employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Cancellation of Award</u>. If Employee breaches or violates any of the Restrictive Covenants, as determined by the Committee, while this Award (including any Substitute Award) remains outstanding and before Shares are issued in settlement of this Award pursuant to this Agreement, this Award will immediately be cancelled without any further action and Employee shall have no further rights with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Recission</u>. In addition to any other remedies available to the Company, if Employee breaches or violates any of the Restrictive Covenants, as determined by the Committee, following such time that Shares are issued in settlement of this Award pursuant to this Agreement and prior to the consummation of any Change of Control, the Company may, if so determined by the Committee, cause Employee to surrender the Shares issued upon settlement of this Award or make the payments, in any such case, as provided in this Section 7(e), by providing notice to Employee (the "Rescission Notice") at the last known address or e-mail address of Employee within 180 days after the Committee obtains knowledge of Employee's breach or violation of any of the Restrictive Covenants. In such event, within 10 business days following the Company's delivery of the Rescission Notice as set forth above, (i) Employee must surrender to the Company the Shares issued upon settlement of this Award pursuant to this Agreement or (ii) if such Shares have been sold or transferred by Employee or if otherwise determined by the Company, the Employee must pay the Company an amount in cash equal to the Fair Market Value of the Shares on the date of the issuance of the Shares to Employee pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Nature of Restrictions</u>. Employee acknowledges that the restrictions contained in this Section 7 are reasonable and necessary to protect the Company's legitimate interests in its confidential information, trade secrets, customer relationships and investment in the training and development of its employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>No Interference</u>. Nothing in this Agreement is intended to interfere with or prohibit Employee from reporting to or participating in an investigation with any federal, state or local government agency about a possible violation of law, from recovering any award offered by such agency associated with such investigation, or from making other disclosures protected by applicable whistleblower statutes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)<u>Survival</u>. The provisions of this Section 7 shall survive the termination of Employee's employment with the Company or any vesting or forfeiture of the Performance Shares.

&nbsp;&nbsp;&nbsp;&nbsp;7

------

**SECTION 8**

**<u>MISCELLANEOUS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights in Shares Prior to Issuance</u>. Prior to the issuance of Shares upon settlement of the Performance Shares subject to this Award, neither Employee nor his or her legatees, personal representatives, or distributees shall (i) be deemed to be a holder of any Shares represented by the Performance Shares awarded hereunder or (ii) have any voting, dividend or other rights with respect to any such Shares.

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-assignability</u>. The Performance Shares subject to this Award shall not be assigned, alienated, pledged, attached, sold, transferred or encumbered by Employee other than by will or by the laws of descent and distribution; provided that, Employee may transfer the Performance Shares during his or her lifetime to a revocable living trust of which Employee is grantor, or to another form of trust indenture of which Employee is a grantor or a beneficiary.

&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Recoupment</u>. This Award is subject to the terms and conditions contained in (i) the Company's Executive Compensation Recoupment Policy, (ii) the Company's NYSE Executive Recoupment Policy, (iii) any amendment and/or restatement of either such policy, and (iv) any other recoupment or clawback policy that may be adopted by the Company in the future (collectively, the "Policies"), any or all of which may permit the Company to recoup all or a portion of awards made to certain employees upon the occurrence of certain events. If any portion of this Award becomes subject to recoupment pursuant to any one or more of the Policies, the Company may utilize any method of recovery specified in any of such Policies in connection with any award recoupments required or permitted under any of such Policies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Law Requirements</u>. The Company shall not be required to issue Shares pursuant to this Agreement unless and until such issuance is in compliance with all applicable legal requirements, including that (i) such Shares have been duly listed upon each stock exchange on which the Company's Common Stock is then registered and (ii) a registration statement under the Securities Act of 1933 with respect to such Shares is then effective.

&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation of Beneficiaries</u>. Employee may file with the Company a written designation of a beneficiary or beneficiaries to receive, upon Employee's death, the Shares determined in accordance with Section 5(b) and subject to all of the provisions of this Agreement. An Employee may from time to time revoke or change any such designation of beneficiary and any designation of beneficiary under the Plan shall be controlling over any other disposition, testamentary or otherwise; provided, however, that if the Committee shall be in doubt as to the right of any such beneficiary to receive Shares, the Committee may recognize only receipt of such Shares by the personal representative of the estate of Employee, in which case the Company, the Committee and the members thereof shall not be under any further liability to anyone.

&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Changes in Capital Structure</u>. Notwithstanding anything contained herein to the contrary in this Agreement, if there is any change in the Common Stock by reason of any extraordinary dividend, stock dividend, spin off, split up, spin out, recapitalization, warrant or rights

&nbsp;&nbsp;&nbsp;&nbsp;8

------

issuance or combination, exchange or reclassification of shares, merger, consolidation, reorganization, sale of substantially all assets or, as determined by the Committee, other similar or relevant event, in any such event as determined by the Committee to affect the Shares, then the number, kind and class of shares of Common Stock available for Performance Shares and the number, kind and class of shares of Common Stock subject to outstanding Performance Shares, as applicable, shall be appropriately adjusted by the Committee. The issuance of shares of Common Stock for consideration and the issuance of rights with respect to Common Stock shall not be considered a change in the Company's capital structure. No adjustment provided for in this Section 8(f) shall require the issuance of any fractional shares.

&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Right to Continued Employment</u>. Nothing in this Agreement shall confer on Employee any right to continued employment or interfere with the right of an Employer to terminate Employee's employment at any time or for any reason.

&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Award</u>. In accepting this Award, Employee acknowledges, understands and agrees that: (i) this Award does not in any way create any contractual or other rights to receive additional grants of performance contingent shares (or benefits in lieu of performance contingent shares) or other equity awards at any time; (ii) all decisions with respect to future performance contingent shares or other equity awards, if any, will be at the sole discretion of the Company; (iii) Employee's participation in the Plan is voluntary; (iv) this Award is not part of normal or expected compensation or salary of Employee for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments; (v) upon the termination of the employment of Employee for any reason, the term of employment of Employee for purposes of this Agreement will not be extended by any notice period mandated under any applicable law and (vi) the future value of the Performance Shares issuable upon any settlement of this Award is unknown, indeterminable and cannot be predicted with certainty.

&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Withholding</u>. Employee must pay or make arrangements acceptable to the Company for the payment of any and all federal, state and local tax withholding that in the opinion of the Company is required by law. Unless Employee satisfies any such tax withholding obligation as provided in the preceding sentence, the Company will withhold shares of Common Stock having a Fair Market Value on the date of withholding equal to the tax withholding obligation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Copy of Plan and Prospectus</u>. By signing this Agreement, Employee acknowledges receipt of a copy of (or an electronic link to) the Plan and the prospectus related to this grant of Performance Shares under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Choice of Law; Venue</u>. This Agreement will be governed by the laws of the State of Missouri, without giving regard to the conflict of law provisions thereof. Any legal action arising out of this Agreement may only be brought in the Circuit Court in St. Louis County and/or the United States District Court in St. Louis, Missouri.

&nbsp;&nbsp;&nbsp;&nbsp;9

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution</u>. An authorized representative of the Company has signed this Agreement, and Employee has signed this Agreement to evidence Employee's acceptance of this Award on the terms specified in this Agreement and the Plan, all as of the Date of Grant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Section 409A</u>. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by Employee on account of non-compliance with Section 409A of the Code. Notwithstanding anything herein to the contrary, if Employee is determined to be a "specified employee" within the meaning of Section 409A of the Code, any payment that is made on account of Employee's termination of employment pursuant to this Award and that does not qualify as a "short-term deferral" within the meaning of Section 1.409A-1(b)(4) of the Treasury Regulations (or any other exemption therefrom) shall be made on the first payroll date which is more than six months following the date of Employee's termination of employment to the extent required to avoid any adverse tax consequences under Section 409A of the Code. To the extent necessary for compliance with Code Section 409A, references to termination of employment under this Agreement shall mean a "separation from service" within the meaning of Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any provision of this Agreement (including Section 7 of this Agreement) shall be determined by a court to be invalid or unenforceable for any reason, any such provisions shall be construed so as to be enforceable to the maximum extent compatible with the applicable laws in effect at the time; and such determination of invalidity or unenforceability shall not affect the remaining provisions of this Agreement (including Section 7 of this Agreement), which shall continue to be given full force and effect. Moreover, if any provision of Section 7 of this Agreement shall be determined by a court to be unenforceable because of the scope or duration thereof, the parties hereby expressly agree that the court making such determination shall have the power to reduce the scope or duration and/or restrict the geographical area of such provision and/or to delete such specific words or phrases which the court shall deem necessary to permit enforcement of such provision in restricted form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. Employee acknowledges and agrees that any breach or threatened breach of any provisions of Section 7 of this Agreement will result in substantial, continuing and irreparable injury to the Company and/or its Affiliates. Therefore, in such event, the Company and/or its Affiliates shall be entitled to seek equitable and/or injunctive relief to prevent any breach or threatened breach of such provisions, and to specific performance of each of the terms thereof, in addition to any other legal or equitable remedies that the Company or any Affiliate may have. The rights and remedies of the parties to this Agreement are cumulative and not alternative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;&nbsp;&nbsp;&nbsp;<u>Deadline to Accept</u>. If Employee wishes to accept the terms of this Agreement, Employee must do so by executing and delivering this Agreement (including by electronic means

&nbsp;&nbsp;&nbsp;&nbsp;10

------

made available to Employee) within 60 days after the Date of Grant. The Company may, in its sole discretion, extend the time within which Employee may accept this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;&nbsp;&nbsp;&nbsp;<u>Modifications and Waivers</u>. The Company may modify, amend or waive any terms of this Agreement, prospectively or retroactively, without the consent of Employee unless any such modification or waiver is deemed by the Committee to be materially adverse to Employee and not required as a matter of law. In addition, the waiver by either party of compliance with any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;&nbsp;&nbsp;&nbsp;<u>Employee Data Privacy</u>. By entering into this Agreement and accepting the Award:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp; Employee acknowledges and consents to the collection, use, processing and transfer, in electronic or other form, of any of Employee's personal data, including, but not limited to, Employee's name, home address and telephone number(s), date of birth, social security number or other identification number, salary, nationality, job title and details of this Award and any other awards granted to Employee under the Plan (collectively, "Data") for the purpose of implementing, administering and managing Employee's participation in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;Employee understands that (i) the Company and its Affiliates may transfer Data amongst themselves as necessary for the purpose of implementing, administering, and managing Employee's participation in the Plan, and (ii) the Company and its Affiliates may transfer Data to any third parties assisting the Company in connection with the implementation, administration and management of the Plan, including any broker or stock plan service provider selected by the Company in connection with the Plan (the "Stock Plan Provider") (any recipients of the Data as provided in clauses (i) or (ii) above, the "Recipients").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;&nbsp;Employee understands that the Recipients may be located in the United States or elsewhere, and that the Recipients' country may have different data privacy laws and protections than Employee's country.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;&nbsp;Employee authorizes the Company, its Affiliates, any Stock Plan Provider and any other Recipients that may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purpose of implementing, administering and managing Employee's participation in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) &nbsp;&nbsp;&nbsp;&nbsp;Employee understands that, if Employee resides in certain jurisdictions where Employee is afforded certain rights, Employee may, at any time, exercise such rights which may include requesting access to the Data, requesting additional information about the storage and processing of Data, requiring any necessary amendments to Data or refusing or withdrawing the consents herein (where Company relies on Employee's consent as the legal

&nbsp;&nbsp;&nbsp;&nbsp;11

------

basis for processing). For additional information, Employee may contact Employee's human resources representative or the Company's Global Privacy Office.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) &nbsp;&nbsp;&nbsp;&nbsp;Employee understands that (i) Employee is providing the consents herein and otherwise agreeing to the terms of this Section 8(r) on a purely voluntary basis, and (ii) that if Employee refuses or withdraws such consent and/or agreement to these terms, Employee's salary from or service with the Company will not be affected and the Company may not be able to grant Awards or administer Employee's participation in the Plan and that Company may, as a result, cancel Employee's ability to participate in the Plan and/or cause the Employee to forfeit this Award and other outstanding Awards under the Plan.

*Signature page follows.*

&nbsp;&nbsp;&nbsp;&nbsp;12

------

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of this ____ day of April, 2026.

**Reinsurance Group of America, Incorporated** 

By: ____________________________

Tony Cheng

President and Chief Executive Officer

**Employee** 

_______________________________

Name:

&nbsp;&nbsp;&nbsp;&nbsp;13

## Exhibit 10.2

**REINSURANCE GROUP OF AMERICA, INCORPORATED**

**FLEXIBLE STOCK PLAN**

**<u>STOCK APPRECIATION RIGHT AWARD AGREEMENT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;Reinsurance Group of America, Incorporated, a Missouri corporation (the "Company"), and ("Employee") hereby agree as follows:

**SECTION 1**

**<u>GRANT OF STOCK APPRECIATION RIGHT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Reinsurance Group of America, Incorporated Flexible Stock Plan, as amended and restated effective May 21, 2025 (the "Plan"), and pursuant to action of the Committee charged with the Plan's administration, the Company has granted to Employee, effective March [_], 2026 (the "Date of Grant"), subject to the terms, conditions and limitations stated in this Stock Appreciation Right Award Agreement (this "Agreement"), the Plan and the Company's executive compensation recoupment policies (as discussed in Section 8(c)), a stock appreciation right ("SAR"), which is granted with respect to shares of Common Stock (each, a "SAR Share"). The SAR is exercisable as provided in Section 4 (the "Award").

**SECTION 2**

**<u>TERMS OF THE PLAN</u>**

This Award is granted under and is expressly subject to all the terms and provisions of the Plan, which terms are incorporated herein by reference. This Agreement and the Plan contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings with respect to such subject matter. The Plan and this Agreement are administered by the Committee. Any determination under the Plan or this Agreement made by the Committee shall be at the Committee's sole discretion. Capitalized terms used and not otherwise defined in this Agreement shall have the same meanings ascribed to them in the Plan.

**SECTION 3**

**<u>EXERCISE PRICE PER SAR SHARE</u>**

&nbsp;&nbsp;&nbsp;&nbsp;The "Exercise Price" per SAR Share shall be $[_____], which is the Fair Market Value of one share of Common Stock as of the Date of Grant.

**SECTION 4**

**<u>EXERCISE OF SAR</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Right to Exercise</u>. Subject to the terms of this Section 4 and Section 5, 6, and 7, this SAR is exercisable at any time prior to the Expiration Date, but only to the extent vested on the date of such exercise.

663862

------

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Terms of Exercise</u>. Upon exercise of any vested portion of the SAR in accordance with this Section 4, Employee or the individual, trust or entity authorized to exercise such SAR as provided herein or the Plan (collectively, the "Exercisor") shall be entitled to receive an amount equal to the excess of (i) the Fair Market Value of the specified number of SAR Shares as of the date of exercise (which shall be determined by multiplying the number of SAR Shares being exercised by the Fair Market Value of one share of Common Stock on the date of exercise) over (ii) an amount equal to the Exercise Price Per Share multiplied by the number of SAR Shares being exercised. Such excess, if any, may be paid either (x) in whole or fractional shares of Common Stock, the number of which shall be determined using the Fair Market Value of one share of Common Stock as of the date of exercise, or (y) in cash, or any combination of whole or fractional shares of Common Stock and cash, with such method of payment to be determined by the Committee from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Method of Exercise</u>. The vested portion of the SAR may be exercised in whole or in part by the Exercisor at any time or from time to time in accordance with procedures established by the Committee. As promptly as practicable after such exercise of the SAR, the Company shall issue the number of shares of Common Stock or pay the amount of cash, as applicable, determined pursuant to Section 4(b) above to the Exercisor. Each exercised SAR will be cancelled.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Automatic Exercise</u>. Notwithstanding the foregoing, if the Fair Market Value of an SAR Share on the Expiration Date or, if applicable, the earlier termination date of the SAR in accordance with Section 5(c) or the second paragraph of Section 5(d) (each, a "Covered Termination Event") exceeds the Exercise Price, then to the extent the SARs have not theretofore been exercised, expired or otherwise terminated, the Company shall cause the SARs to be automatically exercised immediately prior to its termination on the Expiration Date or, if applicable, following the earlier Covered Termination Event, and, as promptly as practicable thereafter, deliver to the Employee, subject to Section 8(i), the amount (in cash or shares of Common Stock) that would have been payable to such person pursuant to Section 4(b) if the SAR had actually been exercised by Employee.

**SECTION 5**

**<u>CONDITIONS AND LIMITATIONS ON RIGHT TO EXERCISE SAR SHARES</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Vesting</u>. Subject to this Section 5 and subject to Sections 6 and 7, this SAR shall vest in three equal annual installments, with one-third vesting on the first anniversary of the Date of Grant, one-third vesting on the second anniversary of the Date of Grant, and one-third vesting on the third anniversary of the Date of Grant (such period, through the third anniversary of the Date of Grant, the "Vesting Period"). The SAR must be exercised, if at all, no later than ten years from the Date of Grant (the "Expiration Date"). The SAR may be exercised in full or in part, subject to this vesting schedule, at any time prior to the Expiration Date. Upon a partial exercise of this SAR, the number of SAR Shares available for future exercise shall be reduced by the portion of the SAR so exercised.

&nbsp;&nbsp;&nbsp;&nbsp;2

------

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Demotion or Transfer</u>. If Employee is demoted or transferred to a position with the Company or any of its Affiliates in which Employee is no longer eligible to participate in the Plan prior to the expiration of the Vesting Period, as determined by the Committee, the unvested portion of the SARs awarded to Employee hereunder as of the date of such demotion or transfer shall be forfeited unless otherwise determined by the Committee, and Employee shall have no further rights with respect to such unvested portion of the SARs.

&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disability or Death</u>. Notwithstanding the vesting schedule set forth in Section 5(a) above, if Employee ceases to be employed by the Company or any of its Affiliates prior to the Expiration Date due to Disability or death, the SAR shall become immediately 100% vested with respect to the entire portion of the SAR not exercised prior to the date of Employee's termination of employment due to Disability or death, and the SAR may be exercised at any time within five years following the earlier to occur of Employee's termination of employment due to death or Disability, but in no event later than the Expiration Date. Should this Section 5(c) become operative because of Employee's death, or should Employee die after Employee's Disability, then the SAR may be exercised by the legal representative of Employee's estate, Employee's revocable living trust, or any beneficiary designated in accordance with Section 8(e) below (as applicable, the "Beneficiary").

&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, "Disability" shall mean disability as defined in any long-term disability plan maintained by the Company or an Affiliate which covers Employee or, in the absence of any such plan, a physical or mental condition of Employee arising prior to the Expiration Date which prevents Employee from continuing employment with the Company and its Affiliates, all as determined by the Committee in its discretion.

&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Retirement</u>. If Employee ceases to be a full-time employee of the Company or any of its Affiliates (as may be determined by the Company or such Affiliate) at any time prior to December 31 in the year of the Date of Grant (the "Retirement Forfeiture End Date") due to Retirement, the SAR awarded to Employee hereunder shall be forfeited, unless otherwise determined by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;If Employee ceases to be employed by the Company or any of its Affiliates due to Retirement following the Retirement Forfeiture End Date but prior to the Expiration Date, the SAR shall continue to vest following such Retirement as provided in Section 5(a) above through the end of the Vesting Period and shall remain exercisable as if Employee had continued his or her employment with the Company or its Affiliates following such Retirement through the end of the Vesting Period, subject to Section 6 below. Notwithstanding the vesting schedule set forth in Section 5(a) above, upon Employee's death following any such Retirement referred to in the immediately preceding sentence but prior to the Expiration Date, the SAR shall become immediately 100% vested with respect to the entire portion of the SAR not exercised prior to Employee's death, and the SAR may be exercised at any time within five years following Employee's death (but in no event later than the Expiration Date) by the Beneficiary. In no event may any portion of this SAR be exercised after the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;3

------

For purposes of this Agreement, "Retirement" shall mean Employee's termination of employment with the Company and its Affiliates after Employee has attained a combination of age and years of service that equals at least 65; provided that, (A) Employee has been employed by the Company and its Affiliates for at least five years and (B) the maximum number of years of service credited for purposes of this calculation shall be ten.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Termination</u>. Except as otherwise provided in this Section 5, unless otherwise determined by the Committee, (i) the SAR may be exercised only by Employee while serving as an officer or employee of the Company or any of its Affiliates or within 30 days following termination of employment, whether such employment termination is voluntarily or involuntarily, and (ii) Employee shall have no further rights with respect to the portion of the SAR that was unvested as of the date of any termination of employment. Notwithstanding the foregoing, Employee may exercise the SAR following termination only to the extent the SAR was vested and had not been exercised prior to such termination, and in no event may the SAR be exercised after the Expiration Date.

**SECTION 6**

**<u>CHANGE OF CONTROL</u>**

&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything contained herein to the contrary, upon the consummation of any Change of Control at any time while any portion of this SAR is outstanding and unexercised subject to this Award in accordance with Sections 4 or 5 above, the provisions of Article IX of the Plan will apply.

Subject to the foregoing, following any Change of Control in respect of which the SARs continue to remain outstanding and/or are assumed or for which an award is substituted (a "Substitute Award") in accordance with Article IX of the Plan, the original terms of this Award shall continue in effect, except that upon any involuntary termination of Employee's employment by the Company or an Affiliate (including for purposes of this Section 6, any successor thereof resulting from the Change of Control) following such Change of Control other than for Cause, the SARs subject to this Award shall immediately thereupon vest in full (treating the date of such involuntary termination as the last day of the Vesting Period), and shall remain exercisable for five years following such involuntary termination date, but in no event will be exercisable following the Expiration Date. For purposes of this Section 6, "Cause" shall mean (a) any conduct, act or omission that is contrary to Employee's duties as an officer or employee of the Company or any of its Affiliates, or that is inimical or in any way contrary to the best interests of the Company or any of its Affiliates or (b) any violation of any terms of the restrictive covenants set forth in Section 7 of this Agreement (the "Restrictive Covenants"), in each case as determined by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;4

------

**SECTION 7**

**<u>RESTRICTIVE COVENANTS</u>**

In exchange for the consideration provided to Employee pursuant to this Agreement, which Employee acknowledges is in addition to any compensation for services performed, Employee agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Non-Compete</u>. For the duration of Employee's employment with the Company or any of its affiliates or subsidiaries, including, but not limited to, RGA Enterprise Services Company, and for a period of 12 months following the termination of Employee's employment, Employee shall not, directly or indirectly, be employed by or provide any services for any person, business, firm, company, or other entity engaged in the same or similar lines of business as the Company or that competes with the Company in any way, without the written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Non-Solicit</u>. For the duration of Employee's employment with the Company or any of its affiliates or subsidiaries, including, but not limited to, RGA Enterprise Services Company, and for a period of 12 months following the termination of Employee's employment, Employee shall not, directly or indirectly, solicit, induce, persuade, or advise, or attempt to or encourage another person or entity to solicit, induce, persuade, or advise, any person employed by the Company or any person retained by the Company as an independent contractor or contingent worker, to terminate their employment or contract relationship with the Company, or to obtain employment or commence a contract relationship with another person or entity, without the written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Confidentiality</u>. Employee shall keep in strict confidence all confidential and/or proprietary information of the Company, its affiliates, and subsidiaries in accordance with applicable Company policies and procedures. Confidential and/or proprietary information includes, but is not limited to, any trade secrets, processes, formulas, data, know-how, inventions, improvements, techniques, training methods, business management methods, financial data, technical data and documentation, contracts, strategic planning, product/service specifications, communication systems, marketing plans, forecasts, customer and supplier lists and contacts, price and cost lists, prototypes, computer programs, databases, drawings, models, marketing data, projections, client and employee information, books, records, accounts, data processing information, or any document in any form in Employee's possession which refers or relates to the Company's business and affairs. Confidential and proprietary information shall not include information that was, is, or becomes generally available to the public through no fault of the Employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Cancellation of Award</u>. If Employee breaches or violates any of the Restrictive Covenants, as determined by the Committee, while any portion of this Award (including any Substitute Award) remains outstanding and before Shares are issued in settlement of any portion of this Award pursuant to this Agreement, such portion of this Award will immediately be cancelled without any further action and Employee shall have no further rights with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;5

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Recission</u>. In addition to any other remedies available to the Company, if Employee breaches or violates any of the Restrictive Covenants, as determined by the Committee, following such time that Shares are issued upon the exercise of this Award pursuant to this Agreement and prior to the consummation of any Change of Control, the Company may, if so determined by the Committee, cause Employee to surrender the Shares issued upon the exercise of this Award or make the payments, in any such case, as provided in this Section 7(e), by providing notice to Employee (the "Rescission Notice") at the last known address or e-mail address of Employee within 180 days after the Committee obtains knowledge of Employee's breach or violation of any of the Restrictive Covenants. In such event, within 10 business days following the Company's delivery of the Rescission Notice as set forth above, (i) Employee must surrender to the Company any Shares issued upon the exercise of this Award pursuant to this Agreement provided that Employee continues to hold such Shares, (ii) to the extent that cash was paid to Employee upon the exercise of this Award pursuant to this Agreement, Employee must surrender the amount of such cash payment to the Company, or (iii) to the extent that Shares were issued upon exercise of this Award pursuant to this Agreement but such Shares have been sold or transferred by Employee or if otherwise determined by the Company, the Employee must pay the Company an amount in cash equal to the Fair Market Value of such Shares on the date of the issuance of the Shares to Employee pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Nature of Restrictions</u>. Employee acknowledges that the restrictions contained in this Section 7 are reasonable and necessary to protect the Company's legitimate interests in its confidential information, trade secrets, customer relationships and investment in the training and development of its employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>No Interference</u>. Nothing in this Agreement is intended to interfere with or prohibit Employee from reporting to or participating in an investigation with any federal, state or local government agency about a possible violation of law, from recovering any award offered by such agency associated with such investigation, or from making other disclosures protected by applicable whistleblower statutes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)<u>Survival</u>. The provisions of this Section 7 shall survive the termination of Employee's employment with the Company or any vesting or forfeiture of the SARs.

**SECTION 8**

**<u>MISCELLANEOUS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights in Shares Prior to Issuance</u>. Prior to issuance of SAR Shares in accordance with Section 4, neither Employee nor his or her legatees, personal representatives or distributees shall (i) be deemed to be a holder of any shares of Common Stock subject to this Award or (ii) have any voting, dividend, or other rights with respect to any such SAR Shares.

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-assignability</u>. The SAR subject to this Award shall not be assigned, alienated, pledged, attached, sold, transferred or encumbered by Employee other than by will or by the laws of descent and distribution; provided that, Employee may transfer the SAR during

&nbsp;&nbsp;&nbsp;&nbsp;6

------

his or her lifetime to a revocable living trust of which Employee is grantor, or to another form of trust indenture of which Employee is a grantor or a beneficiary.

&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Recoupment</u>. This Award is subject to the terms and conditions contained in (i) the Company's Executive Compensation Recoupment Policy, (ii) the Company's NYSE Executive Recoupment Policy, (iii) any amendment and/or restatement of either such policy, and (iv) any other recoupment or clawback policy that may be adopted by the Company in the future (collectively, the "Policies"), any or all of which may permit the Company to recoup all or a portion of awards made to certain employees upon the occurrence of certain events. If any portion of this Award becomes subject to recoupment pursuant to any one or more of the Policies, the Company may utilize any method of recovery specified in any of such Policies in connection with any award recoupments required or permitted under any of such Policies.

&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Law Requirements</u>. The Company shall not be required to issue SAR Shares pursuant to this Agreement unless and until such issuance is in compliance with all applicable legal requirements, including that (i) such SAR Shares have been duly listed upon each stock exchange on which the Company's Common Stock is then registered and (ii) a registration statement under the Securities Act of 1933 with respect to such SAR Shares is then effective.

&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation of Beneficiaries</u>. Employee may file with the Company a written designation of a beneficiary or beneficiaries to receive, upon Employee's death, the SAR granted hereunder, subject to all of the provisions of this Agreement. An Employee may from time to time revoke or change any such designation of beneficiary and any designation of beneficiary under the Plan shall be controlling over any other disposition, testamentary or otherwise; provided, however, that if the Committee shall be in doubt as to the right of any such beneficiary to receive the SAR, the Committee may recognize only receipt of the SAR by the personal representative of the estate of Employee, in which case the Company, the Committee and the members thereof shall not be under any further liability to anyone.

&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Changes in Capital Structure</u>. Notwithstanding anything contained herein to the contrary in this Agreement, if there is any change in the Common Stock by reason of any extraordinary dividend, stock dividend, spin off, split up, spin out, recapitalization, warrant or rights issuance or combination, exchange or reclassification of shares, merger, consolidation, reorganization, sale of substantially all assets or, as determined by the Committee, other similar or relevant event, in any such event as determined by the Committee to affect the Shares, then the number, kind and class of shares of Common Stock available for SARs and the number, kind and class of shares of Common Stock subject to outstanding SARs and the exercise price thereof, as applicable, shall be appropriately adjusted by the Committee. The issuance of shares of Common Stock for consideration and the issuance of rights with respect to Common Stock shall not be considered a change in the Company's capital structure. No adjustment provided for in this Section 8(f) shall require the issuance of any fractional shares.

&nbsp;&nbsp;&nbsp;&nbsp;7

------

&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Right to Continued Employment</u>. Nothing in this Agreement shall confer on Employee any right to continued employment or interfere with the right of an Employer to terminate Employee's employment at any time or for any reason.

&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Award</u>. In accepting this Award, Employee acknowledges, understands and agrees that: (i) this Award does not in any way create any contractual or other rights to receive additional grants of stock appreciation rights (or benefits in lieu of stock appreciation rights) or other equity awards at any time; (ii) all decisions with respect to future restricted stock appreciation rights or other equity awards, if any, will be at the sole discretion of the Company; (iii) Employee's participation in the Plan is voluntary; (iv) this Award is not part of normal or expected compensation or salary of Employee for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments; (v) upon the termination of the employment of Employee for any reason, the term of employment of Employee for purposes of this Agreement will not be extended by any notice period mandated under any applicable law and (vi) the future value of the SAR Shares issuable upon any settlement of this Award is unknown, indeterminable and cannot be predicted with certainty.

&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Withholding</u>. Employee must pay or make arrangements acceptable to the Company for the payment of any and all federal, state and local tax withholding that in the opinion of the Company is required by law. Unless Employee satisfies any such tax withholding obligation as provided in the preceding sentence, the Company will withhold shares of Common Stock having a Fair Market Value on the date of withholding equal to the tax withholding obligation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Copy of Plan and Prospectus</u>. By signing this Agreement, Employee acknowledges receipt of a copy of (or an electronic link to) the Plan and the prospectus related to this grant of the SAR Shares under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Choice of Law; Venue</u>. This Agreement will be governed by the laws of the State of Missouri, without giving regard to the conflict of law provisions thereof. Any legal action arising out of this Agreement may only be brought in the Circuit Court in St. Louis County and/or the United States District Court in St. Louis, Missouri.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution</u>. An authorized representative of the Company has signed this Agreement, and Employee has signed this Agreement to evidence Employee's acceptance of the award on the terms specified in this Agreement and the Plan, all as of the Date of Grant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Section 409A</u>. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest

&nbsp;&nbsp;&nbsp;&nbsp;8

------

or other expenses that may be incurred by Employee on account of non-compliance with Section 409A of the Code. Notwithstanding anything herein to the contrary, if Employee is determined to be a "specified employee" within the meaning of Section 409A of the Code, any payment that is made on account of Employee's termination of employment pursuant to this Award and that does not qualify as a "short-term deferral" within the meaning of Section 1.409A-1(b)(4) of the Treasury Regulations (or any other exemption therefrom) shall be made on the first payroll date which is more than six months following the date of Employee's termination of employment to the extent required to avoid any adverse tax consequences under Section 409A of the Code. To the extent necessary for compliance with Code Section 409A, references to termination of employment under this Agreement shall mean a "separation from service" within the meaning of Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any provision of this Agreement (including Section 7 of this Agreement) shall be determined by a court to be invalid or unenforceable for any reason, any such provisions shall be construed so as to be enforceable to the maximum extent compatible with the applicable laws in effect at the time; and such determination of invalidity or unenforceability shall not affect the remaining provisions of this Agreement (including Section 7 of this Agreement), which shall continue to be given full force and effect. Moreover, if any provision of Section 7 of this Agreement shall be determined by a court to be unenforceable because of the scope or duration thereof, the parties hereby expressly agree that the court making such determination shall have the power to reduce the scope or duration and/or restrict the geographical area of such provision and/or to delete such specific words or phrases which the court shall deem necessary to permit enforcement of such provision in restricted form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. Employee acknowledges and agrees that any breach or threatened breach of any provisions of Section 7 of this Agreement will result in substantial, continuing and irreparable injury to the Company and/or its Affiliates. Therefore, in such event, the Company and/or its Affiliates shall be entitled to seek equitable and/or injunctive relief to prevent any breach or threatened breach of such provisions, and to specific performance of each of the terms thereof, in addition to any other legal or equitable remedies that the Company or any Affiliate may have. The rights and remedies of the parties to this Agreement are cumulative and not alternative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;&nbsp;&nbsp;&nbsp;<u>Deadline to Accept</u>. If Employee wishes to accept the terms of this Agreement, Employee must do so by executing and delivering this Agreement (including by electronic means made available to Employee) within 60 days after the Date of Grant. The Company may, in its sole discretion, extend the time within which Employee may accept this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;&nbsp;&nbsp;&nbsp;<u>Modifications and Waivers</u>. The Company may modify, amend or waive any terms of this Agreement, prospectively or retroactively, without the consent of Employee unless any such modification or waiver is deemed by the Committee to be materially adverse to Employee and not required as a matter of law. In addition, the waiver by either party of compliance with any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;9

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;&nbsp;&nbsp;&nbsp;<u>Employee Data Privacy</u>. By entering into this Agreement and accepting the Award:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp; Employee acknowledges and consents to the collection, use, processing and transfer, in electronic or other form, of any of Employee's personal data, including, but not limited to, Employee's name, home address and telephone number(s), date of birth, social security number or other identification number, salary, nationality, job title and details of this Award and any other awards granted to Employee under the Plan (collectively, "Data") for the purpose of implementing, administering and managing Employee's participation in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;Employee understands that (i) the Company and its Affiliates may transfer Data amongst themselves as necessary for the purpose of implementing, administering, and managing Employee's participation in the Plan, and (ii) the Company and its Affiliates may transfer Data to any third parties assisting the Company in connection with the implementation, administration and management of the Plan, including any broker or stock plan service provider selected by the Company in connection with the Plan (the "Stock Plan Provider") (any recipients of the Data as provided in clauses (i) or (ii) above, the "Recipients").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;&nbsp;Employee understands that the Recipients may be located in the United States or elsewhere, and that the Recipients' country may have different data privacy laws and protections than Employee's country.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;&nbsp;Employee authorizes the Company, its Affiliates, any Stock Plan Provider and any other Recipients that may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purpose of implementing, administering and managing Employee's participation in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) &nbsp;&nbsp;&nbsp;&nbsp;Employee understands that, if Employee resides in certain jurisdictions where Employee is afforded certain rights, Employee may, at any time, exercise such rights which may include requesting access to the Data, requesting additional information about the storage and processing of Data, requiring any necessary amendments to Data or refusing or withdrawing the consents herein (where Company relies on Employee's consent as the legal basis for processing). For additional information, Employee may contact Employee's human resources representative or the Company's Global Privacy Office.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) &nbsp;&nbsp;&nbsp;&nbsp;Employee understands that (i) Employee is providing the consents herein and otherwise agreeing to the terms of this Section 7(r) on a purely voluntary basis, and (ii) that if Employee refuses or withdraws such consent and/or agreement to these terms, Employee's salary from or service with the Company will not be affected and the Company may not be able to grant Awards or administer Employee's participation in the Plan and that Company may, as a result, cancel Employee's ability to participate in the Plan and/or cause the Employee to forfeit this Award and other outstanding Awards under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;10

------

*Signature page follows.*

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;11

------

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of this ___ day of April, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Company"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Reinsurance Group of America, Incorporated**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:&nbsp;&nbsp;&nbsp;&nbsp;Tony Cheng

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: President and Chief Executive Officer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Employee"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:

&nbsp;&nbsp;&nbsp;&nbsp;12

## Exhibit 10.3

**REINSURANCE GROUP OF AMERICA, INCORPORATED**

**FLEXIBLE STOCK PLAN**

**<u>RESTRICTED STOCK UNIT AGREEMENT</u>**

Reinsurance Group of America, Incorporated, a Missouri corporation (the "Company"), and ("Employee"), hereby agree as follows:

**SECTION 1**

**<u>GRANT OF RSUs</u>**

Pursuant to the Reinsurance Group of America, Incorporated Flexible Stock Plan, as amended and restated effective May 21, 2025 (the "Plan"), and pursuant to action of the Committee charged with the Plan's administration, the Company has granted to Employee, effective March [_], 2026 (the "Date of Grant"), subject to the terms, conditions and limitations stated in this Restricted Stock Unit Agreement (this "Agreement"), the Plan and the Company's executive compensation recoupment policies (as discussed in Section 7(c)), an award of restricted stock units ("RSUs") with respect to shares of Common Stock (the "Award").

**SECTION 2**

**<u>TERMS OF THE PLAN</u>**

This Award is granted under and is expressly subject to all the terms and provisions of the Plan, which terms are incorporated herein by reference. This Agreement and the Plan contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings with respect to such subject matter. The Plan and this Agreement are administered by the Committee. Any determination under the Plan or this Agreement made by the Committee shall be at the Committee's sole discretion. Capitalized terms used and not otherwise defined in this Agreement shall have the same meanings ascribed to them in the Plan.

**SECTION 3**

**<u>TERMS OF GRANT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Vesting Period</u>. The RSUs will ratably vest in three equal annual installments, with one-third vesting on the first anniversary of the Date of Grant, one-third vesting on the second anniversary of the Date of Grant, and one-third vesting on the third anniversary of the Date of Grant (each such day, a "Vesting Date" and the period between the Date of Grant and the third anniversary thereof, the "Vesting Period").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Payment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)<u>RSUs Payable In Common Stock</u>. Subject to Sections 4, 5 and 6 below, if Employee is continuously employed by the Company and its Affiliates from the Date of Grant to

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

663849

------

a particular Vesting Date, as applicable, as soon as reasonably practicable, and in any event no later than the 60th day following the applicable Vesting Date, the Company shall deliver to Employee one share of the Company's Common Stock (each, a "Share") for each RSU vesting on such Vesting Date under this Agreement in settlement of such RSUs; provided, however, that any fractional RSU for the first two Vesting Dates shall be rounded down to the nearest whole Share and the RSUs vesting on the final Vesting Date shall be such number necessary to ensure the full award of RSUs granted pursuant to this Agreement shall have had the opportunity to vest by the end of the Vesting Period; provided, further, that the Committee shall have the discretion to reduce or eliminate the number of Shares deliverable hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)<u>Dividend Equivalents</u>. The RSUs shall not include dividend equivalent payments or dividend credit rights.

**SECTION 4**

**<u>CONDITIONS AND LIMITATIONS ON RIGHT TO RECEIVE</u>**

**<u>COMMON SHARES</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Demotion or Transfer</u>. If Employee is demoted or transferred to a position with the Company or any of its Affiliates in which Employee is no longer eligible to participate in the Plan prior to the expiration of the Vesting Period as determined by the Committee, the unvested RSUs awarded to Employee hereunder shall be forfeited unless otherwise determined by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Death</u>. If Employee ceases to be employed by the Company or any of its Affiliates prior to the expiration of the Vesting Period due to his or her death, the Company shall settle the RSUs subject to this Award by issuing to the legal representative of Employee's estate, Employee's revocable living trust or any beneficiary designated in accordance with Section 7(e) below (as applicable, the "Beneficiary") a pro rata portion of the Shares that would have been issued to Employee under this Agreement in settlement of this Award at the end of the Vesting Period had Employee remained in continuous employment with the Company or its Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;2

------

Such pro rata portion shall be determined by multiplying the number of RSUs subject to this Award that are unvested at the time of Employee's death by a fraction, as follows:

---

| | | |
|:---|:---|:---|
| Date of death | Fraction numerator | Fraction denominator |
| Between the Date of Grant and the first anniversary thereof | Number of months elapsed since Date of Grant | 36 |
| After the first anniversary of the Date of Grant until the second anniversary of the Date of Grant | Number of months elapsed since first anniversary of Date of Grant | 24 |
| After the second anniversary of the Date of Grant until the third anniversary of the Date of Grant | Number of months elapsed since second anniversary of Date of Grant | 12 |

---

Employment for any portion of a month during the Vesting Period shall be deemed employment for that month. Such settlement shall occur as soon as reasonably practicable, and in any event no later than the 60th day following the Company's receipt of notice of Employee's death from the Beneficiary. Any RSUs subject to this Award in excess of the pro rata portion of the Shares to be issued pursuant to this Section 4(b) shall be cancelled effective as of Employee's death, and Employee's successors and assigns shall have no further rights with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Disability</u>. If Employee ceases to be employed by the Company or any of its Affiliates prior to the expiration of the Vesting Period due to his or her Disability, the Company shall settle the RSUs subject to this Award by issuing to Employee (or such Employee's legal representative) a pro rata portion of the Shares that would have been issued to Employee in settlement of this Award at the end of the Vesting Period had Employee remained in continuous employment with the Company or its Affiliates. Such pro rata portion shall be determined by

&nbsp;&nbsp;&nbsp;&nbsp;3

------

multiplying the number of RSUs subject to this Award that are unvested at the time that Employee's employment terminates on account of Disability by a fraction, as follows:

---

| | | |
|:---|:---|:---|
| Date of Disability | Fraction numerator | Fraction denominator |
| Between the Date of Grant and the first anniversary thereof | Number of months elapsed since Date of Grant | 36 |
| After the first anniversary of the Date of Grant until the second anniversary of the Date of Grant | Number of months elapsed since first anniversary of Date of Grant | 24 |
| After the second anniversary of the Date of Grant until the third anniversary of the Date of Grant | Number of months elapsed since second anniversary of Date of Grant | 12 |

---

Employment for any portion of a month during the Vesting Period shall be deemed employment for that month. Such settlement shall occur as soon as reasonably practicable, and in any event no later than the 60th day following the Company's determination that a Disability has occurred. For purposes of this Agreement, "Disability" shall mean disability as defined in any long-term disability plan maintained by the Company or an Affiliate which covers Employee or, in the absence of any such plan, a physical or mental condition of Employee arising during the Vesting Period which prevents Employee from continuing employment with the Company and its Affiliates, all as determined by the Committee in its discretion. Any RSUs subject to this Award in excess of the pro rata portion of the Shares to be issued pursuant to this Section 4(c) shall be cancelled effective as of Employee's termination of employment on account of Disability, and Employee shall have no further rights with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Retirement</u>. If Employee ceases to be a full-time employee of the Company or any of its Affiliates (as may be determined by the Company or such Affiliate from time to time) at any time prior to December 31 in the year of the Date of Grant (the "Retirement Forfeiture End Date") due to Retirement, all of the RSUs awarded to Employee hereunder shall be forfeited, unless otherwise determined by the Committee.

If Employee ceases to be employed by the Company or any of its Affiliates due to Retirement at any time during the Vesting Period after the Retirement Forfeiture End Date, the Company shall settle the RSUs subject to this Award (subject to Sections 5 and 6) by issuing to Employee (or, upon Employee's death following Retirement, the Beneficiary) the Shares that would have been issued to Employee in settlement of this Award at the end of the Vesting Period had Employee remained in continuous employment with the Company or its Affiliates. Such settlement shall occur as soon as reasonably practicable following the last day of the Vesting Period, and in any event no later than the 60th day following such date.

&nbsp;&nbsp;&nbsp;&nbsp;4

------

For purposes of this Agreement, "Retirement" shall mean Employee's termination of employment with the Company and its Affiliates after Employee has attained a combination of age and years of service that equals at least 65; provided that, (A) Employee has been employed by the Company and its Affiliates for at least five years and (B) the maximum number of years of service credited for purposes of this calculation shall be ten.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Other Termination</u>. Except as otherwise provided in this Section 4, if Employee's continuous employment with the Company and its Affiliates is terminated prior to the end of the Vesting Period, whether voluntarily or involuntarily (including, for the avoidance of doubt, Retirement prior to the Retirement Forfeiture End Date), all of the unvested RSUs subject to this Award shall be immediately thereupon forfeited, and Employee will have no further rights with respect to such RSUs, unless otherwise determined by the Committee.

**SECTION 5**

**<u>CHANGE OF CONTROL</u>**

Notwithstanding anything contained herein to the contrary, upon the consummation of any Change of Control prior to the vesting or forfeiture of the RSUs subject to this Award in accordance with Sections 3 or 4 above, the provisions of Article IX of the Plan will apply. Subject to the foregoing, following any Change of Control in respect of which the RSUs continue to remain outstanding and/or are assumed or for which an award is substituted (a "Substitute Award") in accordance with Article IX of the Plan, the original terms of this Award shall continue in effect, except that upon any involuntary termination of Employee's employment by the Company or an Affiliate (including for purposes of this Section 5, any successor thereof resulting from the Change of Control) following such Change of Control other than for Cause, the RSUs subject to this Award shall immediately thereupon vest and be settled as provided in Section 3(b)(1) (treating the date of such involuntary termination as the last day of the Vesting Period). For purposes of this Section 5, "Cause" shall mean (a) any conduct, act or omission that is contrary to Employee's duties as an officer or employee of the Company or any of its Affiliates, or that is inimical or in any way contrary to the best interests of the Company or any of its Affiliates or (b) any violation of any terms of the restrictive covenants set forth in Section 6 of this Agreement (the "Restrictive Covenants"), in each case as determined by the Committee.

**SECTION 6**

**<u>RESTRICTIVE COVENANTS</u>**

In exchange for the consideration provided to Employee pursuant to this Agreement, which Employee acknowledges is in addition to any compensation for services performed, Employee agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Non-Compete</u>. For the duration of Employee's employment with the Company or any of its affiliates or subsidiaries, including, but not limited to, RGA Enterprise Services Company, and for a period of 12 months following the termination of Employee's employment, Employee shall not, directly or indirectly, be employed by or provide any services for any person, business, firm, company, or other entity engaged in the same or similar lines of business

&nbsp;&nbsp;&nbsp;&nbsp;5

------

as the Company or that competes with the Company in any way, without the written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Non-Solicit</u>. For the duration of Employee's employment with the Company or any of its affiliates or subsidiaries, including, but not limited to, RGA Enterprise Services Company, and for a period of 12 months following the termination of Employee's employment, Employee shall not, directly or indirectly, solicit, induce, persuade, or advise, or attempt to or encourage another person or entity to solicit, induce, persuade, or advise, any person employed by the Company or any person retained by the Company as an independent contractor or contingent worker, to terminate their employment or contract relationship with the Company, or to obtain employment or commence a contract relationship with another person or entity, without the written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Confidentiality</u>. Employee shall keep in strict confidence all confidential and/or proprietary information of the Company, its affiliates, and subsidiaries in accordance with applicable Company policies and procedures. Confidential and/or proprietary information includes, but is not limited to, any trade secrets, processes, formulas, data, know-how, inventions, improvements, techniques, training methods, business management methods, financial data, technical data and documentation, contracts, strategic planning, product/service specifications, communication systems, marketing plans, forecasts, customer and supplier lists and contacts, price and cost lists, prototypes, computer programs, databases, drawings, models, marketing data, projections, client and employee information, books, records, accounts, data processing information, or any document in any form in Employee's possession which refers or relates to the Company's business and affairs. Confidential and proprietary information shall not include information that was, is, or becomes generally available to the public through no fault of the Employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Cancellation of Award</u>. If Employee breaches or violates any of the Restrictive Covenants, as determined by the Committee, while any portion of this Award (including any Substitute Award) remains outstanding and before Shares are issued in settlement of any portion of this Award pursuant to this Agreement, such portion of this Award will immediately be cancelled without any further action and Employee shall have no further rights with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Recission</u>. In addition to any other remedies available to the Company, if Employee breaches or violates any of the Restrictive Covenants, as determined by the Committee, following such time that Shares are issued in settlement of any portion of this Award pursuant to this Agreement and prior to the consummation of any Change of Control, the Company may, if so determined by the Committee, cause Employee to surrender such Shares issued upon settlement of this Award or make the payments, in any such case, as provided in this Section 6(e), by providing notice to Employee (the "Rescission Notice") at the last known address or e-mail address of Employee within 180 days after the Committee obtains knowledge of Employee's breach or violation of any of the Restrictive Covenants. In such event, within 10 business days following the Company's delivery of the Rescission Notice as set forth above, (i) Employee must surrender to the Company the Shares issued upon settlement of any portion of

&nbsp;&nbsp;&nbsp;&nbsp;6

------

this Award pursuant to this Agreement or (ii) if such Shares have been sold or transferred by Employee or if otherwise determined by the Company, the Employee must pay the Company an amount in cash equal to the Fair Market Value of the Shares on the date of the issuance of the Shares to Employee pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Nature of Restrictions</u>. Employee acknowledges that the restrictions contained in this Section 6 are reasonable and necessary to protect the Company's legitimate interests in its confidential information, trade secrets, customer relationships and investment in the training and development of its employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>No Interference</u>. Nothing in this Agreement is intended to interfere with or prohibit Employee from reporting to or participating in an investigation with any federal, state or local government agency about a possible violation of law, from recovering any award offered by such agency associated with such investigation, or from making other disclosures protected by applicable whistleblower statutes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)<u>Survival</u>. The provisions of this Section 6 shall survive the termination of Employee's employment with the Company or any vesting or forfeiture of the RSUs.

**SECTION 7**

**<u>MISCELLANEOUS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Rights in Shares Prior to Issuance</u>. Prior to the issuance of Shares upon settlement of the RSUs subject to this Award, neither Employee nor his or her legatees, personal representatives or distributees shall (i) be deemed to be a holder of any Shares represented by the RSUs awarded hereunder or (ii) have any voting, dividend or other rights with respect to any such Shares. &nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Non-assignability</u>. The RSUs subject to this Award shall not be assigned, alienated, pledged, attached, sold, transferred or encumbered by Employee other than by will or by the laws of descent and distribution; provided that, Employee may transfer the RSUs during his or her lifetime to a revocable living trust of which Employee is grantor, or to another form of trust indenture of which Employee is a grantor or a beneficiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Recoupment</u>. This Award is subject to the terms and conditions contained in (i) the Company's Executive Compensation Recoupment Policy, (ii) the Company's NYSE Executive Recoupment Policy, (iii) any amendment and/or restatement of either such policy and (iv) any other recoupment or clawback policy that may be adopted by the Company in the future (collectively, the "Policies"), any or all of which may permit the Company to recoup all or a portion of awards made to certain employees upon the occurrence of certain events. If any portion of this Award becomes subject to recoupment pursuant to any one or more of the Policies, the Company may utilize any method of recovery specified in any of such Policies in connection with any award recoupments required or permitted under any of such Policies.

&nbsp;&nbsp;&nbsp;&nbsp;7

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Securities Law Requirements</u>. The Company shall not be required to issue Shares pursuant to this Agreement unless and until such issuance is in compliance with all applicable legal requirements, including that (i) such Shares have been duly listed upon each stock exchange on which the Company's Common Stock is then registered and (ii) a registration statement under the Securities Act of 1933 with respect to such Shares is then effective.

&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation of Beneficiaries</u>. Employee may file with the Company a written designation of a beneficiary or beneficiaries to receive, upon Employee's death, the Shares determined in accordance with Section 4(b) and subject to all of the provisions of this Agreement. An Employee may from time to time revoke or change any such designation of beneficiary and any designation of beneficiary under the Plan shall be controlling over any other disposition, testamentary or otherwise; provided, however, that if the Committee shall be in doubt as to the right of any such beneficiary to receive Shares, the Committee may recognize only receipt of such Shares by the personal representative of the estate of Employee, in which case the Company, the Committee and the members thereof shall not be under any further liability to anyone.

&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Changes in Capital Structure</u>. Notwithstanding anything contained herein to the contrary in this Agreement, if there is any change in the Common Stock by reason of any extraordinary dividend, stock dividend, spin off, split up, spin out, recapitalization, warrant or rights issuance or combination, exchange or reclassification of shares, merger, consolidation, reorganization, sale of substantially all assets or, as determined by the Committee, other similar or relevant event, in any such event as determined by the Committee to affect the Shares, then the number, kind and class of shares of Common Stock available for RSUs and the number, kind and class of shares of Common Stock subject to outstanding RSUs, as applicable, shall be appropriately adjusted by the Committee. The issuance of shares of Common Stock for consideration and the issuance of rights with respect to Common Stock shall not be considered a change in the Company's capital structure. No adjustment provided for in this Section 7(f) shall require the issuance of any fractional shares.

&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Right to Continued Employment</u>. Nothing in this Agreement shall confer on Employee any right to continued employment or interfere with the right of an Employer to terminate Employee's employment at any time or for any reason.

&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Award</u>. In accepting this Award, Employee acknowledges, understands and agrees that: (i) this Award does not in any way create any contractual or other rights to receive additional grants of restricted stock units (or benefits in lieu of restricted stock units) or other equity awards at any time; (ii) all decisions with respect to future restricted stock units or other equity awards, if any, will be at the sole discretion of the Company; (iii) Employee's participation in the Plan is voluntary; (iv) this Award is not part of normal or expected compensation or salary of Employee for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments; (v) upon the termination of the employment of Employee for any reason, the term of employment of Employee for purposes of this Agreement will not be extended by any notice period mandated

&nbsp;&nbsp;&nbsp;&nbsp;8

------

under any applicable law and (vi) the future value of the Shares issuable upon any settlement of this Award is unknown, indeterminable and cannot be predicted with certainty.

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Withholding</u>. Employee must pay or make arrangements acceptable to the Company for the payment of any and all federal, state and local tax withholding that in the opinion of the Company is required by law. Unless Employee satisfies any such tax withholding obligation as provided in the preceding sentence, the Company will withhold shares of Common Stock having a Fair Market Value on the date of withholding equal to the tax withholding obligation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Copy of Plan and Prospectus</u>. By signing this Agreement, Employee acknowledges receipt of a copy of (or an electronic link to) the Plan and the prospectus related to this grant of the RSUs under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Choice of Law; Venue</u>. This Agreement will be governed by the laws of the State of Missouri, without giving regard to the conflict of law provisions thereof. Any legal action arising out of this Agreement may only be brought in the Circuit Court in St. Louis County and/or the United States District Court in St. Louis, Missouri.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution</u>. An authorized representative of the Company has signed this Agreement, and Employee has signed this Agreement to evidence Employee's acceptance of the award on the terms specified in this Agreement and the Plan, all as of the Date of Grant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Section 409A</u>. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by Employee on account of non-compliance with Section 409A of the Code. Notwithstanding anything herein to the contrary, if Employee is determined to be a "specified employee" within the meaning of Section 409A of the Code, any payment that is made on account of Employee's termination of employment pursuant to this Award and that does not qualify as a "short-term deferral" within the meaning of Section 1.409A-1(b)(4) of the Treasury Regulations (or any other exemption therefrom) shall be made on the first payroll date which is more than six months following the date of Employee's termination of employment to the extent required to avoid any adverse tax consequences under Section 409A of the Code. To the extent necessary for compliance with Code Section 409A, references to termination of employment under this Agreement shall mean a "separation from service" within the meaning of Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any provision of this Agreement (including Section 6 of this Agreement) shall be determined by a court to be invalid or unenforceable for any reason, any such provisions shall be construed so as to be enforceable to the maximum extent compatible with the applicable laws in effect at the time; and such determination of invalidity or unenforceability shall not affect the remaining provisions of this Agreement (including Section 6

&nbsp;&nbsp;&nbsp;&nbsp;9

------

of this Agreement), which shall continue to be given full force and effect. Moreover, if any provision of Section 6 of this Agreement shall be determined by a court to be unenforceable because of the scope or duration thereof, the parties hereby expressly agree that the court making such determination shall have the power to reduce the scope or duration and/or restrict the geographical area of such provision and/or to delete such specific words or phrases which the court shall deem necessary to permit enforcement of such provision in restricted form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. Employee acknowledges and agrees that any breach or threatened breach of any provisions of Section 6 of this Agreement will result in substantial, continuing and irreparable injury to the Company and/or its Affiliates. Therefore, in such event, the Company and/or its Affiliates shall be entitled to seek equitable and/or injunctive relief to prevent any breach or threatened breach of such provisions, and to specific performance of each of the terms thereof, in addition to any other legal or equitable remedies that the Company or any Affiliate may have. The rights and remedies of the parties to this Agreement are cumulative and not alternative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;&nbsp;&nbsp;&nbsp;<u>Deadline to Accept</u>. If Employee wishes to accept the terms of this Agreement, Employee must do so by executing and delivering this Agreement (including by electronic means made available to Employee) within 60 days after the Date of Grant. The Company may, in its sole discretion, extend the time within which Employee may accept this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;&nbsp;&nbsp;&nbsp;<u>Modifications and Waivers</u>. The Company may modify, amend or waive any terms of this Agreement, prospectively or retroactively, without the consent of Employee unless any such modification or waiver is deemed by the Committee to be materially adverse to Employee and not required as a matter of law. In addition, the waiver by either party of compliance with any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;&nbsp;&nbsp;&nbsp;<u>Employee Data Privacy</u>. By entering into this Agreement and accepting the Award:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp; Employee acknowledges and consents to the collection, use, processing and transfer, in electronic or other form, of any of Employee's personal data, including, but not limited to, Employee's name, home address and telephone number(s), date of birth, social security number or other identification number, salary, nationality, job title and details of this Award and any other awards granted to Employee under the Plan (collectively, "Data") for the purpose of implementing, administering and managing Employee's participation in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;Employee understands that (i) the Company and its Affiliates may transfer Data amongst themselves as necessary for the purpose of implementing, administering, and managing Employee's participation in the Plan, and (ii) the Company and its Affiliates may transfer Data to any third parties assisting the Company in connection with the implementation, administration and management of the Plan, including any broker or stock plan service provider selected by the Company in connection with the Plan (the "Stock Plan Provider") (any recipients of the Data as provided in clauses (i) or (ii) above, the "Recipients").

&nbsp;&nbsp;&nbsp;&nbsp;10

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;&nbsp;Employee understands that the Recipients may be located in the United States or elsewhere, and that the Recipients' country may have different data privacy laws and protections than Employee's country.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;&nbsp;Employee authorizes the Company, its Affiliates, any Stock Plan Provider and any other Recipients that may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purpose of implementing, administering and managing Employee's participation in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) &nbsp;&nbsp;&nbsp;&nbsp;Employee understands that, if Employee resides in certain jurisdictions where Employee is afforded certain rights, Employee may, at any time, exercise such rights which may include requesting access to the Data, requesting additional information about the storage and processing of Data, requiring any necessary amendments to Data or refusing or withdrawing the consents herein (where Company relies on Employee's consent as the legal basis for processing). For additional information, Employee may contact Employee's human resources representative or the Company's Global Privacy Office.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) &nbsp;&nbsp;&nbsp;&nbsp;Employee understands that (i) Employee is providing the consents herein and otherwise agreeing to the terms of this Section 7(r) on a purely voluntary basis, and (ii) that if Employee refuses or withdraws such consent and/or agreement to these terms, Employee's salary from or service with the Company will not be affected and the Company may not be able to grant Awards or administer Employee's participation in the Plan and that Company may, as a result, cancel Employee's ability to participate in the Plan and/or cause the Employee to forfeit this Award and other outstanding Awards under the Plan.

*Signature page follows.*

&nbsp;&nbsp;&nbsp;&nbsp;11

------

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of this ___ day of April, 2026.

**Reinsurance Group of America, Incorporated** 

By: ____________________________

Tony Cheng

President and Chief Executive Officer

**Employee** 

_______________________________

Name:

&nbsp;&nbsp;&nbsp;&nbsp;12

## Exhibit 31.1

Exhibit 31.1

**<u>CEO CERTIFICATION</u>**

I, Tony Cheng, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp; I have reviewed this quarterly report on Form 10-Q of Reinsurance Group of America, Incorporated;

2.&nbsp;&nbsp;&nbsp;&nbsp; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp; Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp; Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp; The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 8, 2026 | <u>/s/ Tony Cheng</u> |
| | Tony Cheng |
| | President & Chief Executive Officer |

---

## Exhibit 31.2

Exhibit 31.2

**<u>CFO CERTIFICATION</u>**

I, Axel André, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp; I have reviewed this quarterly report on Form 10-Q of Reinsurance Group of America, Incorporated;

2.&nbsp;&nbsp;&nbsp;&nbsp; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp; Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp; Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp; The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 8, 2026 | <u>/s/ Axel André</u> |
| | Axel André |
| | Executive Vice President and Chief Financial Officer |

---

## Exhibit 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Reinsurance Group of America, Incorporated and subsidiaries, (the "Company"), for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Tony Cheng, Chief Executive Officer of the Company, certifies, to his best knowledge and belief, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: May 8, 2026 | <u>/s/ Tony Cheng</u> |
| | Tony Cheng |
| | President & Chief Executive Officer |

---

## Exhibit 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Reinsurance Group of America, Incorporated and subsidiaries, (the "Company"), for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Axel André, Chief Financial Officer of the Company, certifies, to his best knowledge and belief, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: May 8, 2026 | <u>/s/ Axel André</u> |
| | Axel André |
| | Executive Vice President and Chief Financial Officer |

---

<br>